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Cancer is a leading disease for mortality. In the past 30 years, the standard treatments 
have been surgery followed by radiotherapy and/or chemotherapy. If they fail, patients 
have a less than 10% chance of survival with other treatments. None of the existing 
single modality treatments, such as chemotherapy, radiotherapy, hyperthermia therapy, 
immunotherapy, anti-angiogenesis therapy or gene therapy can guarantee to cure 
cancer. It is also unlikely that any magic anticancer drug can be discovered in the next 
few years to completely cure cancer, since the problems in drug delivery would always 
be there. Instead, multimodality treatment can do an excellent job, superior to any 
single modality treatment in current practice. Multimodality treatment has been 
investigated for their synergistic effects that may dramatically improve outcomes and 
reduce the side effects of each single modality treatment. To better achieve the 
multimodality treatment of cancer, nanomedicine can provide a fantastic platform for 
multimodality treatment. It is believed that co-delivery of various therapeutic agents by 
nanocarriers can further magnify the synergistic effects of the designated 
multimodality treatment. In this PhD work, nanomedicine for multimodality treatment 
of cancer was proposed. The proof-of-concept experiments were conducted with the 
vitamin E TPGS (D--tocopheryl polyethylene glycol 1000 succinate) polymer-based 
delivery systems, such as prodrugs, micelles, nanoparticles or hybrid nanocarriers, to 
co-deliver therapeutic agents and to study their anti-cancer synergistic effects. Chemo-, 
immune- and/or thermo-therapeutic agents were delivered to cancer cells 
simultaneously by targeting ligand-conjugated nanocarriers. Their properties of size, 
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surface charge, shape and morphology, surface composition, agent load, controlled 
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Chapter 1: Introduction 
1.1 Background 
Cancer is a leading cause of death owing to its uncontrolled growth and metastasis. 
Because of its lethality, it has cost huge amount of time and money, which, for example, 
has reached overall 201.5 billion dollars in 2008, US. With the huge amount of 
investment, it is reported that the 5-year survival rate, diagnosed between 2003 and 
2008, has been improved to 68%, compared to 49% in 1975-1977. The improvement in 
cancer therapy is achieved due to the development of modern technology of diagnosis 
and therapeutics. Among them, the emergence of nanomedicine should be one of the 





, nanomedicine has come to our daily life to change and to improve the way 
we cure cancer. It provides us a useful tool to solve the problem of drug formulation 
and to achieve sustained, controlled and targeted delivery of therapeutic agents. 
However, current treatment for cancer is still at the stage of prolonging survival period 
and improving quality of life for patients, not curable. In cancer Facts and Figures 2013, 
it is estimated that about 580,350 Americans will die of cancer in 2013, which is the 
second most common cause of death in the US. Cancer is also the No.1 killer in many 
Asian countries such as Singapore, where the cancer death rate is 29.3% in 2009 
among all other diseases. In the past 30 years, the standard treatments have been 
surgery followed by radiotherapy and/or chemotherapy. If they fail, patients have a less 
than 10% chance of survival with other treatments. It is unlikely that any magic 
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anti-cancer drug can be discovered in the next few years to completely cure cancer, 
since the problems in drug delivery would always be there. Instead, multimodality 
treatment can do an excellent job, superior to any treatment in current practice, and 
nanomedicine can provide a fantastic platform for multimodality treatment. Currently, 
none of the existing single modality treatments, such as chemotherapy, radiotherapy, 
immunotherapy, hyperthermia therapy, anti-angiogenesis therapy, photodynamic 
therapy and gene therapy, can cure cancer alone. For example, surgery may trigger 
faster metastatic processes. Radiotherapy and chemotherapy may be inefficient due to 
the radio-insensitivity and the multi-drug resistance (MDR) of cancer cells. Moreover, 
these therapies also damage healthy cells due to their lack of any specificity. 
Consequently, combinations of these treatments, such as combination chemotherapy 
(chemotherapy combined with more than one anticancer drug), chemotherapy and 
gene therapy, chemotherapy and hyperthermia therapy, chemotherapy and biotherapy, 
and chemotherapy, biotherapy and thermotherapy, have been investigated for their 
synergistic effects that may dramatically improve outcomes and reduce the side effects 
of each single modality treatment. These are called ‘1+1>>2’ effects [1]. 
One of the major focuses in nanomedicine is to apply nanotechnology for sustained, 
controlled and targeted delivery of therapeutic agents. It can be expected that 
co-delivery of the various therapeutic agents by nanocarriers, such as polymeric 
nanoparticles (NPs), micelles, liposomes, nanohydrogels, dendrimers, solid lipid 
nanoparticles (SLNs), inorganic nanocarriers, and the hybrids of these nanocarriers, 
could further magnify the synergistic effect of the designated multimodality treatment. 
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Therefore, we propose the nanomedicine for multimodality treatment of cancer. The 
concept and property of nanomedicine for multimodality treatment of cancer are 
illustrated in Figure 1.1. The justifications for this hypothesis are that: nanomedicine 
is advantageous in: 1) Prolonged blood circulation period; 2) High transportation 
efficiency; 3) Ligand conjugation for targeting; 4) Sustained and controlled release of 
therapeutic agents; 5) Make-up to escape from multi-drug resistance (MDR) proteins; 
6) Co-delivery of agents; Meanwhile, nanomedicine for multimodality treatment will 
take all the advantages above and also achieve: 1) Simultaneous delivery of agents to 
the active site; 2) Precise ratio control of the loading agents; 3) Further overcoming 





Figure 1.1 Schematic illustration of the concept and property of nanomedicine for 
multimodality treatment of cancer. 
 
1.2 Research Objective 
To sum up the objective of this PhD work, we dedicate to designing and developing 
new nanocarriers based on TPGS polymers for multimodality treatment of cancer. The 
focus lies on better formulation of different therapeutic agents in one nano delivery 
system to achieve synergistic effect for cancer therapy, especially for breast cancer 
therapy. Hydrophobic and hydrophilic therapeutic agents will be delivered by the 
nano delivery system simultaneously with precise ratio control. The enhanced 
anti-cancer effect is expected to be achieved with such a strategy. 
5 
 
To achieve the purpose, first, we will develop folic acid-conjugated TPGS2k micelles 
for targeted delivery of docetaxel. It will be demonstrated that TPGS2k, as the 
nanocarrier material, also has anti-cancer effect, which together with its loading agent 
can achieve multimodality treatment of cancer. Then, we plan to synthesize 
TPGS-cisplatin prodrugs and to form docetaxel-loaded TPGS-cisplatin prodrug 
micelles. Such system is fabricated to co-deliver hydrophobic and hydrophilic drugs 
for dual-drug multimodality treatment of cancer. Furthermore, we intend to apply the 
TPGS-cisplatin prodrugs to form prodrug nanoparticles for better stability and better 
controlled release. Three therapeutic agents, cisplatin for chemotherapy, docetaxel for 
chemotherapy, and herceptin for targeting and immunotherapy, will be co-delivered 
by these prodrug nanoparticles. We want to achieve precise ratio control of docetaxel 
and cisplatin within the prodrug nanoparticles and discuss the anti-cancer effect of the 
prodrug nanoparticles with different drug ratios. Last but not least, we will synthesize 
PLA-TPGS nanoparticles to load docetaxel for chemotherapy, herceptin for targeting 
and immunotherapy, and iron oxides for hyperthermia therapy. By introducing three 
different treatments into one nano delivery system, we hope that the therapeutic effect 
for cancer can be improved synergistically. 
1.3 Thesis Outline 
In this thesis, the concept and the property of nanomedicine for multimodality 
treatment of cancer are proposed and concluded in Chapter 1. Chapter 2 is related to 
the literature review, especially on the interaction between multimodality treatments, 
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the outcomes of clinical multimodality treatment of cancer, the mechanisms behind 
nanomedicine and nanomedicine for multimodality treatment, and the current results 
of nanomedicine for multimodality treatment of cancer. Chapter 3 represents the 
design and synthesis of TPGS2k. micelles for docetaxel delivery. The result supports 
the fact that nanocarrier material can be also considered as anti-cancer agent for 
multimodality treatment. Chapter 4 describes the fabrication of docetaxel-loaded 
TPGS-cisplatin prodrug micelles for hydrophobic and hydrophilic drug delivery and 
dual-drug multimodality treatment. Chapter 5 expatiates on the formulation of 
TPGS-cisplatin prodrug nanoparticles for co-delivery of cisplatin, docetaxel and 
herceptin. The drug ratio is precisely controlled and the enhanced anti-cancer effect is 
studied. Chapter 6 introduces the work of multimodality treatment of cancer with 
herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded 
PLA-TPGS/TPGS-COOH nanoparticles. The conclusions and recommendations of 
this PhD work are exhibited in Chapter 7. 
1.4 Contributions 













Chapter 2: Literature Review 
2.1 Cancer and cancer stem cell 
Cancer is a leading disease worldwide. Cancer cells grow and proliferate in defiance of 
normal controls, invade surrounding tissues and colonize distant organs. Cancer is 
thought to derive from a single cell which has encountered an initial mutation; but to 
become cancerous, a variety of additional mutations and epigenetic events are required 
by the progeny of this cell. The whole process usually takes many years and reflects the 
operation of a Darwinian-like process of evolution. Cancer cells possess many special 
properties as they can evolve, multiply, and spread. Cancer cells change the signaling 
pathways to lose the tight control of cell proliferation and show defects in 
differentiation and in the control mechanisms of cell division and apoptosis. In fact, 
nearly all cancer cells are genetically unstable, generated by failure to repair DNA 
damage or failure to correct replication errors, as well as show defects in chromosome 
segregation during mitosis. This genetic instability will accelerate the accumulation of 
genetic and epigenetic changes, and will finally lead to tumors. Except for the changes 
in the cancer cells themselves, origination of a tumor also depends on stromal cells 
which present in the tumor microenvironment, such as new blood vessels which help 




Figure 2.1 Properties of cancer. 
 
Two major properties of cancer make it a lethal disease: first, they lose the normal 
restraints on cell growth and division; second, they invade and colonized territories 
(Figure 2.1). Among them, the second property, also called metastasis, makes them 
difficult to eradicate by surgery or local irradiation, leading to 90% cancer-associated 
mortality. During the metastasis process, cancer cells from the primary tumor 
experience the following steps: locally, they invade the surrounding tissue; 
systemically, they enter lymph and blood vessels, circulate to microvessels of distant 
tissues. Some of the cells exit from the blood stream, and survive and adapt to the 
foreign microenvironment of these tissues. This process leads to the formation of a 
secondary tumor [3, 4]. In short, physical translocation and colonization are the two 
major phases during metastasis. Understanding the mechanism of metastasis will help 
us prevent it at early stage or cure patients efficiently.  
A prevalent explanation about derivation of cancer is Cancer Stem Cell (CSC) 
Hypothesis. Cancer stem cells are defined as a subpopulation of tumor cells, as many as 
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about 25% of the cancer cells within some tumors, that possess the ability to self-renew 
and to generate the heterogeneous lineages of cancer cells which comprise the tumor 
[5-7]. Three characters of CSCs make them capable of driving tumorigenesis: (1) 
long-term self-renewal; (2) differentiation into tumor bulk populations; (3) unlimited 
potential for proliferation and tumorigenic growth. Besides, in some malignancies 
possess, CSCs have the ability to drive tumor angiogenic response and vasculogenic 
mimicry. CSCs also show increased resistance to chemotherapeutic agents and ionizing 
radiation [8, 9].  
For the hypothesis, there are still many contentions such as: whether tumors derive 
from organ stem cells which retain self-renewal properties but acquire epigenetic and 
genetic changes for tumorigenicity; or whether tumor stem cells are proliferative 
progenitors which acquire self-renewal capacity [10]. However, the existence of cancer 
stem cells has already breaking the traditional notion. Conventional anti-cancer 
approaches might fail to eradicate the CSCs. For example, CSC’s extremely strong 
chemoresistance has been reported in human leukemia, malignant melanoma, brain 
cancer, breast cancer, pancreatic cancer and colorectal cancer [11-16]. Furthermore, 
CSC’s radioresistance has been identified in brain and breast cancers [17, 18]. Targeted 
therapy towards CSCs should be studied and developed. 
2.2 Therapy methods 
The traditional methods for cancer therapy include surgery, chemotherapy and 
radiation therapy. Recently, with the development of modern technology, other therapy 
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methods have also been studied such as angiogenesis inhibitors therapy, biological 
therapy, photodynamic therapy, hyperthermia therapy and gene therapy. 
2.2.1 Surgery 
Surgery is one of the earliest ways for cancer therapy. The purpose is to remove tumors 
or cancerous tissue as much as possible, which is often effective and considered as the 
primary procedure for tumors large enough to be operated. However, it is difficult to 
eradicate the tumor and it is usually inevitable to leave affected cells. Surgery may also 
change the growth rate of the remaining cancer cells by triggering a faster metastatic 
process. In many cases, patients die of metastatic cancer after the primary tumor has 
been successfully removed [19]. 
2.2.2 Chemotherapy 
Chemotherapy is defined as using chemotherapeutical agents to kill or control the 
cancer cells. The cancer chemotherapeutic agents are often toxic or even 
life-threatening. The principle that drugs could be administered to induce tumor 
regression was first established in 1942, when the nitrogen mustard was used to destroy 
the lymphoid tumor. In 1958, the first solid tumor was cured by a single agent, 
methotrexate. Then, the combination chemotherapy (POMP regimen) is used to induce 
long term remissions for acute lymphoblastic leukaemia. Lymphomas were cured with 
combination chemotherapy in the late 1960s. In the 1970s, chemotherapy was 
demonstrated as adjuvant treatment to improve cure rate after the surgical removal of 
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tumors. From then on, several chemotherapy agents, such as cisplatin in 1978 and 
paclitaxel in 1992, were approved by FDA. So far, there have been hundreds of 
anticancer agents available for clinical use; some are synthetic chemicals and others are 
natural extracts. [20] 
2.2.3 Radiotherapy 
Radiation therapy uses high-energy radiation, such as X-rays, gamma rays and charged 
particles, to shrink tumors and kill cancer cells. Radiation therapy includes 
external-beam radiation therapy and internal radiation therapy. In external-beam 
radiation therapy, the radiation is sent by a machine outside the body. In internal 
radiation therapy, the radiation comes from the radioactive material placed in the body 
near the cancer cells. It works by damaging a cancer cell's DNA, making it unable to 
multiply. Cancer cells are highly sensitive to radiation. Nearby healthy cells can be 
damaged as well, but they are resilient and can fully recover. [21, 22] 
2.2.4 Anti-angiogenesis therapy 
Angiogenesis represents the process of formation of new blood vessels, which is 
controlled by certain chemicals produced in the body. Although this is helpful for 
normal wound healing, cancer can grow with the benefit of these new blood vessels. 
Angiogenesis provides cancer cells with oxygen and nutrients. This allows cancer cells 
to multiply, invade nearby tissue, and metastasize. Angiogenesis inhibitor is a kind of 
chemicals which interfere with the signals to form new blood vessels. 
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Anti-angiogenesis therapy is a method to inhibit growth of cancer by blocking the 
formation of new blood vessels. [23-25] 
2.2.5 Biological therapy 
Biological therapy, also called immunotherapy, is to induce the immune system to cure 
cancer. The approach of biological therapy includes: (1) making cancer cells more 
recognizable by the immune system and more susceptible to be destructed by the 
immune system; (2) increasing the killing power of immune system cells; (3) stopping 
the process of altering of normal cells and cancer cells; (4) enhancing the ability of 
repairing normal cells destroyed by other types of treatments; (5) preventing the 
metastasis of cancer cells. [26] 
2.2.6 Photodynamic therapy 
Photodynamic therapy (PDT) applies photosensitizing agents and a particular type of 
light to cure cancer. When the photosensitizing agents are accumulated in tumor, a laser 
or other sources of light is delivered to the area inside the body. The photosensitizers in 
the tumor absorb the light and generate reactive oxygen species (ROS). Besides, 
photosensitizers can also destroy the blood vessels in the tumor to inhibit the delivery 
of nutrients and activate the immune system to attack the tumor cells. The side effect is 
that they make skin or eyes sensitive to light. PDT may also cause burns, swelling, pain 
and scarring. The limitation of this method is that the light is hard to pass through more 
than one-third of an inch of tissue. Therefore, PDT is often less effective for large 
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tumors. It is often used to treat tumors under the skin or on the lining of internal organs. 
It cannot be used to treat metastatic cancer cells. [27, 28] 
2.2.7 Hyperthermia therapy 
Hyperthermia therapy is a kind of heat therapy which makes body tissue exposed to 
high temperatures. It has been shown that high temperature can damage and kill cancer 
cells, usually with minimal injury to normal tissues. Hyperthermia includes local, 
regional and whole-body hyperthermia. In local hyperthermia, heat is focused on a 
small area around a tumor. Several techniques can induce heat such as microwave, 
radiofrequency and ultrasound. In regional hyperthermia, heat is applied on large areas 
of tissue. Whole-body hyperthermia can be used to cure metastatic cancer cells which 
are spread all over the body. [29, 30] 
2.2.8 Gene therapy 
Gene therapy involves delivering genetic material, DNA or RNA, into the cells to cure 
diseases. Gene therapy can treat the diseases permanently. One approach for gene 
therapy is to target healthy cells to enhance their ability of fighting against cancer. 
Other approach is to target cancer cells to destroy them or prevent their growth. One of 
the problems for gene therapy is the precise delivery of genes to their active site. 
Nanoparticles or viruses have been used for gene delivery. [31-33] 
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2.3 Interaction between multimodality treatments and clinical outcomes 
2.3.1 Combination of multi-chemotherapeutic agents 
Combination of multi-chemotherapeutic agents, or multi-drug therapy, might be the 
most commonly used strategy for cancer treatment. Monotherapy causes drug 
resistance and loses its response in patients after several cycles of treatment. While 
combining different anti-cancer drugs together for cancer treatment, just like the 
cocktail therapy for HIV, will not only overcome the drug resistance but also lead to 
synergistic effect, therefore showing prolonged survival for patients.   
2.3.2 Combination of immunotherapy 
The progress of cancer immunotherapy is described as: antigen-presenting cells 
(dendritic cells) captures, processes and presents tumor antigens. These 
tumor-antigen-loaded dendritic cells become maturation and migrate to lymph nodes. 
They further induce T cell and natural killer (NK) cell responses in lymphoid organs. 
Finally, such T cells (also B cells and NK cells) exit the lymph node, enter the tumor 
bed, overcome the immunosuppression and function for anti-tumor effect (Figure 2.2) 




Figure 2.2 Generation and regulation of anti-tumor immunity. Figure taken from 
reference [34]. 
 
The immunotherapy agents include melanoma-differentiation antigens such as 
MART-1, gp100, tyrosinase or TRP-2; cancer-testes antigens such as NY-ESO-1 or 
MAGE-12 [36]; monoclonal antibodies targeting cancer-associated proteins of 
Her2/neu, EGFR, VEGF, CD20, CD52 or CD33. Immunostimulatory monoclonal 
antibodies are also used, including antagonist antibodies such as anti-CTLA-4, 
anti-PD-1, anti-KIR and anti-TGF-β; and agonist antibodies targeting CD40, CD137, 
CD134 and glucocorticoid-induced TNF receptor (GITR) [37]. Besides, cytokines 
such as IL-2, GM-CSF and interferon- are also delivered for immunotherapy[34].  
Cancer vaccines used in immunotherapy are often not sufficient enough for tumor 
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response. The rationale behind combination immunotherapy is various. One strategy is 
multi-immunotherapy which combines different agents to target one or more stages of 
the immune response, stimulating the T cell response and overcoming the 
immunosuppression simultaneously. For example, it is found that T cells express 
multiple inhibitory receptors [38]. Combining immune stimulator such as IL 15 with 
multiple blockades for inhibitory receptors, such as CTLA-4, PD1 and PD-L1, will 
enhance immune response [39, 40].  
In a recent phase I clinical trial, van den Eertwegh et al. combined 
granulocyte-macrophage colony-stimulating factor-transduced allergenic prostate 
cancer cells vaccine (GVAX) with ipilimumab which was an antagonist antibody 
blocking CTLA-4. The whole cell vaccine, GVAX, functioned to stimulate the 
antitumor immune response, while ipilimumab overcome immunosuppression and 
activated T cells. The trial demonstrated a tolerable dose and the safety between these 
two active immunotherapies for patients with metastatic castration-resistant prostate 
cancer. Further studies were needed to assess the synergistic effect between them [41]. 
A similar phase I trial was implemented to show the safety of combination 
immunotherapy between ipilimumab and a poxviral vaccine targeting prostate-specific 
antigen in metastatic castration-resistant prostate cancer [42]. 
A phase I/II clinical trial combining immunotherapy against p53 with interferon-alpha 
(IFN-) was conducted on 11 colorectal cancer patients by Zeetraten et al. All the 
patients vaccinated with p53 synthetic long peptides (p53-SLP) and IFN- were 
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detected with p53-specific T cells in their blood samples, whereas only 2 of 10 patients 
were detected with that when vaccinated with p53-SLP alone. The result indicated that 
compared to treatment with p53-SLP vaccination alone, the combination stimulated 
more p53-specific T cells response. Toxicity of p53-SLP vaccination plus IFN-  was 
Grade 1 or 2, demonstrating the safety of the multimodality treatment [43]. In another 
phase II study, IFN-  was combined with tremelimumab for combination 
immunotherapy. Thirty-seven patients with stage IV melanoma were treated and the 
median progression-free survival and overall survival were 6.4 and 21 months, 
respectively. The trial revealed that combination immunotherapy showed tolerable 
toxicity and promising antitumor efficacy [44]. 
When combining immunotherapy with chemotherapy, some chemotherapeutic agents, 
such as cyclophosphamide, could not only kill cancer cells but also activate immune 
effectors and eliminate immunosuppression. It might also induce the release of tumor 
antigens which could be captured by antigen-presenting cells and induce cytotoxic T 
cells response. For example, myeloid-derived suppressive cells and their induced 
cytokines including IL-6, tumor necrosis facor- and IL-23 could cause gathering of 
regulatory T cells and bring on IL-10 and TGF-β to down-regulate immune response 
[45-47]. When combining immunotherapy and radiotherapy, after the radiotherapy, 
cells might release the tumor antigens, become susceptible to the following 
immunotherapy, and reduce the antigens contributed to T-cell tolerance [45].  
Quoix et al. conducted a phase IIB study on 148 patients with advanced non-small-cell 
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lung cancer. Seventy-four patients received TG4010 therapeutic vaccination in 
combination with cisplatin and gemcitabine, as multimodality treatment group; 
whereas 74 patients received the same chemotherapy alone, as control group. The 
6-months progression-free survival was 43.2% in the multimodality treatment group 
and 35.1% in the control group. The multimodality treatment group showed more 
common but tolerable adverse events than the control group. The result suggested that 
TG4010 promoted the efficacy of chemotherapy in non-small-cell lung cancer patients 
[48]. In another study, forty-nine patients with advanced pancreatic carcinoma were 
treated with dendritic cell (DC)-based immunotherapy in combination with 
gemcitabine and/or S-1 chemotherapy. It was concluded that DC vaccine-based 
immunotherapy plus chemotherapy was safe and effective in patients with advanced 
pancreatic cancer resistant to standard treatment [49]. Another example involved 
combination of immunocytokine L19-IL2 and dacarbazine for treatment of patients 
with metastatic melanoma. L19-IL2 was composed of an antibody fragment specific to 
the EDB domain of fibronectin and of human interleukin-2. Among 29 patients, the 
12-month survival rate and median overall survival were 61.5% and 14.1 months, 
respectively, indicating that such administration of multimodality treatment was safe 
and effective [50].  
A phase II clinical trial attempted to combine immunotherapy with radiotherapy and 
chemotherapy. The trial was conducted on 63 patients with esophageal cancer. Thirty 
patients were assigned into control group treated with cisplatin, 5-fluorouracil and 
radiotherapy alone; while 33 patients were received the same chemo- and radio- 
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therapy combined with six weekly infusions of nimotuzumab, a humanized anti-EGFR 
antibody, at the dose of 200 mg. The objective response rate was found to be 47.8% in 
the group combined with immunotherapy and 15.4% in the control group. Disease 
control rate was 60.9% versus 26.9% in such groups. The trial showed a better efficacy 
for multimodality treatment among chemo-, radio- and immunotherapy [51]. 
2.3.3 Combination of hyperthermia therapy 
Hyperthermia therapy, chemotherapy and/or radiotherapy are often combined together 
for cancer therapy. Preclinical and clinical studies have showed that synergistic effect 
can be achieved among them. Hyperthermia is used as an efficient adjuvant treatment 
with radiotherapy and/or chemotherapy because it causes tumor reoxygenation. When 
tumors are heated up between 39 °C and 43 °C, improvement in oxygenation is 
emerged [52]. This temperature range is called mild hyperthermia due to the minimal 
direct cytotoxicity. The mild hyperthermia will enhance oxygen delivery and decrease 
oxygen consumption, which is able to induce tumor reoxygenation. The reoxygenation 
can last for 24 h after heating [53]. It has been demonstrated that hypoxia plays a role in 
chemoresistance as well as radioresistance. The improvement of tumor oxygenation 
may increase the possibility of a positive response to radiation therapy [54]. Besides, 
the activity of some chemotherapeutic dagents is also oxygen dependent. Therefore, 
hyperthermia will make tumors more sensitive to chemotherapy and radiotherapy [55].  
For example, the Systemic Hyperthermia Oncology Working Group conducted a phase 
II trial in metastatic sarcoma patents which combined the 41.8 °C (60 min) whole-body 
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hyperthermia (WBH) with ICE chemotherapy. The ICE regimen was a combined 
chemotherapy with ifosfamide, carboplatin and etoposide. For the 95 evaluable 
patients, the overall response rate was 28.4%. The median overall survival by 
Kaplan-Meier estimates was 393 days and the median time to treatment failure was 123 
days. Neutropenia and thrombocytopenia were the major toxicity. The clinical trial 
demonstrated the feasibility of the multimodality approach with chemotherapy and 
WBH. It also gave the foundation for phase III clinical trial [56].  
Between 2007 and 2010, a clinical trial on 106 patients with advanced rectal cancer 
was performed to determine the influence of regional hyperthermia to 
chemoradiotherapy on the rates of complete pathological response (pCR). Forty-five 
patients received radiotherapy and 5-fluorouracil (RCT group) and sixty-one received 
the same treatment in combination with regional hyperthermia (HRCT group). pCR 
was recorded as 6.7% for RCT group and 16.4% for HRCT group, which indicated that 
hyperthermia significantly increased pCR rate for advanced rectal cancer patients [57]. 
A clinical trial combined with chemoradiotherapy and hyperthermia was also applied 
to patients with anal cancer. Patients were assigned to two groups, in which 24 patients 
in arm A received chemotherapy with 5-fluorouracil and mitomycin-C combined with 
radiotherapy with intracavitary hyperthermia and 25 patients in arm B received the 
same chemoradiotherapy without hyperthermia. The 5-year follow up showed that 23 
of 24 patients (95.8%) in arm A preserved their anorectal function and avoided 
permanent colostomy, whereas in arm B, 17 of 25 (68.0%) had sphincter preservation. 
Besides, local recurrence-free survival time was significantly higher in the 
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hyperthermia arm. The multimodality treatment of intracavitary hyperthermia and 
chemoradiatherapy provided an effective and safe therapeutic modality [58]. A clinical 
trial was conducted by Westermann et al., which involved triple-modality treatment 
combined full-dose radiotherapy, chemotherapy and locoregional hyperthermia 
therapy for 68 patients suffering from advanced cervical carcinoma. After a median 
follow-up of 538 days, 74% of patients survived without signs of recurrence, and the 
overall survival rate was 84%. Long-term survival data showed that the 5-year 
recurrence-free survival rate was 57.5% and the 5-year overall survival was 66.1% [59, 
60].  
In another study, forty-three patients with stage IIB-III advanced breast cancer (LABC) 
were evaluated by receiving a novel neoadjuvant combination treatment of paclitaxel, 
liposomal doxorubicin and local breast hyperthermia. The results showed a four-year 
overall survival of 75% and an increased five year disease-free survival rate of 63% 
which was higher than the commonly estimated five-year survival rate of 50-60%. It 
was concluded that neoadjuvant therapy using paclitaxel, liposomal doxorubicin and 
hyperthermia was a feasible and well tolerated treatment strategy in patients with 
LABC [61].  
Multimodality treatment was also used for advanced pancreatic cancer as second-line 
treatment. There has been evidence proving that hyperthermia at 40 °C to 42 °C could 
enhance cytotoxicity of gemcitabine and cisplatin. In the clinical trial between 1999 
and 2008, twenty-three patients with advanced or metastatic pancreatic cancer with 
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relapse after gemcitabine mono first line chemotherapy were treated with gemcitabine 
and cisplatin in combination with regional hyperthermia as second-line treatment. The 
median time to second progression was 4.3 months and overall survival was 12.9 
months. Gemcitabine and cisplatin with regional hyperthermia showed clinically 
active for there gemcitabine-pretreated advanced pancreatic cancer patients [62]. The 
regional hyperthermia in combination with platinum-based chemotherapy was also 
tested on children and adolescents with recurrent or refractory germ cell tumors. It 
revealed that 7 out of 10 patients had objective tumor response [63].  
 
Figure 2.3 Hyperthermia temperature and cell responses. Figure taken from reference 
[64]. 
 
Apart from the increased chemo or radio sensitivity induced by heat, hyperthermia will 
also denature and aggregate the proteins to influence DNA repair and cell cycle 
regulation, change the vascularity for enhanced blood flow and drug delivery, 
upregulate the expression of genes to produce the family of heat shock proteins (HSPs) 
(Figure 2.3) [64]. The overexpression of heat shock proteins was turned out to be 
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related to thermoresistance [65]. Suppression the gene expression of HSPs is another 
kind of multimodality treatment. Besides, the expression of HSP70 on cell membrane 
may activate NK cells. The released HSP70 from necrosis cancer cells may bind to 
antigen presenting cells, restrict MHC class I presentation, and stimulate the T-cell 
immune response [66, 67]. It provides the foundation of thermoimmunotherapy.  
Many agents can be used to enhance the effect of locoregional hyperthermia. For 
example, magnetic nanoparticles can produce heat under alternative magnetic fields for 
magnetic fluid hyperthermia. Its heating capacity can be quantified by SAR: 





   
  
where C is the specific heat capacity of the medium,  
  
  
  is the initial slope of the 
time-dependent temperature curve and     is the weight fraction of Fe in the 
medium [68-70]. Gold nanoparticles can be used as photothermal agents due to their 
irradiation of surface plasmon resonance which allows fast conversion of light into heat. 
By controlling the size and shape of gold nanoparticles, the absorbed wavelength can 
be tunable from visible to near-infrared region [71-73]. Carbon nanotubes are another 
type of agents for hyperthermia based on radiofrequency ablation or absorbance of 
near-infrared radiation [74-76]. 
2.3.4 Combination of anti-angiogenesis therapy 
Anti-angiogenesis therapy inhibits growth of cancer by blocking the formation of new 
blood vessels. Angiogenesis represents the process of formation of new blood vessels 
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which is controlled by pro-angiogenic proteins, such as vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), 
placenta-like growth factor (PLGF), transforming growth-factor-β (TGF-β), 
platelet-derived endothelial growth-factor (PD-EGF), pleiotrophin and others [77]. 
Angiogenesis is often involved in tissue regeneration and in chronic inflammatory 
conditions. Cancer will benefit from the new blood vessels for oxygen and nutrients, 
which allow cancer cells to multiply, invade nearby tissue, and metastasis (Figure 2.4) 
[78, 79].  
 
Figure 2.4 Key steps in tumor angiogenesis. Figure taken from reference [79]. 
 
Angiogenesis inhibitor is a kind of chemical which interferes with the signals related to 
formation of new blood vessels. There are two kinds of inhibitors: direct angiogenesis 
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inhibitor and indirect one. Direct angiogenesis inhibitor restrains response of vascular 
endothelial cells to pro-angiogenic proteins; whereas indirect inhibitor blocks the 
synthesis of angiogenic proteins by tumor cells, reduces the activity of the proteins or 
blocks the expression of receptors on endothelial cells [77, 80].  
Anti-angiogenesis therapy is often combined with chemotherapy, radiotherapy or 
immunotherapy for additive or synergistic effect [81]. By ‘normalizing’ tumor vessels 
through anti-angiogenesis therapy, it leads to decreased vascular leakage, lower 
intratumoral-tissue pressure and increased delivery of therapeutic agents. Due to the 
decreased intratumoral pressure, anti-angiogenesis therapy also increases oxygenation 
supply in tumor and leads to sensitivity of a tumor for ionizing radiation. The 
improvement in blood flow and oxygenation also leads to higher level of glucose and 
oxygen as well as amino acids, which will help T cells to keep activity in 
immunotherapy. Besides, combining anti-angiogenesis therapy with immunotherapy 
enhances dendritic-cell function, decreases the number of myeloid-derive stem cells 
and regulatory T cells, and increase lymphocyte infiltration. Besides, a so called 
‘metronomic chemotherapy’, which applied cytotoxic chemotherapeutic agents at low 
dose with frequent administration, is used to magnify the efficacy of angiogenesis 
inhibitors. Additionally, it is found that accelerated proliferation and repopulation of 
cancer cells emerges during intervals of radio- or chemo- therapy. Nevertheless, 
anti-angiogenesis therapy restrains such repopulation [79, 82, 83].  
For example, there is a phase I trial of multimodality treatment with vandetanib and 
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metronomic chemotherapy in advanced breast cancer patients. The therapy showed 
acceptable toxicities including nausea, vomiting, LFTs abnormalities, fatigue and rash. 
Change in platelet proteomic analysis was considered as markers of angiogenesis 
inhibition [84]. In another phase I study of pazopanib in combination with paclitaxel 
and carboplatin for patients with advanced solid tumors, neutropenia and 
thrombocytopenia were showed as the most common dose-limiting toxicities for this 
administration [85]. 
In a phase II trial, bevacizumab as angiogenesis inhibitor was combined with low-dose 
metronomic oral cyclophosphamide for patients with recurrent ovarian cancer. Among 
70 patients, the progression-free survival in 6 months was 56%. Median time to 
progression and survival were 7.2 months and 16.9 months, respectively. The main side 
effects were hypertension, fatigue and pain. The outcomes of the trial demonstrated 
that combination of bevacizumab and metronomic chemotherapy was active in 
recurrent ovarian cancer patients [86]. 
In a phase III trial, a novel anti-angiogenic agent aflibercept was used in combination 
with a fluoropyrimidine-based chemotherapy regimen (FOLFIRI) to treat patients with 
metastatic colorectal cancer who were treated with oxaliplatin or bevacizumab before. 
Six hundred and twelve patients received FOLFIRI with aflibercept while 614 patients 
were treated with FOLFIRI plus placebo. The median survival times were improved 
from 12.06 months to 13.50 months through adding aflibercept to FOLFIRI. The 
improvement was also observed for median progression-free survival from 4.67 
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months to 6.90 months, and response rate from 11.1% to 19.8%. All the result showed 
that multimodality treatment with aflibercept and FOLFIRI achieved significant 
survival benefit compared with FOLFIRI plus placebo in patients with metastatic 
colorectal cancer. However, some side effects about characteristic anti-vascular 
endothelial growth factor effects and chemotherapy-related toxicity were also emerged 
[87]. 
Except for combination with chemotherapy, anti-angiogenesis therapy is also 
administrated together with other therapies. For example, in a current preliminary study, 
dendritic cell-based autologous whole tumor vaccination was utilized together with 
anti-angiogenesis therapy, followed by transfer of autologous vaccine-primed 
CD3/CD28-co-simulatied lymphocytes for recurrent ovarian cancer patients. Among 
six subjects, the therapy was demonstrated to be feasible, well tolerated and elicited 
antitumor immune responses in four subjects, who experienced clinical benifits. Two 
subjects achieved vaccine-induced restoration of antitumor immunity and one achieved 
complete response [88]. In another trial, anti-angiogenesis therapy was combined with 
hormonal therapy on patients with hormone receptor positive breast cancer, who 
received first-line bevacizumab and taxane-including regimen. The median 
progression-free-survival was 4.1 months for patients with bevacizumab 
anti-angiogenesis therapy and 13 months for patients with combination of 
bevacizumab and hormone therapy. The most common severe toxicities were 
proteinuria and hypertension [89].  
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2.3.5 Combination of photodynamic therapy 
Photodynamic therapy (PDT) utilizes photosensitizing agent and a particular type of 
light to cure cancer. When the photosensitizing agent is accumulated in tumor, a laser 
or other source of light is delivered to the areas at the same time. The photosensitizer in 
tumor will be activated from a ground to an excited state and release energy by 
returning to its ground state. The energy can be transferred to oxygen and generate 
reactive oxygen species (ROS), which causes cellular toxicity (Figure 2.5) [27].  
 
Figure 2.5 Mechanism of action of photodynamic therapy. Figure taken from 
reference [27]. 
 
The most commonly used photosensitizer is paophyrin. Other classes of 
photosensitizers include chlorin, bacteriochlorin, phthalocyanine, phenothiazinium 
compound, porphycene, hypericin, chlorophyll derivative, texaphyrin, antracen, 
purpurin and hypocrellin. Among them, 5-aminolevulinic acid, methyl 
5-aminolevulinate, methyl-tetrahydroxyphenyl chlorine and haematoporphyrin 
derivative are approved for clinical use [90, 91].  
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Apart from the direct kill of cancer cells by generation of reactive oxygen species 
(ROS), photodynamic therapy also damages tumor-associated vasculature, leading to 
tumor hypoxia/anoxia and nutrient deficiency. It also activates immune response 
against tumor cells and decreases immunosuppressive effect [92]. These facts provide 
the foundation for photodynamic-based multimodality treatment with chemo-, 
immune- or anti-angiogenesis therapy.  
Currently, there are many clinical trials using photodynamic therapy alone [91]. 
However, most of the photodynamic-related multimodality treatments are still studied 
in animal models [93]. There was one phase I clinical trial in which photodynamic 
therapy was combined with surgery. Twenty-six patients with mesothelioma received 
injection of photosensitizers before surgery. The toxicity mainly led to a systemic 
capillary leak syndrome, wound burns and skin photosensitivity. Fourteen patients 
showed no significant complications with maximally tolerated dose treatment. The trial 
demonstrated the feasibility of combination with surgery and photodynamic therapy 
and further estimation about efficacy is needed [94].  
2.3.6 Combination of gene therapy 
Gene therapy is defined by National Cancer Institute as a treatment that involves 
introducing genetic material (DNA or RNA) into a person’s cells to fight disease. Viral 
vectors have been used to deliver genes to tumor cells [95]. Gene therapy can be direct 
attack on tumor cells. Delivery of tumor-suppressor genes to cancer cells and 
successful expression of them, or delivery of antisense oligonucleotides or rebozymes 
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to block oncogene expression, will lead to cell death or growth inhibition. Additionally, 
delivery of suicide genes, which are enzyme-encoding genes for metabolizing a 
harmless prodrug, can activate prodrugs for cytotoxicity and lead to a bystander effect. 
Except for direct attack on tumor cells, gene therapy also aims to stimulate one’s 
immune response, target to prevent angiogenesis, or overcome the cell resistances and 
make cancer cells more sensitive to other therapies, such as chemotherapy and 
radiotherapy [96, 97]. Theoretically, gene therapy can combine with all the above 
therapies including chemotherapy, immunotherapy, hyperthermia therapy, 
anti-angiogenesis therapy and photodynamic therapy by targeting certain pathways of 
cancer cells and promote the efficacy of other therapies. 
Recently, a cutting edge is about RNA interference (RNAi) therapy involving 
microRNA (miRNA) and small interfering RNA (siRNA) (Figure 2.6). SiRNA is a 
21-23-oligonucleotide dsRNA that guides the ribonucleoprotein complex RISC to 
cleave target mRNA, leading to a reduction in the levels of mRNA and the 
corresponding protein [98]. It shows the potential of anti-cancer effect through 
inhibiting over-expressed oncogenes, blocking cell division and promoting apoptosis. 




Figure 2.6 The miRNA and siRNA pathways of RNAi in mammals. Figure taken 
from reference [100]. 
 
Currently, there are many clinical trials for gene therapy alone without combination 
with other therapies [101]. Many combination gene therapies are still studied at 
preclinical level. RNAi gene therapy has come to clinical trials but has not combined 
with other therapy modalities [100, 102]. One example of combination gene therapy 
was conducted on prostate cancer patients with herpes simplex virus-thymidine kinase 
(HSV-tk) gene delivery followed by the HSV-tk prodrug ganciclovir or valacyclovir. 
There are three separate clinical trials: trial A giving gene therapy in patients failing 
radiotherapy, trial B giving neoadjuvant gene therapy in pre-radical prostatectomy 
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patients, trial C giving gene therapy in combination with radiotherapy. The trials 
evaluated the systemic T-cell response. The result showed that there was increase of 
CD8
+
 T cells in all the treatments, however, trial C revealed significantly larger 
increase than trial A or B and it was the only trial to show increase in activated CD4
+
 T 
cells. It indicated that combination of radiotherapy and gene therapy increased the 
immune response [103].  
A phase I trial was conducted to combine TNFerade biologic, an adenoviral vector that 
expresses the human tumor necrosis factor- gene, with chemoradiotherapy in patients 
with locally advanced esophageal cancer. The result showed that such multimodality 
treatment is active and safe and is associated with long survival [104]. A similar phase 
I/II study with TNFerade biologic in combination with 5-fluorouracil and radiotherapy 
was performed in patients with locally advanced pancreatic cancer. It showed a 
tolerated toxicity with encouraging indication of activity [105]. 
A phase II trial was performed with a recombinant mutant adenovirus with an E1B 
55-kDa deletion, dl1520 (ONYX-015), in patients with liver tumors. It showed that 
combination of dl1520 and 5-fluorouracil, when infused into the hepatic artery, was 
well tolerated [106]. Besides, combination of dl1520 gene therapy with cisplatin and 
5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck 
showed that none of the responding tumors had progressed by 6 months; whereas all 
tumors treated with chemotherapy alone had progressed [107].  
A phase I clinical trial focused on the chemoprotection effect by transferring human 
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MDR1 gene to bone marrow cells in patients receiving high-dose chemotherapy and 
autologous stem-cell transplantation. Normal bone marrow cells showed little 
expression of MDR p-glycoprotein product and therefore susceptible to 
MDR-sensitive chemotherapy. Transplantation of MDR1 gene into them might 
increase the resistance to the combined chemotherapy. The trial indicated the 
feasibility and safety of such administration. Gene therapy here was considered as a 
modality to provide protective effect in combination with chemotherapy [108]. 
2.4 Nanotechnology for multimodality treatment of cancer 
2.4.1 Why nano? 
The development of nanotechnology and its application in medicine in recent decades 
show great potential in improving current status of cancer treatment. The 
nanomedicine enhances therapeutic effect of agents by formulating them into 
nanocarriers. Delivery of the therapeutic agents via nano delivery systems is dedicated 
to solving three main problems in traditional anti-cancer agents: their formulation in 
physiological environment; their accumulation in tumor; their adverse side effect in 
normal organs. Nanomedicine provides practical strategy for these problems and is 
able to achieve advanced anti-cancer effect owing to several reasons, which can be 
concluded as: 
 Prolonged blood circulation period;  
 High transportation efficiency; 
 Ligand conjugation for targeting; 
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 Sustained and controlled release of therapeutic agents; 
 Make-up to escape from multi-drug resistance (MDR) proteins; 
 Co-delivery of agents; 
The prolonged blood circulation period will be achieved via appropriate properties of 
nano delivery systems including size, surface charge and surface modification [109]. 
The size of therapeutic agents delivered by nanocarriers is enlarged from usually less 
than 1 nm for original drug molecules to 10-200 nm for the whole carriers, which is 
advantageous in avoiding the renal clearance and in leaking from the vessels into 
tumors through enhanced permeability and retention (EPR) effect. The slight charge of 
nano systems makes them stably dispersed in the blood and repels other molecules with 
the same electrical property. The PEGylation of nanocarriers, which means to modify 
the surface of nanocarriers with PEG, provides sterical hindrance to prevent 
aggregation as well as to escape from mononuclear phagocyte system (MPS) which is 
considered as the main mechanism of immune clearance to the nano delivery systems. 
Feng’s group has proved in vivo that one 10-mg/kg injection of a 
poly(lactic-co-glycolic acid) (PLGA) nanoparticle (NP) formulation of paclitaxel 
could sustain the drug concentration at the therapeutic window for 168 h compared 
with only 22 h for the same dose of Taxol
®
. The poly(lactide)-D--tocopheryl 
polyethylene glycol succinate (PLA-TPGS) NP formulation of docetaxel can do an 
even better job than Taxotere
®
, with 360 h of sustained therapeutic time compared with 
only 24 h for Taxotere
®
, and with an 8.11-times larger area under the curve [110, 111]. 
The long circulation period of the nano delivery system will help the therapeutic agents 
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accumulate in tumors through passive targeting and EPR effect [112]. 
Nano delivery systems also lead to high transportation efficiency for the therapeutic 
agents. They achieve higher cellular uptake than the naked therapeutic agents because 
they change the way that the cells take them by endocytosis. Endocytosis allows bulk 
therapeutic agents to pass through the cell membrane at a time through engulfing the 
nanocarriers. For example, in a current paper from Feng’s group, TPGS-cisplatin 
prodrug micelles showed 2.3-fold more efficient in cellular uptake than cisplatin and 
22.6-fold more efficient than cisplatin-PEG prodrug, which indicated the superiority of 
nano delivery system [113]. Besides, it has also been showed that there was an optimal 
size for the highest cellular uptake efficiency around 100 nm to 200 nm according to 
different materials, but not the bigger or the smaller the better [114]. 
The enrichment of functional groups and electrostatic interaction on the surface of 
nano delivery systems make it possible to conjugate ligands for targeting. Drug 
targeting has become an area of high interest, especially in the past decades when 
strategic progress has been made in pharmacodynamics - that is, to study what drugs do 
to our body or how drugs act at their targets. In the late 1990s, it was made clear that 
drugs interact with diseased cells through receptors, where they act either as agonists to 
mimic the action of neurotransmitters or to facilitate binding of endogenous 
neurotransmitters, or as antagonists to block access of transmitters to the binding  site. 
Although hundreds of drugs have been of use, surprisingly, they act on only a few 
different types of receptors and only 480 targets have been identified as of 1996. This is 
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an historic progress in medicine that triggered an intensive investigation on drug 
targeting. Various ligands, such as folic acids, peptides, sugar residues, aptamers, 
proteins and antibodies, have been found and applied to conjugates with the drug itself 
or the drug carrier for drug targeting [115]. Nanocarriers with targeting ligands will 
bind the receptors on cell surface and enter the cells via receptor-mediated endocytosis 
(RME), which will improve the cellular uptake efficiency significantly. Such 
conclusion has been demonstrated in many recent papers for targeting ligands such as 
folic acid, transferrin or herceptin [116-119]. 
The therapeutic agents, encapsulated in, conjugated to, or adsorbed on nanocarriers can 
be released at a desired rate over a sufficiently long duration by mechanisms such as 
diffusion and erosion, hydrolysis, degradation, swelling of the nanocarrier materials, or 
breaking of chemical bond triggered by pH/reduction-stimuli etc. The release profile of 
the agents in polymeric nanocarriers often suffers an initial burst release for powerful 
suppression of the tumor growth at the beginning, and then tends to be relatively gentle 
and sustained release for a long period [120]. The sustained and controlled release 
avoids rapid clearance and metabolism of the agents, and keeps the concentration of 
therapeutic agents above the minimum effective level. It provides the possibility that a 
single administration can lead to effective therapy lasting for days, weeks, or even 
months. In addition, the sustained and controlled release helps to keep the 
concentration of therapeutic agents below the maximal tolerant dose, which reduces 
the adverse side effect to certain degree.  
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MDR can be pharmacokinetic resistance due to the low availability of therapeutic 
agents at tumor site, or cellular resistance due to reasons such as the development of 
excretion transporters (e.g. P-glycoprotein), mutation of drug targets, up-regulation of 
anti-apoptotic modulators and activation of gene repair pathways, etc. Overexpression 
of P-glycoprotein (P-gp) is a main and direct reason to cause decreased agent 
accumulation. P-gp is a glycoprotein in cell membrane. It pumps the small therapeutic 
molecules out of cells by a mechanism that requires ATP. A variety of tissues have been 
found to express P-gp in an inducible form, e.g., in kidney, liver, small intestine, colon, 
uterine epithelium, and adrenal gland. The normal function of P-gp has not been firmly 
established, but it is well known that P-gp can cause the removal of toxic substances 
from the cells. Nano delivery systems, with their small size and appropriate surface 
coating, may have the ability to overcome the MDR problem and thus greatly improve 
the efficacy of the loading agents. Nanocarriers provide protection of the loading 
agents from transporter proteins and allow the agents to enter the cells through 
receptor-mediated endocytosis with bulky amount of molecules to antagonize the rapid 
elimination of free agents via the P-gp pump [121].  
Nano delivery systems also make it possible for co-delivery of bioactive agents for 
multimodality treatment. It will be discussed in details in the following parts.  
2.4.2 Why nanomedicine for multimodality treatment of cancer? 
Nanomedicine for multimodality treatment of cancer will take all the advantages of 
nano delivery systems mentioned above. In addition, it is also superior to the clinical 
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administration of different therapeutic agents in several aspects including: 
 Simultaneous delivery of agents to the active site; 
 Precise ratio control of the loading agents; 
 Overcoming MDR; 
Nano delivery system can simultaneously deliver different agents to the active site, 
which cannot be achieved by traditional medicine. Such simultaneous delivery is able 
to cause special interaction between the agents, which cannot be achieved by 
administrating different therapeutic agents separately. For example, anti-angiogenesis 
therapy may decrease vascular leakage and intratumor pressure, which will 
temporarily improve oxygenation, delivery of therapeutic agents and sensitivity to 
radiation and chemotherapy. However, such favorable change in tumor vasculature is 
transient [82]. Contrarily, long-term therapy with anti-angiogenesis agent may lead to 
insufficient delivery of therapeutic agents and increased resistance to chemotherapy 
owing to overexpression of hypoxia-inducible factor-1. Therefore, synergistic effect 
of anti-angiogenesis therapy in combination with chemotherapy/radiotherapy can be 
only achieved by simultaneous delivery of corresponding agents to a tumor.  
In traditional medicine, administration dose can be managed, but the dose at its active 
site cannot be precisely controlled. When we consider the situation of multimodality 
treatment, the problem becomes serious because it is well-known that there is an 
optimal ratio for therapeutic agents to achieve their best synergistic effect. 
Nanomedicine for multimodality treatment allows us to load different therapeutic 
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agents with exact ratio; more importantly the loading ratio can be sustained until they 
penetrate the membrane of cancer cells and reach their active site with the protection of 
nanocarriers. For example, Mi et al. has demonstrated that when combining docetaxel 
and cisplatin together in nanoparticles, all the formulations with different drug ratios 
showed enhanced anti-cancer effect than single administration of any of the two drugs 
at the same total drug concentration. However, there was an optimal ratio to achieve the 
highest cancer cell toxicity and the ratio could be quantitatively controlled by the 
nanoparticles [120]. 
It has been discussed that nano delivery systems are advantageous in make-up to 
escape from multi-drug resistance (MDR) proteins. Furthermore, nanomedicine for 
multimodality treatment of cancer is able to overcome MDR not only through the 
protection of nanocarriers but also through down-regulating some MDR related 
proteins. MDR inhibitors, such as small interfering RNAs, mainly involve two 
mechanisms including down-regulation of excretion transporters, such as P-gp or 
MRP-1 proteins, or down-regulation of cellular anti-apoptotic proteins, such as Bcl-2 
protein. Except for the inherent property of nano delivery systems for overcoming 
MDR, co-delivery of these anti-MDR agents together with other chemotherapeutic 
agents in one nano delivery system will help to overcome MDR more. Currently, there 
was an editorial about siRNA-based nanomedicine [122] and an example of 
co-delivery of doxorubicin and P-gp siRNA in silica nanoparticles [123], in which the 
mechanisms of overcoming MDR by nanomedicine for multimodality treatment was 
discussed in detail.  
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2.4.3 Examples of nanomedicine for multimodality treatment of cancer 
Nano delivery systems provide a useful tool for that. An important example was 
reported in Nature 2005. Before that, few papers showed the advantages of 
combination therapy in the same nano delivery system. Sengupta et al. has 
demonstrated the superiority with phospholipid coated Doxorubicin-PLGA conjugated 
nanoparticles loaded with combretastatin A4. It showed that the tumor growth 
inhibition efficiency of these nanoparticles was not only higher than that of 
monotherapy with single agent-loaded nanoparticles, but also higher than that of 
separate administration of doxorubicin-loaded nanoparticles and combretastatin 
A4-loaded nanoparticles [124].  
After the specific advantages of nanomedicine for multimodality treatment were 
demonstrated in this nature paper, a lot of multimodality treatment using 
nanotechnology was reported. For example, Jaemoon Yang et al. developed 
multifunctional magneto-polymeric nanohybrids by encapsulating doxorubicin and 
magnetic nanocrystal into amphiphilic block copolymer and conjugating herceptin to 
the surface. The herceptin-modified nanoparticles showed ultrasensitive targeted 
detection by MRI and excellent synergistic effects for the inhibition of tumor growth 
[125]. 
Sun et al. synthesized a triblock copolymer, poly(ethylene 
glycol)-b-poly(ε-caprolactone)-b-poly(2-aminoethyl ethylene phosphate) 
(mPEG-PCL-PPEEA), micelleplex to deliver paclitaxel in PCL the core and polo-like 
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kinase 1 specific siRNA at the cationic PPEEA shell for a combination of 
chemotherapy and gene therapy. The result revealed both in vitro and in vivo that 
micelleplex is capable of delivering siRNA and paclitaxel simultaneously to the same 
tumor cells. A synergistic tumor suppression effect was induced in the MDA-MB-435s 
xenograft murine model and 1000-fold less paclitaxel was needed compared with that 
needed in monochemotherapy [126]. 
Lammers et al. developed copolymers of N-(2-hydroxypropyl)methacrylamide 
(HPMA) to form liposomes and simultaneously delivered doxorubicin and 
gemcitabine. As compared to control regimens, the multimodality liposomes increased 
the efficacy of the combination of gemcitabine and doxorubicin without increasing its 
toxicity, and it more strongly inhibited angiogenesis and induced apoptosis [127]. 
Huang et al. designed dtACPP decorated dendrigraft poly-L-lysine (DGL)-PEG, 
dtACPP-PEG-DGL (dtACPPD), nanoparticles, in which dtACPP was an activatable 
cell-penetrating peptide that is dual-triggered by the lowered tumor extracellular pH 
and metalloproteinase 2. Doxorubicin (DOX) was used as chemotherapeutic agents 
and intercalated into a double helix of DNA, shVEGF as anti-VEFG agent, to form a 
plasmid-DOX complex, shVEGF-DOX. The condensed nanoparticles, 
dtACPPD/shVEGF-DOX, were formed through electrostatic interactions between 
cationic DGL and negatively charged plasmid shVEFG for combination of 
chemotherapy and genetic anti-angiogenesis therapy. Its anti-tumor efficacy was 
evaluated in glioma-bearing mice with median survival time of 58.5 days, compared 
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with 24.0 days for control, 27.0 days for free DOX, 29.0 days for shVEGF, 38.0 days 
for dtACPPD/shVEFG, and 35.0 days for dtACPPD/DOX, indicating a promising 
anti-tumor efficacy for the multimodality treatment [128]. 
Wang et al. developed targeted polymeric micelles with vβ3 integrin-targeting 
peptide conjugated PEG-PLA to combine anti-angiogenesis therapy and chemotherapy. 
Chemotherapeutic agent, doxorubicin, was conjugated to PEG-PLA and 
anti-angiogenesis agent, combretastatin A4, was loaded into micelles. In B16-F10 
tumor-bearing mice, it could be concluded from both tumor volumes and survival times 
that combination of chemotherapy and anti-angiogenesis therapy in targeted polymeric 
micelles showed stronger tumor growth inhibition and significantly higher survival 
rate compared with the corresponding monotherapy groups [129].  
More examples will be concluded in the next section. 
2.5 Approaches of nanomedicine for multimodality treatment of cancer 
2.5.1 Polymeric nanoparticles 
Polymeric nanoparticles are usually prepared with biodegradable polymers. They are 
formed through the entangling of polymers into a dense structure with thermodynamic 
stability in aqueous solvent. They are used as delivery carriers due to their tunable size, 
high loading efficiency, easily functionalized surface, high biocompatibility and 
bioavailability. Many biodegradable polymers are synthesized recent years including 
the FDA approved ones, such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) 
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(PLGA) and poly(caprolactone) (PCL). They show several deficiencies including too 
much hydrophilicity for encapsulation of hydrophilic drugs and two much mechanical 
strength for desired release of the encapsulated agents. PEGylated copolymers are 
developed to modify their amphiphilicity, reduce the degradation rate, improve the 
performance and increase the biocompatibility [130], such as PLA-PEG, PLGA-PEG 
and PLA-TPGS. Among them, TPGS as a PEGylated vitamin E showed advantages of 
both PEG and vitamin E including extending the half-life of the drug in plasma, 
enhancing the cellular uptake of the drug, overcoming multidrug resistance, inhibiting 
P-glycoprotein and promoting anti-cancer effect [131, 132]. As multimodality 
treatment vehicles, polymeric nanoparticles could load agents in their core or be coated 
with the agents on the surface by chemical conjugation or physical adsorption. 
Compared with other delivery systems, such as micelle or liposomes, polymeric 
nanoparticles show higher stability in aqueous solvent and more desirable controlled 
release due to their dense structure.  
Wang and colleagues encapsulated doxorubicin and paclitaxel in methoxy 
poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) nanoparticles by 
double emulsion method for combination chemotherapy.  Cell viability of A549, 
HepG2 and B16 cancer cells showed that co-delivery of the drugs had better 
anti-cancer effect than the delivery of either one at the same concentrations. Besides, 
the co-delivery nanoparticles achieved the highest anti-cancer effect with a 
doxorubicin versus paclitaxel concentration ratio of 2:1 [133]. The same group further 
developed positively charged nanoparticles with mPEG-PLGA and ε-polylysine (EPL) 
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blends to co-deliver doxorubicin and paclitaxel in the core via double emulsion and 
survivin siRNA on the shell via absorption. The tumor inhibition effect in B16-F10 
melanoma-bearing mice was significantly improved compared with the monotherapy 
or dual-therapy, formulated by nanoparticles or not. Such multimodality treatment also 
showed low to no toxic effects on the major organs [134]. The conclusion was also 
proved in another work from the same group in which Ho’s group designed PLGA 
nanoparticles with RGD peptide-modified surface and encapsulated paclitaxel and 
combretastatin A4 in the polymeric core for combination of chemo- and 
anti-angiogenesis therapy. The tumor growth inhibition was evaluated in B16-F10 
tumor-bearing mice and it showed that tumor growth was significantly inhibited by the 
RGD targeted dual-modality therapy nanoparticles from day 8, and from day 10 by the 
non-targeted dual-modality therapy nanoparticles. There was discernable but 
insignificant tumor growth inhibition for the two corresponding targeted single 
modality nanoparticles [135]. The conclusion was further proved in another work of 
this group in which pacitaxel was conjugated to mPEG-PLA with ester bond and 
combretastatin A4 was encapsulated in the core [136].  
Chang and colleagues developed mitoxantrone (MTO, anti-cancer drug)-conjugated 
palmitoleic acid cationic nanoparticles for Mcl-1-specific anticancer siRNA 
complexation. In vitro result revealed a reduced KB cell viability by 81% compared to 
a reduction of 68% through lipofectamine 2000-mediated transfection of siMcl-1. In 
vivo result in KB-bearing mice represented a reduced tumor size by 83% compared to 
untreated controls [137]. Fan et al. designed and prepared the tumor necrosis 
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factor-related apoptosis-inducing ligand-encoding plasmid gene (pTRAIL) condensed 
PEI-β cyclodextrin (PEI-CD)/adamantine-doxorubicin (Ad-Dox) nanoparticles. The 
survival rate of SKOV-3-bearing mice was 70% for the multimodality treatment 
group, while was 10% for the PEI-CD/Ad-Dox group and 30% for the 
PEG-CD/pTRAIL group. The result demonstrated the excellent effectiveness of this 
system in inhibiting tumor growth in vivo [138].  
Lai’s group synthesized TPGS coated 4-armed porphyrin-poly(lactic acid) (PPLA) 
nanoparticles to load doxorubicin for both photodynamic therapy and chemotherapy. 
TPGS could decrease the P-glycoprotein activity and increase the intracellular 
accumulation doxorubicin, therefore used to improve the efficacy of the nanoparticles. 
The result showed that the combination system achieved synergistic effect by testing 
the reduction of cancer cell survival and analyzing the combination index [139]. Conte 
et al. developed amphiphilic block copolymer nanoparticles based on 
poly(ε-caprolactone)-poly(ethylene oxide) (PEO), PEO-PCL or PEO-PCL-PEO, to 
delivery chemotherapeutic agent docetaxel and photosensitizer zinc-phthalocyanine 
(ZnPc). The 72 h nanoparticle cytotoxicity, evaluated in HeLa cells, strongly decreased 
as compared to nanoparticles loaded only with docetaxel. Tumor growth, carried out in 
A375-bearing mice, was significantly slower in the group treated with the 
docetaxel/ZnPc multimodality treatment than that in animals receiving free docetaxel 
treatment or docetaxel loaded nanoparticles treatment without loading of ZnPc [140]. 
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2.5.2 Polymeric micelles 
Polymeric micelles are composed of amphiphilic polymers with the hydrophilic ‘head’ 
regions in contact with surrounding solvent and the hydrophobic single-tail regions in 
the micelle core. Compared with other delivery systems, micelles show technical ease, 
high biocompatibility and high efficiency in drug delivery. They also show advantages 
in passively targeting tumor area through enhanced permeability and retention (EPR) 
effect, due to their small size ranging from 10 nm to 100 nm. Prolonged circulation 
time in blood could be achieved because of the small scale of micelles as well as the 
steric hindrance caused by the presence of hydrophilic shells. The application of 
micelles in drug delivery often achieves favorable biodistribution, higher therapeutic 
effects and lower side effects for the delivered therapeutic agents. Multimodality 
treatment could be achieved with micelles via loading hydrophobic therapeutic agents 
in their cores or via conjugating/electrostatically adsorbing the hydrophilic therapeutic 
agents to their shells. 
Cho and colleagues delivered multi-drugs for combinatory chemotherapy with 
poly(ethylene glycol)-b-poly(ε-caprolactone) micelles. The micelles loaded with 
paclitaxel, cyclopamine and gossypol showed significantly reduced tumor volume and 
prolonged survival over paclitaxel alone in ES-2 and SKOV3 xenograft models [141]. 
Another three-in-one micelles loading paclitaxel, 
17-allylamino-17-demethoxygeldanamycin (17-AAG) and rapamycin were developed 
by Shin et al. with poly(ethylene glycol)-b-poly( D, L-lactic acid) (PEG-b-PLA). The 
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micelles exerted strong synergy in MCF-7 and 4T1 breast cancer cells by analyzing 
their combination index [142]. 
Zhao and colleagues developed a herceptin-conjugated TPGS immunomicelle for 
co-delivery of docetaxel and siPlk1. SiPlk1 was conjugated to TPGS via disulfide bond, 
and docetaxel was encapsulated inside the hydrophobic micelle core. The loading ratio 
of the two agents was precisely controlled and the release of agents could be triggered 
by intracellular glutathione. The IC50, which is the drug concentration needed to kill 50% 
of the cancer cells in a designated time period, was 1.72, 0.042, 0.0032 and 0.000671 
mg/mL for SK-BR-3 cells after 24 h treatment by Taxotere, docetaxel formulated in the 
TPGS micelles, TPGS-siPlk1/TPGS micelles, and the herceptin-conjugated 
TPGS-siPlk1/TPGS micelles, respectively. The docetaxel encapsulated TPGS micelle 
with surface conjugated siPlk1 achieved much better efficacy than the docetaxel 
encapsulated TPGS micelle without siPlk1 on breast cancer cell lines [143]. Zheng et 
al. co-delivered docetaxel and siRNA-Bcl-2 with poly(ethylene 
glycol)-b-poly(L-lysine)-b-poly(L-leucine) (PEG-PLL-PLLeu) cationic micelles for 
multimodality treatment. The hydrophobic PLLeu core loaded the hydrophobic drugs, 
while the PLL polypeptide cationic backbone electrostatically adsorbed the negatively 
charged siRNA. The micelles showed obvious down-regulation of the anti-apoptotic 
Bcl-2 gene and significant enhancement of anti-cancer effect compared to siRNA or 
docetaxel alone in MCF-7 xenograft murine model [144]. Hu and colleagues 
developed supramolecular micelles self-assembled from 
poly(ethylenimine)-β-cyclodextrin with adamantine conjugated paclitaxel 
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encapsulated in core and shRNA sticked to the shell surface. In vitro study revealed that 
paclitaxel and shRNA simultaneously delivered to SKOV-3 cells, down-regulated the 
expression of surviving and Bcl-2 expression, and caused synergistic cell apoptosis. It 
also showed on mice bearing SKOV-3 xenografts that the inhibition rate of the 
combination group was about 3.5 fold of that of the free paclitaxel group [145]. 
Peng et al. synthesized amphiphilic 4 armed star-shaped chlorine-core poly(ethylene 
glycol)-b -poly(ε-caprolactone) diblock copolymer (CSBC) to form paclitaxel-loaded 
micelles for combination of photodynamic therapy and chemotherapy. The star-shaped 
chlorine-core copolymers were considered as photosensitizers as well as materials for 
drug delivery system. The in vitro result on MCF-7 breast cancer cells showed that the 
cell inhibition increased from 35% by paclitaxel alone to 62% by paclitaxel plus 
photodynamic therapy at 7 J/cm
2
 light irradiation. Besides, delivery of paclitaxel by 
this photodynamic therapy-functionalized drug carrier improved the cytotoxicity of 
paclitaxel synergistically with a combination index value below 0.8 [146]. In another 
work, CSBC micelles were used to encapsulate 7-ethyl-10-hydroxy-camptothecin, as 
chemotherapeutic agent, for multimodality treatment. The combined effects were 
assessed in an HT-29 human colon cancer xenograft, which showed synergistic effect 
between chemotherapy and photodynamic therapy with 60% regression of 
well-established tumors; while for monotherapy there was no complete response after 




Liposomes are vesicles composed of lipid bilayers with water in their interior. They are 
a mimic of cell membrane and one of the earliest FDA approved drug delivery systems 
due to their high biocompatibility. Hydrophilic agents could be loaded in their aqueous 
interior, while hydrophobic agents are embedded into the lipid bilayers. Further 
modification with PEG or targeting ligand or agent loading can be occurred on the 
surface of liposomes. Compared with polymeric micelles or nanoparticles, liposomes 
showed advantages in loading both hydrophilic and hydrophobic agents, especially 
with high loading efficiency for hydrophilic ones. However, liposomes suffer many 
problems such as too big size, low stability of structure, low loading efficiency and 
undesired release profile compared with other delivery systems. To improve the 
performance of liposomes, polymeric liposomes are developed with better stability, 
desirable controlled release as well as functional group for further decoration. 
Zucker et al. co-encapsulated the vincristine and topotecan in the nanoliposomes which 
were composed of Phospholipon 100H, cholesterol and PEG-DSPE2k. The necrosis 
area after different treatments in tumor-bearing mice was evaluated. Treatment with the 
free drugs resulted in 29% of tumors with necrosis, while for liposomal vincristine and 
liposomal topotecan the response rate was 43% and 38%, respectively. Treatment with 
liposomes containing both of the drugs leaded to appearance of necrosis in almost all 
the tumors (91% response), indicating significantly improvement in efficacy [148].  
Zhang and colleagues encapsulated doxorubicin and combretastatin A4 together in 
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Arg-Gly-Asp (RGD) modified liposomes composed of DSPE-PEG, DSPE-PEG-RDG, 
cholesterol and egg phosphatidylcholine, in which combretastatin A4 was incorporated 
into the lipid bilayer membrane and doxorubicin was loader into the inner phase of the 
liposomes. The release rate of doxorubicin was proved to be much slower than that of 
combretastatin A4 in vitro. The RGD modified liposomes with both doxorubicin and 
combretastatin A4 showed the highest efficacy for tumor growth inhibition in B16-F10 
tumor-bearing mice, compared with the groups of RGD-modified liposomal 
doxorubicin or RGD-modified liposomal combretastatin A4 or co-encapsulated 
liposomes without RGD modification [149].  
Kang et al. encapsulated MEK inhibitor in lipid bilayers of 
N’,N’’-dioleylglutamide-based (DG) cationic liposomes (DGL) and complexed 
Mcl1-specifice siRNA (siMcl1) to the liposomes. The liposomes were composed of 
dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), DG and cholesterol. 
Co-delivered liposomes successfully reduced expression of Mcl1 and pERK1/2 
proteins and effectively reduced tumor cell survival in vitro than other treatments with 
single-agent liposomal delivery. In KB tumor-xenografted mice, at 17 days after tumor 
inoculation liposomal siMcl1 suppressed tumor size by 47%, while co-delivery of 
MEK inhibitor and siMcl1 suppressed tumor size by 79% [150]. Wang et al. developed 
liposomes with EPC, cholesterol and DSPE-PEG for co-delivery of doxorubicin and 
antisense oligonucleotides (ASO) targeted to hypoxia-inducible factor 1  (HIF1A) 
mRNA as a suppressor of cellular resistance and angiogenesis. Mice bearing 
A2780/AD human multidrug-resistant ovarian cancer were evaluated. The apoptosis 
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induction by the liposomal doxorubicin-ASO combination was 4-fold and more than 
1.5-fold higher than that by free doxorubicin and liposomal doxorubicin, respectively. 
Beside, Co-delivery of doxorubicin and ASO in one liposomal system was 
significantly more effective in the induction of apoptosis and tumor shrinkage when 
compared with liposomal doxorubicin and liposomal ASO delivered separately in 
different liposomal systems. Simultaneous delivery of the agents also decreased the 
adverse side effects of heart and liver than the free doxorubicin or co-agents delivered 
separately. The result showed that delivery of APO prevented the development of 
resistance by down-regulating BCL2, HSP90, vascular endothelial growth factor 
proteins, and therefore enhanced the efficacy of chemotherapy to an extent that cannot 
be achieved by individual components applied separately [151]. Ko and colleagues 
constructed cationic liposomes loaded with the proapoptotic peptide, D-(KLAKLAK)2, 
and the Bcl-2 antisense oligodeoxynucleotide, G3139, for multimodality treatment. 
The peptide was first condensed with the G3139 to obtain negatively charged 
complexes which were then entrapped into DOTAP/DOPE cationic liposomes. 
Treatment of B16-F10 tumor-bearing mice with the liposomes loaded with the 
peptide/G3139 led to significant tumor growth inhibition of 60% as compared to that of 
34% for the treatment with the liposomes loaded with G3139 alone. The result showed 
that liposomal combination of proapoptotic peptide and gene therapy led to 
significantly enhanced antitumor efficacy [152]. Chen’s group simultaneously 
delivered doxorubicin and Msurvivin T34A plasmid with truncated human basic 
fibroblast growth factor (tbFGF) peptide-mediated cationic liposomes composed of 
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DOTAP and cholesterol. The IC50 of such co-delivery system in the Lewis lung 
carcinoma (LLC) cells was 3-fold lower than that of the free doxorubicin. In 
LLC-bearing mice, the average tumor volume was decreased by 80% after 18 days of 
treatment with the co-delivery system, whereas it was decreased by 70% with 
liposomal doxorubicin and 41% with Msurvivin T34A, indicating such system was 
efficient to simultaneously deliver drugs and DNA [153].  
2.5.4 Nanohydrogels 
Nanohydrogels are 3D networks of cross-linked hydrophilic polymers with high water 
content and with size usually less than 200 nm. They combine the advantages of 
hydrogels and nanoparticles for drug formulation and delivery. The cross-linking of 
nanohydrogels is either through physical interaction such as hydrophilic-hydrophobic 
interactions, electrostatic interactions or hydrogen bonding, or through chemical 
interaction with covalent bond [154]. The swelling of nanohydrogels in aqueous 
environment is determined by type of polymers, degree of cross-linking and external 
environment [155]. According to the different types of polymers, they could respond to 
external environmental change such as the change of pH or temperature to achieve 
stimuli-controlled release. Nanohydrogels are promising in delivery of therapeutic 
agents for multimodality treatment, especially for hydrophilic biomolecules such as 
peptides, proteins and oligonucleotides. They show high biocompatibility due to their 
high water content [156, 157]. 
Few examples of nano-sized gels have been developed for multimodality treatment till 
54 
 
now. Thayumanavan’s group currently proposed polymeric nanogels to co-deliver 
lipophilic small molecules and proteins, which showed great potential for combination 
cancer treatment. In details, the nanogels were prepared from a random copolymer 
synthesized with a hydrophilic oligo(ethylene glycol) methacrylate and a lipophilic 
methacrylate monomer containing a pyridyldisulfide (PDS) moiety. The hydrophobic 
small molecules could be encapsulated via self-assembly of the polymer and stabilized 
by cross-linking of thiol-disulfide among the PDS units with dithiothreitol. The 
residual PDS moieties after cross-linking were conjugated with Cys-Arg-Arg-Arg 
tri-arginine moiety which could provide positively charged surface of the nanogels and 
conduct cell-penetration as targeting ligand. The positively charged surface could then 
load negatively charged proteins for co-delivery. The nanogels showed efficient cell 
uptake [158]. In addition, Zhao et al. fabricated nano-scale gels with glycol chitosan 
and benzaldehyde terminated poly(ethylene glycol)-block-poly(propylene 
glycol)-block-poly(ethylene glycol) (OHC-PEO-PPO-PEO-CHO), cross-linked by the 
increase of pH. The gels were used to co-deliver paclitaxel and doxorubicin. They 
showed significant prolongation of the survival rate in B16-F10 tumor-bearing mice 
[159]. 
2.5.5 Dendrimers 
Dendrimers are symmetrical and spherical macromolecules, exhibiting tree-like 
structure with numerous dendritic arms stretching from a core. Number of branching 
shell is denoted as generation (G). Compared with other delivery system, they often 
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show advantages in size uniformity, rapid cellular entry, reduced macrophage uptake, 
target ability and more facile passage across biological barriers by transcytosis [160, 
161]. Their reactive surface with abundant functional groups makes them easier to load 
different therapeutic agents efficiently through conjugation. Meanwhile, their interior 
shows solvent-filled void space for drug encapsulation. Therefore, they are promising 
nano delivery system for multimodality treatment. 
Han et al. reported to use peptide HAIYPRH (T7)-conjugated polyethylene 
glycol-modified poly(amido amine) G5 dendrimers (PAMAM-PEG-T7) for 
co-delivery of doxorubicin (DOX) and therapeutic gene encoding human tumor 
necrosis factor-related apoptosis-inducing ligand (pORF-hTRAIL). T7 was chosen as 
targeting ligand for transferring receptor. DOX-DNA complex was formed first and 
loaded into the dendrimers via electrostatic interactions. On day 22 after treatment, 
mice bearing Bel-7402 xenografts treated with DNA-DOX-loaded T7-dendrimers 
showed decrease of tumor volume by 77.09% compared to control group, while 
DOX-loaded T7-dendrimers, DNA-loaded T7-denfrimers inhibited tumor growth by 
41.49% and 46.89% at the same dose, respectively, demonstrating the advantages of 
combination of chemotherapy and gene therapy [162]. Lee and colleagues applied 
PAMAM G4 dendrimers as nanocarriers to conjugate with single-stranded CpG 
oligonucleotides as immune-stimulating agents (sONT-DEN). A9 RNA aptamers 
targeted to prostate-specific membrane antigen were hybridized with the sONT-DEN 
to create double-stranded oligonucleotide-conjugated dendrimers (Apt-dONT-DEN). 
Doxorubicin was then intercalated into the base pairs of dONTs 
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(DOX/Apt-dONT-DEN). The dONTs functioned as both loading sites for doxorubicin 
and immune-stimulating agents. In vitro experiment demonstrated that the system 
successfully induced immune response as valid immune adjuvant. The anti-tumor 
effect of this chemo-immuno multimodality treatment was evaluated in 22RV1 
tumor-bearing mice. The DOX/Apt-dONT-DEN group showed higher tumor growth 
inhibition than the Apt-dONT-DEN group or the DOX/dONT-DEN group, and even 
better than the free doxorubicin group with 4 times higher dose [163]. 
2.5.6 Solid lipid nanoparticles 
Solid lipid nanopraticls (SLNs) are a class of lipospherical nanocarriers with average 
diameter between 10-1000 nm, formed with lipids which remain in a solid state at 
room temperature and body temperature. They combine the advantages of liposomes 
and polymeric nanoparticles, and show high stability in physiological environment. 
Their preparation processes usually do not need to induce toxic organic solvents. They 
can load both hydrophilic and hydrophobic agents, especially showing advantages in 
proteins or peptides delivery. They also show good potential for large scale production 
[164, 165].  
Bae et al. reported apolipoprotein E-free low-density lipoproteins (LDL)-mimic solid 
lipid nanoparticles with core/shell structure, where cholesteryl, oleate and triglyceride 
were embedded in an amphiphilic shell of DOPE, DSPE-PEG, cholesterols and 
DC-chol. Paclitaxel and QDs were co-encapsulated within the core of SLNs (PQSLNs) 
and Bcl-2 siRNA were complexed with their cationic surface via electrostatic 
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interactions. The platform could achieve both in situ fluorescence imaging and 
synergistic anti-cancer effect by combination of chemo- and gene therapy. The cell 
viability test showed that suppressing of Bcl-2 protein alone with QSLN/Bcl-2 caused 
no significant cytotoxicity; treating with PQSLN alone decreased cell viability by 
30.9%; treating with PQSLN/Bcl-2 siRNA complexes decreased cell viability by70.8%. 
The IC50 of PQSLN/Bcl2 siRNA was 20 times lower than that of Taxol. The CI value of 
PQSLN/Bcl-2 siRNA was smaller than 0.5. It also showed that the platform 
synergistically promoted the apoptotic death of cancer cells by activating 
caspase-mediated pathways [166]. Sutaria et al. encapsulated aspirin (ASP) and 
curcumin (CUR) into the solid lipid nanoparticles composed of stearic acid and utilized 
the dual-drug SLN (ACS) together with free sulforaphane for the chemoprevention of 
pancreatic cancer. Cell viability studies in MIA PaCa-2 and Panc-1 cells demonstrated 
that combination of low doses of the drugs significantly reduced cell viability by 43.6 
and 48.49%, respectively, which showed the superiority of the multimodality treatment 
to the individual treatment [167].  
2.5.7 Inorganic nanoparticles 
Apart from the above organic delivery systems, mainly composed of polymers or lipids, 
there are other types of delivery systems composed of inorganic materials, including 
carbon nanotubes or graphene oxide, gold nanoparticles, and magnetic nanoparticle 
such as iron oxide nanoparticles. They are studied as nano delivery systems for 
multimodality treatment of cancer due to their unique photo or thermal properties. 
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Silica nanoparticles are also utilized as nanocarriers due to their high stability, high 
biocompability, high uniformity as well as fabrication and modification ease. These 
nano-sized particles are able to load other therapeutic agents via physical interaction or 
co-valence bond for multimodality treatment.  
Carbon nanotubes or graphene oxide are able to deliver therapeutic agents as well as to 
generate fatal heat upon NIR irradiation. Once they are uptaken by the cells, they may 
also interact with proteins and DNA to affect the cellular signaling or mechanism of 
other therapies. For example, Mahmood et al. applied single-wall carbon naotubes 
(SWNTs) as delivery vehicles for etoposide delivery. Carbon nanotubes were 
considered as anti-cancer agents and their toxicity were studied. They were showed to 
initiate the apoptotic cascade via caspase pathways and interfere with resistance 
mechanisms at this level, therefore led to increased anti-cancer effect in combination 
with etoposide, compared with the lower efficacy of etoposide or SWNTs alone [168]. 
Wang et al. synthesized polyethylenimine (PEI)-conjugated SWNTs and bound with 
DSPE-PEG2000-Maleimide for further conjugation with the tumor targeting NGR 
(Cys-Asn-Gly-Arg-Cys-) peptide. Such delivery system was then loaded with hTERT 
siRNA as SWNT-PEI/siRNA/NGR for combination of gene and photothermal therapy. 
The system exhibited highest anti-tumor effect under NIR laser irradiation in PC-3 
tumor-bearing mice without obvious toxicity in main organs, compared with the single 
treatment with siRNA or SWNT or the combination treatment without targeting ligand 
[169]. The same group also loaded docetaxel via pi-pi accumulation onto the NGR 
conjugated-SWNTs for combination of chemo- and photothermal therapy. The 
59 
 
therapeutic efficiency of docetaxel was enhanced through near-infrared 
irradiation-mediated tumor destruction by the photothermal effect on the carbon 
nanotubes [170]. Zhang et al. made doxorubicin-laded PEGylated nanographene oxide 
(NGO-PEG-DOX) to co-deliver drug and heat to the tumorigenic region for 
multimodality treatment. Comparing the effect of tumor inhibition treated with free 
doxorubicin, NGO-PEG with NIR and NGO-PEG-DOX with NIR in EMT6 
tumor-bearing mice, it showed that combining chemotherapy with photothermal 
therapy with NGO-PEG-DOX was superior to chemotherapy or photothermal 
treatment alone. Beside, the delivery platform also reduced the side effects of 
doxorubicin according to the systematic toxicity study [171]. 
Gold nanoshells, nanoparticles or nanorods can generate localized heat to destroy 
cancer cells by absorbing near-infrared radiation (NIR). Therefore they are used as 
photothermal agents as well as nano delivery vehicles together with other therapeutic 
agents for combination cancer treatment. For example, You et al. loaded doxorubicin 
into hollow gold nanospheres coated with polyethylene glycol for combination of 
chemotherapy and thermotherapy. Doxorubicin was loaded through electrostatic 
interaction and released through photothermal triggered release. Treatment with the 
platform followed by NIR laser irradiation was demonstrated with significantly greater 
anti-cancer effect than treatment with the platform alone without NIR irradiation, with 
free doxorubicin or with liposomal doxorubicin [172]. Huang et al. synthesized gold 
nanorods with cysteine-containing elastin-like polypeptides to load heat-shock protein 
(HSP) 90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin (17-AGG). The gold 
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nanorods-polypeptides led to hyperthermia and cancer cell death by laser irradiation. 
HSP90 inhibitor could reduce the resistance of cells to hyperthermia and enhance the 
efficacy. The result showed that combination of gold nanorods thermotherapy and 
release of 17-AGG, both induced by laser irradiation, led to significant death of cancer 
cells than treatment with hyperthermia alone or 17-AGG alone [173]. Kuo et al. used 
gold-poly(styrene-alt-maleic acid) (PSMA) nanorods or gold polyethylenimine (PEI) 
nanoparticles to conjugate with hydrophilic photosensitizer, indocyanine green (ICG), 
for combination of photodynamic therapy and photothermal therapy. Their synergistic 
effect was demonstrated on A549 malignant cells [174]. 
Magnetic nanoparticles, such as superparamagnetic iron oxides, are another type of 
commonly used agents for thermotherapy. They can generate localized heat to destroy 
cancer cells under exposure to an alternating magnetic field. Barick et al. developed 
peptide mimic shell cross-linked magnetic nanocarriers (PMNCs) with high density of 
amine and carboxyl groups on the shell for conjugation of doxorubicin. The system 
showed a pH trigged release. Cytotoxicity evaluated on HeLa cells showed about 10% 
decrease in cell viability for treatment with doxorubicin, about 10% decrease with 
doxorubicin-PMNCs, 13% decrease with PMNCs in the presence of AC magnetic field, 
and 28% decrease with doxorubicin-PMNCs in the presence of AC magnetic field, 
indicating a good potential of this platform for multimodality treatment [175]. Xu et al. 
made graphitic carbon-coated iron magnetic nanoparticles to stack anti-cancer drugs, 
doxorubicin or erlotinib, onto the carbon shell. The nanoparticles produced heat to kill 
cancer cells when radio frequency applied. The drugs can be released either by radio 
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frequency heating stimuli or by pH stimuli. The multimodality treatment showed 
enhancement on the efficacy, especially for doxorubicin efficiency with a 3.5 fold 
increase in cellular death in pancreatic cancer cells [176].  
Silica-based nanoparticles are versatile for loading both hydrophobic and hydrophilic 
therapeutic agents, or they are connection for organic and inorganic materials. 
Therefore they are also frequently used to form nano delivery system for multimodality 
treatment. For example, Chen et al. proposed a controllable F
-
 ion-assisted etching 
strategy to develop the inorganic mesoporous silica nanocapsules (IMNCs). The 
nanocapsules contained hollow core interior for hydrophobic agents and mesoporous 
shell for hydrophilic agents. Dual drugs, camptothecin and doxorubicin, were 
co-delivered by these nanocapsules. The cytotoxicity of dual-drug-loaded IMNCs 
evaluated in doxorubicin-resistant MCF-7/ADR cancer cells is 62.8%, much higher 
than 21.7% of free doxorubicin and 47.3% of doxorubicin-loaded IMNCs [177]. Meng 
et al. reported phosphonate functionalized mesoporous silica nanoparticles (MSNPs) 
for co-delivery of doxorubicin and P-gp siRNA. The phosphonate group on MSNPs 
allowed electrostatic binding of doxorubicin to the porous interior, and also allowed 
exterior coating with polyethylenimine for P-gp siRNA complexing. The particles 
achieved a pH triggered drug release. Cytotoxicity in KB-V1 cells showed the rank of 
anti-cancer efficiency as follows: 
siRNA-PEI-Dox-MSNPs>PEI-Dox-MSNPs≈Dox-MSNPs>free Dox. The IC50 of the 
co-delivered MSNPs was about 2.5 times lower than that of free Dox or other 




Liu et al. combined chemotherapy and photothermal therapy by docetaxel-loaded 
PEGylated gold nanoshells on silica nanorattles (pGSNs+DOC). The gold nanoshells 
were used as NIR-adsorbing agents for thermotherapy. The in vivo experiments in H22 
tumor-bearing mice revealed that with a near-infrared light exposure for 3 minutes after 
injection of the nanoparticles for 6 h, the group treated with pGSNs+DOC showed an 
average tumor inhibition rate of 85.4% which was higher than that of 57.4% for the 
group treated with Taxotere
®
 alone. The nano platform also reduced the systematic 
toxicity of Taxotere
®
 [178]. The same group further improved the anti-cancer effect of 
this platform by conjugating transferring on it as targeting ligand. Its efficacy was 
demonstrated in MCF-7 cells and MCF-7 tumor-bearing mice [179]. Shen and 
colleagues developed doxorubicin-loaded mesoporous silica-encapsulated gold 
nanorods (DOX-GNRs@mSiO2) for combination of chemotherapy and photothermal 
therapy. Near-infrared illumination led to the photothermal effect of GNRs@mSiO2 
and the light-triggered release of doxorubicin. The authors demonstrated the 
synergistic effect of the combined treatment and low systematic toxicity of the delivery 
platform in A549 tumor-bearing mice [180]. Ma et al. reported a similar platform of 
doxorubicin-loaded mesoporous silica-encapsulated iron oxide nanoparticles with gold 
nanorods caps and also achieved synergistic effect of combined chemo- and 
photo-thermo therapy in vitro as well as magnetic resonance imaging in vivo [181]. In 
addition to gold-silica nanocarriers, Pd nanosheet-covered hollow mesoporous silica 
nanoparticles were also reported for combination of chemotherapy and photothermal 
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therapy. In this system, doxorubicin was encapsulated in the hollow mesoporous silica 
particles and Pd nanosheets were deposited on the surface. The synergistic anti-cancer 
effect of this system was demonstrated in vitro. It showed that under certain degree of 
NIR irradiation 90.5% cells were killed by the system; while without NIR irradiation 
28.3% cells were killed. If there was no drug loaded in this system, 47% cells were 
killed [182]. 
2.5.8 Hybrid nanocarriers 
Hybrid nanocarriers are made up of the combination of formerly mentioned nano 
delivery systems. Each of the systems is of advantages and disadvantages in agent load, 
agent encapsulation efficiency, cellular uptake, pharmacokinetics and biodistribution. 
Hybrid nanocarriers will overcome the drawbacks and improve the performance, 
therefore achieve better delivery efficiency as well as therapeutic effect for 
multimodality treatment. Besides, the hybrid carriers will also provide broad 
possibility to load multi-types of therapeutic agents together. 
Nanoparticles with lipid shell and polymer core are most commonly used hybrid 
nanocarriers. They enhance the biocompatibility of polymeric nanoparticles and 
improve the stability and release-controllability of lipid-based carriers. For example, 
Zheng et al. fabricated PLGA core lecithin/DSPE-PEG shell nanoparticles to 
co-deliver doxorubicin and indocyanine green for combination of chemotherapy and 
photothermal therapy. The nanoparticles showed higher temperature response and 
faster doxorubicin release under laser irradiation. The fluorescence of doxorubicin and 
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indocyanine green allowed the real time monitoring for the process of delivery. Both in 
vitro and in vivo experiments were conducted to evaluate the anti-cancer effect of the 
hybrid nanocarriers. Compared with chemo or photothermal treatment alone, the 
multimodality treatment synergistically suppressed MCf-7 or doxorubicin-resistant 
MCF-7/ADR tumor growth and prevented tumor recurrence in tumor-bearing mice 
[183].  
Another type of hybrid nanocarriers is prodrug-based nanoparticles or micelles. Such 
hybrid will improve the loading efficiency of hydrophilic agents and inhibit the 
over-quick release of agents. Prodrug could reduce the adverse side effect and realize 
stimuli-triggered release. Manufacturing nanocarriers with prodrug could further 
achieve the advantages of nano systems mentioned in section 2.4.1. Prodrug 
nanoparticles composed of PLA-cisplatin, PLA-doxorubicin or PLA-camptothecin 
were also fabricated for synergistic multi-drug therapy [184-186]. 
Nam et al. developed paclitaxel prodrug micelles for co-delivery gene and drug. 
Paclitaxel was conjugated with poly(ethylene glycol) (PEG) and arginine-grafted 
poly(cystaminebisacrylamide-diaminohexane) (ABP). The ABP-PEG-Paclitaxel 
polymers self-assembled into cationic polymeric micelles with conjugated paclitaxel 
core and formed polyplexes with plasmid DNA, mouse interleukin-12 (IL-12) gene. 
The paclitaxel achieved stimuli-controlled release in reductive conditions. The 
polyplexes showed higher anticancer potency than paclitaxel alone [187]. Besides, 
Xiao et al. conjugated hydrophilic drug oxaliplatin and hydrophobic drug daunorubicin 
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separately to the amphiphilic dopolymer methoxyl-poly(ethylene 
glycol)-block-poly(lactide-co-2-methyl-2-carboxyl-propylene carbonate) 
(MPEG-P(LA-co-MCC)). The two prodrug polymers then co-assembled into 
composite micelles. The composite successfully co-delivered hydrophilic and 
hydrophobic drugs and released drugs via reduction or acid hydrolysis in cancer cells. 
The synergistic effect was achieved in vitro in SKOV-3 cells and in vivo in H22 
tumor-bearing mice compared with free drug group or micelle-formulated single drug 
therapy [188]. They same group also applied this strategy to co-delivered cisplatin and 
paclitaxel for multi-drug therapy [189]. 
Recently, a highly efficient ionic dendrimer photosensitizer with a porphyrin or 
phthalocyanine core was developed for photodynamic therapy that sterically prevents 
or weakens aggregation and self-quenching of the photosensitive molecules [190]. 
Formulation of micelles or nanoparticles with these dendrimer photosensitizers can 
load drugs or other therapeutic agents in and achieve multimodality treatment with 
photodynamic therapy. For example, Son et al. fabricated hollow nanocapsules with 
dendritic porphyrin (DP) and poly(allylamine hydrochloride) (PAH). The PAH/DP 
multilayer nanocapsules were further filled with doxorubicin and cross-linked to 
achieve multimodality treatment and controlled drug release. In vitro study in HeLa 
cells showed that combination with doxorubicin and DP resulted in higher toxicity than 
either chemotherapy or PDT alone [191].  
Park et al. designed liposomal phlymeric gels (nanolipogels) to co-deliver 
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transforming growth factor-β (TGF-β) inhibitor (SB505124) and interleukin-2 (IL-2) 
for combination immunotherapy. In details, TGF-β inhibitor was solubilized by 
methacrylate-β-cyclodextrin to form acrylated-CD-SB505 complex. The complex and 
IL-2 were entrapped in a biodegradable functionalized PLA-PEG-PLA polymer 
matrix with a PEGylated PC/DSPE-PEG-NH2/cholesterol liposomal coating. Then, 
the photoinduced polymerization of the polymer and acrylated-CD resulted in gel 
formation. The SB505 can be released via hydrolysis of the polymer ester groups. 
IL-2 loaded in the polymer-hydrogel space outside the CD can be released 
simultaneously. The nanolipogels inhibited tumor growth significantly, increased 
survival of B16/B6 tumor-bearing mice and increased the activity of natural killer cells 
and of intratumoral-activated CD8
+
 T-cell infiltration. It was demonstrated that the 




Figure 2.7 Structure of TPGS. 
D--tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) is a 
water-soluble derivative of natural vitamin E, which is formed by esterification of 
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vitamin E succinate with polyethylene glycol (PEG) (Figure 2.7). It has advantages of 
PEG and Vitamin E in application of various drug delivery devices, including 
extending the half-life of the drug in plasma and enhancing the cellular uptake of the 
drug. Typically, the molecular weight of TPGS with PEG1000 segment is 1513. 
TPGS has amphiphilic structure of lipophilic alkyl tail and hydrophilic polar head 
with a hydrophile-lipophile balance (HLB) value of 13.2 and with a critical micelle 
concentration (CMC) of 0.02% w/w. TPGS safety issue has been investigated in 
detail. It has been reported that the acute oral median lethal dose (LD50), which is 
defined as the quantity of an agent that will kill 50 percent of the test subjects within 
a designated period, is>/7 g/kg for young adult rats of both sexes. US FDA has 
approved TPGS as a safe pharmaceutical adjuvant used in drug formulation. TPGS 
has been used as an absorption enhancer, emulsifier, solubilizer, additive, permeation 
enhancer and stabilizer. TPGS has also been served as the excipient for overcoming 
multidrug resistance (MDR) and as the inhibitor of P-glycoprotein (P-gp) for 
increasing the oral bioavailability of anticancer drugs. TPGS-based nanocarriers can 
significantly enhance the solubility, permeability and stability of the formulated drugs. 
TPGS has been proved to be an efficient emulsifier for synthesis of nanoparticles of 
biodegradable polymers, resulting in high drug encapsulation efficiency, high cellular 
uptake and high therapeutic effects [131]. Feng’s group has realized 168h effective 
paclitaxel (PTX) chemotherapy by the TPGS-emulsified PLGA nanoparticles 
formulation in comparison with Taxol of only 22 h effective chemotherapy at the 
same 10 mg/kg body weight of rats. Moreover, they have found that 400% higher 
68 
 
drug tolerance can be achieved, which could result in 360% AUC as a quantitative 
measurement of the in vivo chemotherapeutical effects. It means that the animal 
immune system failed to recognize and thus eliminate the nanoparticles. They proved 
in vivo the feasibility of nanomedicine, which had been one of the two major 
concerns for the newly emerging area nanomedicine as future medicine. They then 
further confirmed such advantages of nanomedicine that the PLA-TPGS nanoparticle 
formulation of PTX and docetaxel (DOC) can realize 336 h and 360 h sustained 
effective chemotherapy respectively in comparison 23 h chemotherapy of Taxotere at 
the same 10 mg/kg body weight for rats. Also, a more desirable biodistribution of the 
drug could be resulted with less drug in kidney, liver, heart and more in blood and 
lung. Oral delivery and drug delivery across the blood e brain barrier can also be 
achieved by further development of the nanoparticle technology with enhanced size 
and size distribution, surface functionalization, and copolymer synthesis. 
2.7 Therapeutic agents 
2.7.1 Herceptin 
Herceptin® (Trastuzumab) is a humanized recombinant anti-HER2 monoclonal 
antibody. As targeting ligand, it has been widely used in the various nanocarriers of 
anti-cancer drugs. HER2/neu is a member of the epidermal growth factor receptor 
(EGFR) family, which is a receptor tyrosine-specific protein family consisting of four 
semihomologous receptors: EGFR, HER2/neu, HER3 and HER4. It is well known 
that HER2 is overexpressed in 25–30% of invasive breast cancers. Herceptin can 
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specifically bind to the membrane region of HER2/neu with a high affinity and inhibit 
signal transduction as well as cell proliferation. As a US FDA-approved first-line 
therapeutic agent for HER2-overexpressing breast cancer, it not only shows 
significant biostatic activity as a single agent for immunotherapy, but also 
demonstrates synergistic anti-tumor effects with chemotherapeutic agents such as 
docetaxel. Moreover, herceptin has been widely applied to various nanocarriers to 
realize sustained, controlled and targeted drug delivery for HER2-positive cancer 
therapy [115]. Herceptin exerts its anti-tumor effect through multiple mechanisms, 
including blockage of survival signaling pathways, reduction of angiogenesis, 
antibody-dependent cellular toxicity, inhibition of HER2 extracellular domain 
cleavage, and hindrance of DNA repair [193]. However, after receiving herceptin 
monotherapy, most of the patients of initial response develop resistance within one 
year. Combination of herceptin with chemotherapeutic agents such as docetaxel, 
vinorelbine, cisplatin, carboplatin, or paclitaxel has achieved highest pooled response 
rates [194]. 
2.7.2 Docetaxel 
Docetaxel is a semi-synthetic analogue of paclitaxel, an extract from the bark of the 
rare Pacific yew tree Taxus brevifolia. Due to scarcity of paclitaxel, extensive 
research has been carried out leading to the formulation of docetaxel - an esterified 
product of 10-deacetyl baccatin III, which is extracted from the renewable and readily 
available European yew tree. It is used mainly for the treatment of breast, ovarian, 
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prostate, and non-small cell lung cancer. Docetaxel shows very low water solubility 
and thus it is dissolved in polyoxyethylene-20-sorbitan monooleate (polysorbate 80 or 
Tween 80). The cytotoxic nature of docetaxel is due to its ability to perturb the cell 
mitosis by binding to the β-subunit of tubulin in the microtubules of a cell. 
Microtubules, a component of cytoskeleton, have a function of correctly segregating 
chromosomes during cell division. When the binding and stabilization of 
microtubules by docetaxel happens, microtubules are unable to depolymerize or 
disassemble into free tubulin. As a result, late G2 and early M phases of the cell cycle 
are blocked and division fails. Eventually, apoptosis takes place [195]. 
Docetaxel is mainly distributed and metabolized in liver, especially by CYP3A4 and 
CYP3A5 isoenzymes. A major fraction of drugs is also distributed in spleen, intestine 
and plasma proteins. Meanwhile, about 80% of the dose is excreted through feces and 
about 6% is eliminated renally [196]. The adverse effects of docetaxel include 
neutropenia, anaemia, febrile neutropenia and alopecia.  
2.7.3 Cisplatin 
cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a 
chemotherapy drug  with a yellow crystal appearance. Its anti-cancer properties are 
used to treat cancers including sarcoma, small cell lung cancer, lymphoma and 
ovarian cancer. It is platinum-based molecule with square planar geometry and its 
chemical formula is Pt(NH3)2Cl2. It has a molecular weight of 300.045. It is soluble in 
water and thus delivered to the body in aqueous form. Cisplatin leads to cytotoxicity 
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by forming a platinum complex which binds to DNA. The formation of 
platinum-DNA adducts prevents the strands from uncoiling and separating. When 
DNA is cross-linked in this manner, it causes the cells to undergo apoptosis, or 
systematic cell death [197]. Toxic side effects of cisplatin include neurotoxicity, 
emetogenesis and nephrotoxicity [198]. 
2.7.4 Iron oxide 
Superparamagnetic iron oxides (IOs, Fe3O4) are used in this research as hyperthermia 
therapy agent. Iron oxides are often used as hyperthermia agent because of their high 
biocompatibility and their heat response to the applied magnetic field [199]. When 
exposing iron oxides to an alternating magnetic field at a specified frequency, it can 
produce enough heat for cancer treatment due to its high specific absorption rate (SAR) 
[199, 200]. Encapsulation of iron oxides in nano delivery systems will help them 
accumulate inside the cancer cells with passive and active targeting mechanism [201, 
202]. Therefore, local hyperthermia can be realized to reduce the heat injury to healthy 
cells. However, cancer cells may present thermotolerance due to the existence of a 
class of heat-shock proteins (HSPs) [203]. Hyperthermia will increase the expression 
of HSPs in cancer cells, which leads to higher resistance to hyperthermia therapy. To 
further enhance its efficacy, hyperthermia therapy is often used together with 
chemotherapy [204, 205]. It has been shown that mild hyperthermia between 39 °C and 
43 °C will enhance the cytotoxicity of the chemotherapy agents including docetaxel 
and paclitaxel [206, 207]. In addition, some HSPs inhibitor drugs can also help to 
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Chapter 3: Formulation of Docetaxel by Folic Acid-Conjugated 
D-α-Tocopheryl Polyethylene Glycol Succinate 2000 (Vitamin E 
TPGS2k) Micelles for Targeted Multimodality Treatment 
3.1 Introduction 
Low solubility in water and most pharmaceutical agents is always considered as a main 
disadvantage for most of the potent anti-cancer drugs such as paclitaxel and docetaxel 
due to their bulky polycyclic structure. Various drug delivery systems, such as 
polymeric or inorganic nanoparticles, dendrimers, liposomes and micelles, have been 
developed to solve this problem and further to promote sustained, controlled and 
targeted delivery of anti-cancer drugs [209-213]. Among them, micelles are used most 
often due to their technical ease, high biocompatibility and high efficiency in drug 
delivery. Micelles can encapsulate a drug of poor solubility in their hydrophobic core 
and stabilize the drug within the hydrophilic corona, thus enhancing its bioavailability 
[214-216]. Moreover, compared with other delivery systems, micelles show 
advantages to passively target tumor area through the leaky vasculature because of the 
enhanced permeability and retention (EPR) effect due to its small size ranging from 10 
nm to 100 nm [217]. Long circulation time of micelles can also be achieved because of 
the steric hindrance caused by the presence of a hydrophilic shell and the small scale of 
micelles. The use of micelles often achieves favorable biodistribution and higher 
therapeutic effects and lower side effects of the drug [209, 218]. However, traditional 
micelles have limitations such as high critical micelle concentration (CMC) which 
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decreases the stability of micelles in the plasma, low encapsulation efficiency which 
increases the amount of the micelles for a given drug dose, and lack of active targeting 
effects which lowers therapeutic efficiency and causes side effects [219, 220].  
D-α-tocopheryl polyethylene glycol succinate (Vitamin E TPGS or TPGS) is a 
water-soluble derivative of natural vitamin E, i.e. a PEGylated Vitamin E (Vitamin E 
conjugated with polyethylene glycol (PEG)), which has amphiphilic structure 
comprising lipophilic alkyl tail and hydrophilic polar head portion. Its bulky structure 
and large surface area make it an excellent emulsifier, solubilizer, and bioavailability 
enhancer of hydrophobic drugs. It has also been found that vitamin E TPGS could 
inhibit P-glycoprotein mediated multi-drug resistance and thus greatly enhance oral 
drug delivery [110, 221, 222]. One of the most sophisticated designs of drug delivery 
systems is that the carrier materials can also be of therapeutic effects which may either 
treat the side effects caused by, or promote synergistic effects with, the encapsulated 
anticancer drug. So far there has been no such drug delivery system available in the 
literature except for one example, i.e. the Poly(D,L-lactide-co-glycolide)/ 
montmorillonite (PLGA-MMT) nanoparticle formulation of paclitaxel. MMT is 
medical clay. MMT is a potent detoxifier for various toxins that may result in a host of 
common symptoms, including nausea, vomiting, and diarrhea, most of which are 
typical symptoms of the side effects caused by anticancer drugs. The PLGA-MMT 
nanoparticle drug delivery system thus represents a new concept in developing drug 
delivery systems, formulating the drug carrier from a material, which is can also have 
therapeutic effects to mediate the side effects of the drug to be delivered [223]. Our 
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present work provides another example, in which the material of the drug delivery 
system itself also possesses therapeutic effects and further promotes synergistic effects 
with the encapsulated drug.  In fact, vitamin E analogues such as TPGS are the 
so-called ‘mitocans’ which have been found to have selective cytotoxicity for cancer 
cells. TPGS acts by destabilizing the organelles, unleashing their apoptogenic potential, 
resulting in the death of malignant cells and thus suppressing of tumor growth [224].  
Nevertheless, one of the disadvantages of TPGS in micelle formulation is its high CMC 
(0.2 mg/mL), which decreases the stability of micelles in physiological environment. 
Also, the chain length of PEG in TPGS is not long enough to ensure the micelles to 
extend blood circulation times to reduce liver accumulation. Thus, till now, TPGS was 
usually used together with other lipids or synthetic copolymers to form micelles and 
the presence of TPGS in the micelles has greatly improved the drug encapsulation 
efficiency and stability of the micelles [225, 226].  In this work, we synthesized a new 
TPGS2k amphiphilic polymer via reaction between tocopheryl succinate and PEG of 
molecular weight 2000 (mPEG2000). The mPEG2000 used here was considered as a 
prototype to demonstrate the concept since other TPGS with longer chain length can 
also be developed in a similar way. The new synthesized TPGS2k showed much low 
CMC value compared with the traditional TPGS. This change makes it possible to form 
stable micelles by TPGS alone without any other polymers or lipids. In fact, long chain 
PEG helps the micelles escape from being recognized and eliminated by the 
reticuloendothelial system (RES). Furthermore, through the strategy of synthesis, 
reactive functional groups can be easily induced by selecting different functionalized 
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PEG at the polymer termini for further attachment of targeting moieties such as folates, 
aptamers, anti-bodies or peptides. For example, our group used folic acid (FOL), an 
oxidized form of folate, as a model targeting probe, which is efficiently internalized 
into the cells through the receptor-mediated endocytosis even conjugated with a wide 
variety of bioactive molecules. Folate receptors are over-expressed in most types of 
human cancer cells such as ovarian, breast and prostate cancers while only minimally 
distributed in normal tissues [119, 227, 228]. We thus further synthesized the 
TPGS3350-FOL conjugate which is mixed with TPGS2k to form micelles for targeted 
docetaxel delivery to the cancer cells of folate receptor overexpression. It can be 
predicted that such a new design of the micelles drug delivery system should achieve 
much higher drug encapsulation efficiency, much higher cellular uptake of the 
formulated drug, much longer circulation time in the plasma, and thus much higher 
therapeutic effects and much lower side effects.  
Docetaxel was used in this work as a model anti-cancer drug, which is a semi-synthetic 
analogue of paclitaxel. Docetaxel has been shown superior to paclitaxel in a number of 
preclinical models due to its improved cellular uptake and increased potency of 
promoting the assembly of microtubules as an inhibition of the disassembly process of 
tubulin [229]. However, the nonionic surfactant Tween 80
®
 (polysorbate 80) and 
ethanol used in its current clinical dosage form Taxotere
®
 has been found to cause 
serious side effects such as neurotoxicity, fluid retention and musculoskeletal toxicity 
[230-232]. We hope that our new design of micelles, i.e. those consisting of TPGS2k 
and TPGS3350-FOL conjugates, would provide an ideal solution for the adjuvant 
77 
 
problems of docetaxol as well as other anticancer drugs and further, to realize a 
sustained, controlled and targeted drug delivery. Moreover, TPGS micelles formulation 
may also achieve synergistic effects with the formulated docetaxel [233]. 
3.2 Materials and methods 
3.2.1 Materials 
Docetaxel (anhydrous, 99.56%) was purchased from Shanghai Jinhe Bio-Technology 
Co. Ltd, China. Taxotere
® 
was provided by National Cancer Center (Singapore). 
Poly(ethylene glycol) methyl ether (MW 2000), D-α-Tocopheryl succinate, 
polyoxyethylene bis (amine) (MW 3350), folic acid, dichloromethane (DCM), 
N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), 
Nhydroxysuccinimide (NHS), triethylamine (TEA), dimethyl sulfoxide (DMSO), 
coumarin-6, phosphate buffered saline (PBS, pH 7.4), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsin-EDTA solution and propidium iodide (PI) were all purchased from 
Sigma-Aldrich (St. Louise, MO, USA). Tween-80 was from ICN Biomedicals, Inc. 
(OH, USA). Triton X-100 was provided by USB Corporation (OH, USA). Fetal bovine 
serum (FBS) was purchased from Gibco Life Technologies (AG, Switzerland). 
Penicillin-streptomycin solution was from Invitrogen. Dulbecco’s Modified Eagle’s 
Medium (DMEM) was from Sigma. All solvents used in this study were HPLC grade. 
MCF7 breast cancer cells and NIH/3T3 fibroblast cells were provided by American 





System (Millipore Corporation, Bedford, USA). 
3.2.2 Synthesis of TPGS2k and TPGS3350-FOL 
D-α-Tocopheryl succinate and MPEG2k was weighed and dissolved in DCM together 
with DCC and DMAP with stoichiometric ratio of 1:1:2:0.1 respectively and left to stir 
overnight in nitrogen environment at dark. The solution was then filtered to remove the 
by-products and precipitated in cold diethyl ether. The precipitate obtained was washed 
by diethyl ether again, and dissolved in water and dialyzed against water. The milky 
dispersion was filtered to remove impurities and the filtrate was collected. 
D-α-tocopheryl polyethylene glycol 2000 succinate (TPGS2k) powder was obtained 
after freeze drying of the filtrate.  
For amine terminated TPGS, tocopheryl succinate, PEG3350 bis-amine, DCC and NHS 
were weighed and dissolved in DCM separately with stoichiometric ratio of 1:1.2:2:2 
respectively. The solution was mixed with 20 μl of TEA and left to stir in a nitrogen 
environment at dark for 2 days. The solution was then filtered to remove by-product 
and precipitated in cold diethyl ether. The purifying procedure was in the same way as 
that for TPGS2k. D-α-tocopheryl amino polyethylene glycol 3350 succinate 
(TPGS3350-NH2) powder was obtained after freeze drying the filtrate.  
TPGS3350-FOL was synthesized following the same procedure as above mentioned by 
weighing TPGS3350-NH2, folic acid, DCC and NHS with stoichiometric ratio of 1:1:2:2 




3.2.3 Preparation of micelles 
Docetaxel (5 mg) or Coumarin-6 (1 mg) was dissolved in chloroform first and was then 
added into a chloroform solution of TPGS2k (50 mg). The organic solvent was removed 
by rotary vacuum evaporation. The film formed was additionally freeze-dried in 
vacuum, and then hydrated with 15 mL 1X PBS buffer, incubated at 37°C for 30 min, 
and then sonicated for a few minutes. The resultant mixture was filtered through 0.2 
μm polyethersulfone syringe filter in a sterile environment to remove the crystalline 
docetaxel or Coumarin-6. The targeting micelles were prepared in a same way with 
TPGS2k replaced by TPGS2k and TPGS3350-FOL mixture at a weight ratio of 9:1, which 





Figure 3.1 Preparation scheme for folic acid conjugated TPGS2k micelles loaded with 
docetaxel as a model drug. 
 
3.2.4 Characterization of TPGS2k micelles  
Micelle size & size distribution  
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Laser light scattering (90 Plus Particle Size, Brookhaven Instruments Co. NY, USA) 
was used to measure average particle size and size distribution of the TPGS2k micelles 
and FA micelles. The micelles were sonicated at 0°C for half an hour before 
measurements to ensure that the particles were well dispersed. The size was tested at 
room temperature. 
TPGS2k micelles were also stored at 4°C for one month, and the samples were tested for 
the changes in particle size and size distribution. 
Drug encapsulation efficiency (EE) 
The amount of docetaxel encapsulated in the micelles was measured by high 
performance liquid chromatography (HPLC, Agilent LC1100). A reversed phase 
Inertsil
®
 ODS-3 column (150×4.6 mm, pore size 5 mm, GL Science Inc., Tokyo, Japan) 
was used. 1 mL micelles were freeze-dried and dissolved in 1 mL DCM. After 
evaporating DCM, 3 mL mobile phase (50:50 v/v acetonitrile/water solution) was 
added to dissolve the drugs. The solution was then filtered by 0.45 mm PVDF syringe 
filter for HPLC analysis. The column effluent was detected at 230 nm with a UV/VIS 
detector. The EE is calculated as (actual amount of the drug encapsulated in micelles) 
/(initial amount of the drug used in the micelles)×100%. 
Determination of the critical micelle concentration (CMC)  
CMC of TPGS2k was determined by pyrene as a florescent probe [236-238]. A 1.2 
mg/mL solution of TPGS2k was prepared in dichloromethane. Different volume of this 
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solution was added to 15 mL empty vials. Then 50 μl of 1.8×10-4 M solution of pyrene 
in dichloromethane was added in every vial and mixed well. The dichloromethane was 
left to evaporate for 24 h in order to form a pyrene film in the vial. Finally, 15 mL 
Milli-Q water was added to the vials to get a final pyrene concentration of 6.0×10
-7 
M 
for each vial and TPGS2k solutions with concentrations ranging from 0.008 mg/mL to 
0.4 mg/mL. The solutions were kept on a shaker at 37 °C for 24 h to reach equilibrium 
before fluorescence measurement.  
Fluorescence spectra were recorded on a luminescence spectrometer (PTI 
Quantamaster) at room temperature. The excitation spectra were scanned from 306 to 
346 nm at the emission wavelength of 373 nm. Excitation and emission bandwidths 
were 5 nm and 10 nm, respectively. The fluorescence intensity ratio of I328/I324 was 
analyzed as a function of micelle concentration. 
3.2.5 Controlled drug release 
4 mL micelles solution was placed in a dialysis bag (molecular mass cut-off 2 kDa) 
with 0.1% w/v Tween-80. The dialysis bags were incubated in 20 mL of 1X PBS buffer 
(pH 7.4) containing 0.1% w/v Tween-80 at 37 °C with gentle shaking, and the 
incubation medium were changed to new one at every predetermined time points. The 
collected incubation medium containing the released drug was freeze-dried and 
dissolved in DCM. After the evaporation of DCM, docetaxel quantity was determined 




3.2.6 Cell culture 
MCF7 breast cancer cells, which are of folate overexpression, and NIH/3T3 fibroblast 
cells, which lack folate overexpression, were employed. NIH/3T3 was selected as 
negative control group for folic acid reception in breast cancer cells. The Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% 
penicillin-streptomycin solution was utilized as the cell culture medium. Cells were 
cultivated in humidified environment at 37°C with 5% CO2. Before experiment, the 
cells were pre-cultured until confluence was reached to 75%. 
3.2.7 In vitro cellular uptake 
For quantitative cellular uptake analysis, MCF7 cells were seeded into 96-well black 
plates (Costar, IL, USA) at 5×10
3
 cells/well (0.1 mL) and after the cells reached 80% 
confluence, the medium was changed to the suspension of coumarin-6 loaded micelles 
at a micelles concentration of 0.250 mg/mL for 0.5 and 2.0 h, respectively. After 
incubation, the micelles suspension in the testing wells was removed and the wells 
were washed with 0.1 mL PBS three times to remove the micelles outside the cells. 
After that, 50 μL of 0.5% Triton X-100 in 0.2 N NaOH solution was added to lyse the 
cells. Microplate reader (Genios, Tecan, Switzerland) was used to measure the 
fluorescence intensity from coumarin-6 loaded micelles in the desired wells with 
excitation wavelength at 430 nm and emission wavelength at 485 nm. The cellular 
uptake efficiency was expressed as the percentage of the fluorescence of the testing 
wells over that of the positive control wells. 
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For fluorescent microscope study, MCF7 and NIH/3T3 cells were cultivated in the 
8-well coverglass chamber (LAB-TEK
®
, Nagle Nunc, IL) till 70% confluence. The 
fluorescent micelles dispersed in the cell culture medium at concentration of 0.250 
mg/mL were added into the wells. Cells were washed three times after incubation for 
0.5 and 2 h and then fixed by 70% ethanol for 20 min. The cells were further washed 
thrice by PBS and the nuclei were then counterstained by PI for 45 min. The fixed cell 
monolayer was finally washed thrice by PBS and observed by confocal laser scanning 
microscope (CLSM, Olympus Fluoview FV1000). 
3.2.8 In vitro cell cytotoxicity 
For cytotoxicity measurement, MCF7 cells were incubated in 96-well transparent 
plates (Costar, IL, USA) at 2×10
4
 cells/well (0.1 mL) and after 12 h, the old medium 
was removed and the cells were incubated for 24, 48 h and 72 h in the media containing 
Taxotere
®
 or docetaxel-loaded micelles at the equivalent drug concentration of 25, 2.5, 
0.25 μg/mL. The micelles were sterilized with UV irradiation for 1 day prior to use. 
MTT assay was used to measure the cell viability at given time intervals. The 
absorbance of the wells was measured by the microplate reader with wavelength at 570 
nm and reference wavelength at 620 nm. Cell viability is defined as the percentage of 
the absorbance of the wells containing the cells incubated with the micelles suspension 
over that of the cells only. 
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3.3 Results and discussion 
3.3.1 Characterization of TPGS2k micelles and FA micelles 
Micelle size & size distribution  
The size and size distribution measured by the dynamic light scattering (DLS) were 
shown in Table 3.1 Though the size of most micelles distributed from 12 nm to 20 nm 
as shown in Figure 3.2, there were still a few larger ones, leading the mean sizes of the 
micelles a little bigger. It can be seen that the mean sizes of micelles with or without 
docetaxel are almost the same, i.e. around 30 nm, while the mean size of folic acid 
conjugated micelles is slightly bigger which is about 50 nm. We can also find that no 
significant changes in micelle size or size distribution were recorded after storing the 
micelles at 4 °C for one month, which supports the high stability of the TPGS2k 
micelles. 
Table 3.1 Characteristics of various TPGS2k micelles: particle size, size distribution, 
drug encapsulation efficiency (EE). Data represent mean ± SD, n=3. 





Micelle with no drug 0.312±0.005 - - 
Micelle with no drug  
after 1 month 
0.310±0.004 - - 
Micelle with drug 0.283±0.003 9.09 78.11±0.40 
FA micelles with drug 0.337±0.003 9.09 66.33±1.72 
a
 Drug loading (%) = (weight of drug used/[weight of polymer + drug used]) × 100. 
b
 Drug encapsulation efficiency (%) = (amount of the drug encapsulated in the micelles/ amount 
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Figure 3.2 Size and size distribution of the TPGS2k micelles: (a) the TPGS2k micelle 
with no drug encapsulated inside; (b) the TPGS2k micelle with no drug encapsulated 
inside after one month stored at 4 °C; (c) the docetaxel-loaded TPGS2k micelles; (d) 
the folic acid conjugated, docetaxel-loaded TPGS2k micelles. 
 
Drug encapsulation efficiency (EE) 
Drug encapsulation efficiency is an important factor for drug delivery systems. The 
drug encapsulation efficiency of TPGS2k micelles and folic acid decorated TPGS2k 
micelles determined by HPLC are shown in Table 3.1. The encapsulation efficiency of 
the TPGS2k micelles is 78.1% and that of the FA TPGS2k micelles is 66.3%. It can be 
seen that the new TPGS2k micelles achieve high drug encapsulation efficiency. This is 
mainly because the bulky non-polar head of the TPGS molecules form a strong 




CMC of TPGS2k 
At low concentrations, TPGS2k molecules are well dispersed in the aqueous medium. 
As the concentration is increased, the free energy of the system rises because of 
unfavorable interactions between the hydrophobic domains and surrounding water 
molecules. At a specific concentration, termed the CMC, amphiphilic molecules with 
the appropriate geometry, orient themselves in such a way that the hydrophobic 
segments are isolated from the aqueous environment, achieving a state of minimum 
energy that leads to the formation of colloidal assemblies termed micelles. The CMC of 
TPGS2k can be determined by fluorescence technology. It has been reported that pyrene 
as a fluorescence probe shows high sensitivity to the polarity of its environment. When 
micelles formed, pyrene will be stable in the hydrophobic core of the micelle, thus the 
environment of pyrene was changed from polar to non-polar. Therefore, a red shift of 
the (0,0) band in the emission spectra and an increase of the intensity were observed, 
which is shown in Figure 3.3 (a) . The CMC of TPGS2k can be obtained by plotting the 
I328/I324 ratio of each curve in the excitation spectra versus log concentration of the 
polymer. The maximum change in the slope represents the formation of TPGS2k 
micelles (Figure 3.3 (b)). Using this method, the CMC of TPGS2k was determined to be 
0.0219 mg/mL, which is much lower than that of TPGS1k. The obvious decrease in 
CMC suggests that micelles of TPGS2k would provide good stability for the drug in the 
suspension and great resistance to dissociation even on dilution by the much larger 




Figure 3.3 (a) Excitation spectra of pyrene (λ=373 nm) and (b) Plot of the 
fluorescence intensity ratio of I328/I324 from excitation spectra as a function of TPGS2k 
concentration (λ=373 nm, concentration of pyrene = 6×10-7 mol L-1). 
3.3.2 In vitro drug release 
The in vitro drug release profiles of the docetaxel-loaded TPGS2k micelles and folic 
acid conjugated TPGS2k micelles in 144 h are shown in Figure 3.4, from which an 
initial burst of 16.93% for the TPGS2k micelles and 19.78% for the folic acid 
conjugated TPGS2k micelles in the first 12 h can be observed. This fast release caused 
by certain amount of docetaxel located near the outer surface of the micelles is useful 
to inhibit the growth of cancer cells in the beginning of the treatment. In the 
following hours, the cumulative release sustainably increased, which ensures the 
micelles to possess the ability to sustained treatment of the cancer cells. After 144 h, 












































the cumulative drug release was 72.4% for TPGS2k micelles and 78.4% for folic acid 
conjugated TPGS2k micelles respectively. It shows an almost complete drug release 
from the micelles. It is well-known that in the short period of time, the release of 
hydrophobic drugs from micelles is dominantly due to diffusion. Hence the reason of 
fast release of docetaxel is possibly because the TPGS2k shares an increasing 
hydrophilic part of MPEG2000, which facilitates the water uptake and permeation 
into the micelles core to accelerate the drug release. This reason can be further 
supported by noticing that the drug release from folic acid conjugated TPGS2k 
micelles, which contain a larger hydrophilic part of PEG3350, is a little bit faster than 
that from TPGS2k micelles.  
 
Figure 3.4 In vitro docetaxel release profile from the TPGS2k micelles (lower curve) 
and the folic acid conjugated TPGS2k micelles (upper curve). Phosphate buffered 
saline (PBS, 0.1 M, pH = 7.4) with 0.1% w/v Tween-80 was employed as the release 
medium. Data represent mean ± SD, n=3. 
3.3.3 In vitro cellular uptake of micelles 
The internalization of the micelles into the cells and the targeting effects of the micelles 



































and the folic acid conjugated micelles by MCF-7 human adenocarcinoma cells and 
NIH/3T3 murine fibroblast cells after 2 h incubation with the Coumarin-6 loaded 
micelles, which were visualized by confocal laser scanning microscope (CLSM). 
Coumarin-6 was used as an imaging agent to show the uptake of the micelles. In 
Figure 3.5, the fluorescence from the micelles penetrated into MCF7 cells and 
NIH/3T3 cells were shown in Row 1, 2 and 3, 4, respectively. Row 1 and 3 show the 
images of the cells incubated with the micelles of no targeting effect, and Row 2 and 4 
show the cells incubated with the folic acid decorated micelles. The images in column 
A obtained from FITC channel show the green fluorescence of the coumarin-6 loaded 
micelles; the images in column B obtained from the PI channel show the nuclei in red 
fluorescence stained by the propidium iodide; and the images in column C obtained 
from the merged channels of FITC and PI show that the red fluorescence representing 
the nucleus stained by PI is circumvented by green fluorescence representing the 
coumarin-6 loaded micelles internalized in the cytoplasm. Hence, the qualitative 
cellular uptake can be visually verified by the CLSM images. It can be seen that folic 
acid conjugated micelles in the cytoplasm in Row 2 is much brighter than that of the 
micelles in Row 1. This is because the MCF-7 over-expressed folate receptors and the 
receptor-mediated endocytosis facilitates the uptake of FA micelles [239, 240]. While 
for Row 3 and Row 4, which are images of NIH/3T3 cells without over-expressed 
folate receptors, no obvious difference of fluorescence in the cytoplasm displayed 




Figure 3.5 Confocal laser scanning microscopy (CLSM) images show  
internalization of fluorescent micelles in MCF-7 cells after 2 h incubation. Column A: 
FITC channel showing the green fluorescence from coumarin-6 loaded micelles in the 
cytoplasm. Column B: PI channel showing the red fluorescence from PI stained 
nuclei. Column C: Merged channel of FITC and PI channels. Row 1 and 2 for the 
MCF7 cells. Row 3 and 4 for the NIH/3T3 cells were used. Row 1 and 3 for the 




A quantitative analysis of cellular uptake was conducted by measuring percentage of 
the micelles used in incubation which have been entrapped in the cells. Micelles group 
is noted as negative group to compare with FA micelles group. The active targeting 
effect is demonstrated in vitro. The same concentration of well dispersed micelles (250 
μg/mL) as used in the previous CLSM was applied in this investigation. After 0.5 h and 
2 h incubation, the cellular uptake efficiency of the micelles was measured to be 
21.1±2.49% and 24.7±1.49%, respectively. Instead, after 0.5 h and 2 h incubation, the 
cellular uptake efficiency of the folic acid conjugated micelles was measured to be 
25.2±1.04% and 29.0±0.57%, respectively. The targeting effect of folic acid 
conjugation is thus significant of 19.6% increment for 0.5 h incubation and 17.1% 
increment for 2 h incubation (Figure 3.6 two-tailed student’s t test, P < 0.05). The 
mechanism of the in vitro cellular uptake of the micelles can be assumed to be the 
carrier-mediated endocytosis due to its extra small size [241]. For the folic acid 
conjugated micelles, the receptor-mediated endocytosis (RME) can further facilitate 




Figure 3.6 The diagram of in vitro cellular uptake efficiency of Micelles by MCF-7 
cancer cells after 0.5 h and 2 h incubation respectively at 37ºC. Data represent mean 
± SD, n=6. 
3.3.4 In vitro cytotoxicity 
The MCF-7 cells viability after 24 h, 48 h, 72 h incubation with docetaxel formulated 
in the TPGS2k micelles, the folic acid conjugated micelles (FA micelles) or its clinic 
form Taxotere
®
 at three equivalent drug concentration of 0.25, 2.5, and 25 μg/mL, and 
the placebo TPGS2k micelles (i.e. the TPGS2k micelles without docetaxel loaded) at the 
same micelle weight is shown in Figure 3.7.  For Taxotere
®
, after 24 h treatment at 
0.25, 2.5, and 25 μg/mL drug concentration, the cell viability was found to be 
73.8±2.73%, 66.2±5.37%, and 55.8±5.46% respectively. Instead, after 48 h and 72 h 
treatment at the three designed drug concentration, the cell viability decreased to 
58.3±2.20%, 45.0±1.26%, 38.0±1.48% and 47.9±3.26%, 37.9±0.81%, 29.6±3.35% 




































concentration, after 24 h treatment the cell viability was measured to be 51.8±3.62%, 
45.0±2.19%, 4.62±0.32% for TPGS2k micelles and 36.9±3.83%, 30.2±0.97%, 
3.99±0.58% for folic acid conjugated micelles, respectively. After 48 h and 72 h 
treatment, however, the cell viability was significantly decreased to be 38.4±2.34%, 
36.2±1.18%, 2.88±0.12% and 32.4±0.87%, 34.0±1.80%, 1.16±0.52% for TPGS2k 
micelles, and 32.7±2.87%, 29.4±1.94%, 2.83±0.23% and 31.3±2.82%, 27.7±6.8%, 
3.59±0.30% for folic acid conjugated micelles, respectively. From the above results, it 
can be seen that lower cancer cell viability was achieved by higher drug concentration 
and longer incubation time in general. The micelle formulation of docetaxel, whether 
with folic acid conjugated or not, has shown significant advantages compared with 
Taxotere
®
. Besides, the targeting effect of folic acid conjugated micelles can further 
enhance the therapeutic effects. In fact, the folic acid conjugated micelles achieved the 
lowest cell viability at every of the designed drug concentrations and the incubation 
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Figure 3.7 The diagrams of MCF-7 cancer cell viability at various drug 
concentrations after 24 h (A), 48 h (B), and 72 h (C) treatment. Data represent mean ± 
SD, n=6. 
 
The advantages of the TPGS2k micelle formulation of anticancer drugs with docetaxel 
as a model drug can be further quantitatively demonstrated by the IC50 value (Table 
3.2), which is defined as the drug concentration needed to kill 50% of the incubated 
cells in a designated time period. From Table 3.2, it can be seen that the IC50 for the 
Taxotere
®
 formulation is 103.4, 1.280 and 0.1480 μg/mL at 24, 48, and 72 h 
respectively. It is greatly decreased to be 0.526, 0.251 and 0.233 μg/mL, i.e. a 99.5%, 
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57.5% increase, respectively. The IC50 value is further decreased to be 0.1780, 0.1520 
and 0.1140 ng/mL, i.e. a 99.8%, 88.1% and 23.0% decrease for the folic acid 
conjugated micelles after 24, 48 and 72 hour treatment, respectively in comparison 
with Taxotere
®
 and a 0.3%, 7.7% and 80.5% further decrease based on that for the 
TPGS2k micelle formulation. 
Table 3.2 IC50 of Docetaxel formulated in Taxotere
®
, TPGS2k micelles and FA TPGS2k 










FA micelle with 
DXL 
24 103.4 1.35 0.526 0.178 
48 1.28 1.53 0.251 0.152 
72 0.148 7.58 0.233 0.114 
 
To explore the synergistic effects between docetaxel and TPGS, TPGS2k micelles 
without docetaxel encapsulated of the same micelle weight as those with drug loaded at 
the three designed drug concentrations were also investigated. The MCF-7 cell 
viability was found to be 67.9±5.18%, 62.8±4.16%, 6.79±0.96% after 24 h; 
67.2±2.84%, 63.3±1.62%, 10.1±1.20% after 48 h and 95.9±8.28%, 89.2±3.44%, 
15.03±1.37% after 72 h, respectively. The IC50 value is thus 1.350, 1.530 and 7.58 
μg/mL for the plain TPGS2k micelles after 24, 48 and 72 hour treatment respectively. It 
is clear that the TPGS2k micelles with no drug loaded themselves showed certain 
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cytotoxicity with significance at first 24 and 48 hours. For example, after 24 h 
incubation, the MCF-7 cell viability for the plain TPGS2k micelles is even lower than 
that for Taxotere
®
. The therapeutic effects of the plain TPGS2k micelles are even more 
obvious for at high micelle concentration. However, after 72 h, as the cells continued to 
proliferate, the relative concentration of the micelles decreased in fact, the plain 
micelles therefore showed less cytotoxicity except for the case at the original 25 μg/mL 
micelle concentration. It can thus be concluded that high concentration of TPGS2k 
micelles could inhibit the growth of MCF-7 cells. This finding is consistent with the 
result obtained for Vitamin E in the form of alpha-tocopheryl succinate, which has been 
demonstrated to be able to inhibit growth of several cancer cell lines, including 
pancreas, breast, and prostate [244, 245]. The reason for this can be given as follows. 
Vitamin E succinate (and its analogues) causes generation of a large amount of reactive 
oxygen species (ROS), and these ROS can then diffuse across the mitochondrial 
membrane at which they are activated probably by redox-active iron, so that they can 
catalyse formation of disulfide bridges between Bax monomers. This conformational 
change of Bax exposes the trans-membrane domain of the protein and Bax dimer 
moves to the mitochondrial outer membrane (MOM), where it forms a megachannel. 
Besides, the Vitamin E analogues also bind to the anti-apoptotic Bcl2 and Bcl-XL 
proteins so that the activated Bax or Bak cannot be diverted from forming 
megachannels. The accumulated ROS also triggers the cytochrome c oxidase activity, 
which, as a result, releases cytochrome c that traverses the MOM through the 
megachannel and activates the caspase cascade leading to apoptosis of the cancer cells. 
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Such process can be suppressed in normal cells by the high level expression of 
anti-oxidant enzymes which results in greatly reduced level of ROS accumulation 
[233]. 
Because of such synergistic effect between TPGS2k and docetaxel, lower cancer cell 
viability can be achieved by the TPGS2k micelle formulation of docetaxel than any 
other formulation of the drug. This can be evidenced by comparing the IC50 values 
among Taxotere
®
, TPGS2k micelles without docetaxel and those with the drug. From 
Table 3.2, it can be seen that the IC50 value is 103.4, 1.280 and 0.148 μg/mL for 
Taxotere
®
, which is significantly decreased to 0.526 and 0.251 μg/mL, i.e. a 99.5 and 
80.4% decrease after 24 and 48 treatment respectively with the drug formulated in the 
TOGS2k micelles. However, no synergistic effects were observed afterwards. In fact, 
the IC50 value was increased to be 0.233 μg/mL, which is a 57.4% increase, after 72 
hour treatment. More experiments especially in vivo experiments are needed for a 
better understanding of the synergistic effects between TPGS2k and docetaxel. 
3.4 Conclusions 
A new TPGS2k polymer was successfully synthesized and its CMC has been found to 
be decreased to 0.0219 mg/mL, which is much lower than that of traditional TPGS 
(0.2mg/mL) and thus greatly in favor of its micelle stability. Such a CMC is also lower 
than most of the current polymeric materials for micelle formulation such as 
MPEG–PLA or chitosan oligosaccharide [246, 247]. TPGS2k micelles are thus 
developed for drug delivery of hydrophobic anti-cancer drugs such as docetaxel, which 
99 
 
showed enhanced stability indeed, Drug encapsulation efficiency as high as 80% was 
achieved under drug loading as high as 10%, which thus greatly enhanced the drug 
delivery efficiency in comparison with other drug delivery systems. The TPGS2k are 
further conjugated to ligand such as folic acid for targeted delivery of anticancer drugs, 
which showed further enhancement in cellular uptake and thus in vitro therapeutic 
effects.  In addition, since TPGS2k is a kind of ‘mitocans’, its cytotoxicity for cancer 
cells was explored, and a significant synergistic effects with the formulated docetaxel 
was further investigated. The micelles developed in this work, i.e. those consisting of 
TPGS2k and TPGS3350-FOL conjugates, represents a new concept in the design of drug 
delivery systems – the carrier materials of the drug delivery system can also have 
therapeutic effects, which either modulate the side effects of, or promote a synergistic 
interaction with the formulated anticancer drugs. The TPGS2k micelles thus represent 









Chapter 4: Vitamin E TPGS Prodrug Micelles for Hydrophilic 
and Hydrophobic Drug Delivery and Dual-Drug Multimodality 
Treatment 
4.1 Introduction 
Nanoparticles of biodegradable polymers have been found promising for formulation 
to hydrophobic anticancer drugs such as paclitaxel and docetaxel with high loading and 
high drug encapsulation efficiency as well as high cellular uptake [109, 110, 112, 121, 
248-250]. Single emulsion and double emulsion techniques are applied for 
hydrophobic and hydrophilic drugs respectively. In the single emulsion techniques, the 
hydrophobic drug is loaded in a hydrophobic core of nanoparticles, which thus 
inappropriate to be applied to deliver hydrophilic drugs. Instead, the double emulsion 
technique should be applied to synthesize nanoparticles, in which the hydrophilic drug 
is loaded in a water phase that is added in an oil phase to form the water-in-oil phase. 
Such a first phase is then added to a water phase to form the water-in-oil-water phase. 
As such, the double emulsion technique disadvantages, which include (1) low drug 
loading (the weight ratio of the drug to the nanoparticle) and low encapsulation 
efficiency (the encapsulated amount vs the added amount of the drug in the process) 
due to the drug loss into the water phase in the process and (2) the large initial burst (the 
fast drug release in the first hour), (3) undesired drug release due to the fast diffusion of 
the drug within the nanoparticles, and (4) the undesired particle size (more than 200 nm) 
due to the complicated emulsion process [251].  
101 
 
Prodrug is a strategy used most often in drug formulation, in which the drug is 
conjugated to a polymer. The prodrug carries the drug to the site and then releases the 
drug for action there. It improves the pharmacokinetics of the original drugs, increasing 
the half-life of the drugs in blood [252]. The disadvantages of prodrugs include low 
drug loading and low cellular uptake due to their intrinsic structure. It is thus natural to 
synthesize prodrug nanohydrogels, prodrug micelles, prodrug liposomes, prodrug 
loaded nanoparticles of biodegradable polymers to make use of its advantages and 
avoid its disadvantages, among which prodrug micelles have received high attention 
recently due to its technical simplicity and promising performance in in vitro 
experiments. For example, this research will be focused on conjugation of hydrophilic 
drug to an amphiphilic biodegradable copolymer and use of the prodrug to form 
micelles for co-delivery of both hydrophilic and hydrophobic agents. 
In this research, cisplatin (Cis-diamminedichloroplatinum II) is selected as a model 
hydrophilic drug to demonstrate the concept of prodrug micelles for hydrophilic drug 
formulation. Cisplatin shows anti-cancer effect for a variety of cancers including breast, 
head, neck, testicular, ovarian, bladder and small cell lung cancers [253-256]. The 
mechanism of the drug is to form platinum-DNA adducts after uptake into the nucleus 
of cells and prevent the strands from uncoiling and separating[197]. However, cisplatin 
shows limitations in clinical application. The main limitation is its low solubility and 
high toxicity. Cisplatin is difficult to be well dispersed in the plasma because it is 
poorly soluble in organic solvents and partially soluble in water [257]. Besides, 
patients will suffer from serious side effects including neurotoxicity, emetogenesis and 
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nephrotoxicity. Because nephrotoxicity and emetogenesis can be significantly reduced 
by hyperhydration, neurotoxicity is a main dose-limiting toxic effect of cisplatin [198, 
258]. It will lead to peripheral neuropathy, tinnitus and high-frequency hearing loss.  
Many kinds of molecular biomaterials have been used to form drug delivery systems, 
which include US FDA approved biodegradable polymers such as poly(lactic acid) 
(PLA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL), are used 
most often [259]. However, those polymers could not achieve desired effects in 
prodrug formulation since they were originally synthesized for textile grafts and 
implants in the 1950’s. They are highly hydrophobic and thus not friendly to 
hydrophilic drugs. They have too strong mechanical strength and their degradation is 
too slow, thus resulting in too slow drug release to meet the therapeutic needs. Also, the 
prodrugs made up of those polymers are difficult to be directly conjugated to 
hydrophilic molecular probes for targeting [260]. Synthesized biodegradable polymers 
are thus preferred. For example, Zhang’s group synthesized poly(ethylene 
glycol)-b-poly(L-lactide) (PEG-PLA) and conjugated it to cisplatin to for a prodrug, 
which was composed of a cisplatin complex with two ketobearing ligands conjugated 
to two PEG-PLA chains via an acid responsive Schiff-base linkage. The prodrug 
displayed abilities to kill A2780 human ovarian carcinoma cells several times higher 
than free cisplatin. Nevertheless, the drug loading is only 1 wt % [261, 262]. Jing’s 
group synthesized a biodegradable amphiphilic tri-block copolymer, 
MPEG-b-PCL-b-PLL, which contains pendant amino groups to form a polymeric 
pro-drug of cisplatin. The prodrug was then used to form micelles. The resulted 
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micelles were too large with an average diameter of about 200-220 nm without 
cisplatin and 150-160 nm with cisplatin. Also, the therapeutic effects of such prodrug 
micelles were not enhanced significantly [263].   
We propose to synthesize vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate 
(TPGS) prodrug micelles as a platform to formulate hydrophilic drugs to achieve high 
drug loading, high drug encapsulation efficiency and high cellular uptake of the 
formulated drug. Vitamin E TPGS or simply TPGS (D-alpha-tocopheryl polyethylene 
glycol 1000 succinate) is a water-soluble derivative of natural vitamin E, i.e. a 
PEGylated Vitamin E, which has amphiphilic structure comprising lipophilic alkyl tail 
and hydrophilic polar head portion. TPGS already showed advantages in formulation 
of various anticancer drugs such as doxorubicin, which showed enhanced therapeutic 
effects and reduced side effects [252, 264]. Cis,trans,cis-Pt(NH3)2Cl2(OH)2 is an 
analogue of cisplatin. This Pt (IV) analogue molecule can be further esterified with 
carboxyl or acid anhydride groups [262, 263, 265, 266]. Therefore, through a linker 
with carboxyl group, it is possible to conjugate the drug with TPGS to form a prodrug. 
This prodrug can further be used to form micelles in water to enhance drug loading and 
cellular uptake. Such a formulation of prodrug micelles solves the problem of poor 
solubility of cisplatin and prolongs its half-life in circulation in comparison with 
original cisplatin. Besides, the ester bond would be stable in the blood (pH=7.4) but 
easily cleaved in endosomes (pH=5-6) after uptake by cancer cells [267]. The 
anti-cancer effect of such prodrug micelles can be shown in vitro with a cancer cell line 
HepG2. Compared with direct encapsulation of cisplatin, such prodrug micelles are 
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able to load other hydrophobic therapeutic or imaging agents into the core of micelles 
to achieve multimodality treatment or theranostics. For example, many literatures have 
reported that cisplatin and docetaxel can be combined to achieve synergistic efficacy 
[268-270]. We further loaded docetaxel as hydrophobic anti-cancer drug into the 
TPGS-cisplatin prodrug micelles and assessed its anti-cancer effect in SK-BR-3 cells 
via comparing its IC50 with single drug-loaded TPGS micelles. 
4.2 Materials and methods 
4.2.1 Materials 
Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate, 
C33O5H54(CH2CH2O)23) was from Eastman Chemical Company (Tennessee, USA). 
cis-Diammineplatinum (II) dichloride, Succinic anhydride, 
N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), dimethyl 
sulfoxide (DMSO), coumarin-6, phosphate buffered saline (PBS, pH 7.4), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsin-EDTA solution and propidium iodide (PI), poly(ethylene glycol) (PEG, 
Mn=1000)  were all purchased from Sigma-Aldrich (St. Louise, MO, USA). 
Tween-80 was from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was provided by 
USB Corporation (OH, USA). Fetal bovine serum (FBS) was purchased from Gibco 
Life Technologies (AG, Switzerland). Penicillin-streptomycin solution was from 
Invitrogen (CA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) was from 
Sigma (St. Louise, MO, USA). All solvents used in this study were HPLC grade. 
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HepG2 cancer cells and SH-SY5Y cells were provided by American Type Culture 
Collection (ATCC, USA). The water used was pretreated with the Milli-Q
®
 Plus 
System (Millipore Corporation, Bedford, USA). 
4.2.2 Synthesis of TPGS-cisplatin prodrug and cisplatin-PEG prodrug 
For synthesis of TPGS-cisplatin prodrug, cis, cis, 
trans-Diamminedichlorodihydroxyplatinum and cis, cis, 
trans-Diamminedichlorodisuccinatoplatinum (IV) (cisplatin-SA) were first 
synthesized according to previous methods [267, 271]. TPGS, cis, cis, 
trans-Diamminedichlorodisuccinatoplatinum (IV), DCC and DMAP with a 
stoichiometric molar ratio of 1:10:10:0.1 were then dissolved in DMSO and stirred 
under nitrogen atmosphere at room temperature for 24 h. The presence of 
N,N-dicyclohexylurea (DCU) in the product was removed through filtration, which 
was performed by using Whatman filter paper, Grade 1, pore size 11 μm. The resulting 
mixture was dialyzed against DMSO for 72 h to remove excess DCC and cis, cis, 
trans-Diamminedichlorodisuccinatoplatinum(IV). Then, it was dialyzed against water 
for 24 h to remove DMSO. The product was then freeze-dried. 
For synthesis of cisplatin-PEG prodrug, poly(ethylene glycol) (PEG, Mn=1000), cis, 
cis, trans-Diamminedichlorodisuccinatoplatinum (IV), DCC and DMAP with a 
stoichiometric molar ratio of 1:10:10:0.1 were dissolved in DMSO and stirred under 
nitrogen atmosphere at room temperature for 24 h. The following treatment was the 
same as that for TPGS-cisplatin prodrug. 
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4.2.3 NMR of TPGS-cisplatin prodrug 
The synthesis of cis, cis, trans-Diamminedichlorodisuccinatoplatinum (IV) 
(cisplatin-SA) and conjugation of TPGS-cisplatin prodrug was proved by 
1
H NMR in 
DMSO-d6 at 500 Hz (Bruker ACF300). 
4.2.4 Preparation of TPGS-cisplatin prodrug micelles and docetaxel-loaded 
TPGS-cisplatin prodrug micelles 
TPGS-cisplatin prodrug (50mg) was dissolved in chloroform. The organic solvent was 
removed by rotary vacuum evaporation. The film formed was freeze-dried in vacuum, 
and then hydrated with 5 mL 1X PBS buffer, incubated at 37 °C for 30 min, and then 
sonicated for a few minutes. The resultant mixture was filtered through 0.2 mm 
polyethersulfone syringe filter in a sterile environment.  
For the coumarin-6- or docetaxel- loaded TPGS-cisplatin prodrug micelles, 
TPGS-cispaltin prodrug (50 mg) and coumarin-6 (1 mg) or docetaxel (5 mg) were first 
dissolved in chloroform. The other steps were the same as previously mentioned. 
4.2.5 Characterization of TPGS-cisplatin prodrug micelles and docetaxel-loaded 
TPGS-cisplatin prodrug micelles 
Surface morphology, size and size distribution 
The shape and surface morphology of the particles were investigated by field emission 
transmission electron microscope (FETEM, JEM-2200FS, JEOL, Japan). Size and size 
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distribution of nanoparticles were measured by the dynamic light scattering (DLS) (90 
plus particle size analyzer, Brookhaven Instruction Corporation, TX, USA). The 
samples were prepared by diluting the nanoparticle suspension with deionized water to 
a count rate of 300-500 kcps and sonicated for 5 min before measurement.  
Drug load 
The drug load of TPGS-cisplatin prodrug micelles is defined as weight percentage of 
cisplatin in the micelles. It was analyzed with ICP-MS (Agilent ICP-MS 7500 Series). 
In details, a known weight of TPGS-cisplatin prodrug micelles was taken in glass test 
tube. Then, 2 mL of concentrated nitric acid was added and heated to 90 °C for 45 min. 
Then the samples were diluted with sufficient Milli-Q water. The analysis of platinum 
element was done by ICP-MS and the content of cisplatin in TPGS-cisplatin prodrug 
micelles was calculated according to its atomic mass. 
The amount of docetaxel encapsulated in the micelles was measured by high 
performance liquid chromatography (HPLC, Agilent LC1100). The method was 
described in 3.2.4 “Drug Encapsulation Efficiency”. 
Surface chemistry 
Surface chemistry of nanoparticles was analyzed by X-ray photoelectron spectroscopy 
(XPS, Kratos Ultra DLD, Shimadzu, Japan) under fixed transmission mode with pass 
energy of 80 mV and the binding energy ranged from 0 to 1100 eV. 
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Determination of the critical micelle concentration (CMC) 
CMC of TPGS-cisplatin prodrug micelles were determined by pyrene as a florescent 
probe. The method was described in 3.2.4 “Determination of the critical micelle 
concentration (CMC)”. 
4.2.6 In vitro drug release 
4 mL TPGS-cisplatin prodrug micelles solution was placed in a dialysis bag (molecular 
mass cut-off 1 kDa) with 0.1% w/v Tween-80. The dialysis bags were incubated in 20 
mL buffer (pH=7.4 or pH=5.5) containing 0.1% w/v Tween-80 at 37 °C with gentle 
shaking, and the incubation buffer was collected and replaced by fresh incubation 
buffer at every designated time points. The collected incubation buffer containing the 
released cisplatin was freeze-dried. Then, the platinum element was analyzed with 
ICP-MS as being mentioned in the section of 4.2.5 Drug Load. The error bars were 
obtained from triplicate samples. 
4.2.7 Cell Culture 
HepG2 and SK-BR-3 cells were cultured using Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin solution in 25 




4.2.8 In vitro cellular uptake study 
Qualitative study by confocal microscopy: 
The method was described in 3.2.7. 
Quantitative study by ICP-MS: 
After reaching confluence, cells were detached, counted, and seeded in 6-well 
transparent plate (Costar, IL, USA) at 2×10
5
 cells/mL. After 12 h incubation, medium 
was replaced by cisplatin, cisplatin-PEG prodrug and TPGS-cisplatin prodrug micelles 
suspensions with the same cisplatin concentration. After 0.5 h or 2 h incubation, the 
suspensions were removed. Cells were washed twice with 1X PBS and collected for 
ICP-MS (Agilent ICP-MS 7500 Series). Element platinum was analyzed and compared 
with that in original amount to get cellular uptake efficiency. 
4.2.9 In vitro cytotoxicity 
HepG2 and SK-BR-3 cells were seeded in 96-well transparent plates (Costar, IL, USA) 
at 5×10
3
 cells/well (0.1 mL) and after 12 h, the medium was replaced by different 
therapeutic suspensions with designated concentrations for 24 h, 48 h and 72 h 
incubation. The samples were sterilized with UV irradiation overnight before 
experiment. Cell viability was measured using MTT assay standard protocol. 
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4.3 Results and discussion 
4.3.1 Synthesis of TPGS-cisplatin micelles 
TPGS-cisplatin prodrug was first synthesized. The structure is shown in Figure 4.1A. 
The prodrug micelles were then prepared by self-assembly of this amphiphilic 
TPGS-cisplatin prodrug in water (Figure 4.1B). Such prodrug micelles can further be 
loaded with other drugs or imaging agents through hydrophobic interaction inside the 
core. Therefore, the TPGS-cisplatin prodrug micelles, as a platform, can be used not 
only for delivery of cisplatin but also for multimodality treatment or theranostics with 
other agents. In the article, fluorescent molecule, coumarin-6, and hydrophobic drug, 
docetaxel, were used as model cargoes to show its loading ability for other imaging 
agents or hydrophobic drugs. The uptake of such particles was demonstrated in the 
cancer cell lines.  
 
Figure 4.1 Characterization of TPGS-cisplatin prodrug micelles. (A) Structure of 
TPGS-cisplatin prodrug. (B) Schematic illustration of the formulation of 




4.3.2 NMR of TPGS-cisplatin prodrug 
The conjugation of TPGS-cisplatin prodrug is determined by 
1
H NMR in DMSO-d6. 
The 
1
H NMR spectra of cisplatin-SA and TPGS-cisplatin are shown in Figure 4.2. 
Cisplatin was first conjugated with succinic acid (cisplatin-SA) before reaction with 
TPGS. The structure of cisplatin-SA is shown in Fig 2A. The peak ‘a’ at 12.09 ppm and 
peak ‘b’ at 6.46 ppm are considered as the characteristic peak of -COOH and -NH2 in 
cisplatin-SA respectively. After conjugation with TPGS (Fig. 2B), a peak ‘c’ at 3.51 
ppm can be observed which is a characteristic peak of -CH2 protons of PEG part of 
TPGS. The peaks from 6 ppm to 14 ppm in Fig. 2B were highlighted in the inset. The 
emergence of characteristic peak ‘b’ of -NH2 at 6.45 ppm indicates that the cisplatin-SA 
has been successfully conjugated to TPGS. Besides, the peak ‘a’ at 11.60 ppm in Fig. 
2B may be the other –COOH part of cisplatin-SA. It shows a little shift compared with 
that in Fig. 2A, which may be because one side –COOH in cisplatin-SA has bonded 







H NMR spectra of (A) cisplatin-SA, (B) TPGS-cisplatin with the insert 
for a magnification of the region between 6 and 14 ppm. 
4.3.3 Characterization of TPGS-cisplatin prodrug micelles and docetaxel-loaded 
TPGS-cisplatin prodrug micelles 
Surface morphology, micelle size and size distribution 
Field emission transmission electron microscope (FETEM) was used to image the 
morphology of the TPGS-cisplatin prodrug micelles and docetaxel-loaded 
TPGS-cisplatin prodrug micelles (Figure 4.3). It shows that the micelles are generally 
spherical in shape. Using the dynamic light scattering (DLS), the average size and size 
distribution of the micelles was shown in Table 4.1 (mean±SD, n=3). The size of the 
micelles shown in the TEM figure is a little bigger than that tested from DLS, which is 
because of the low melting point of TPGS (approximately 38 °C). The micelles suffer 
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from the melting and expansion in a certain extent under the high energy electron beam 
in TEM which make them seemed bigger in TEM image than in DLS test. It is believed 
that the size between 10-100 nm will be superior to escape the first-pass elimination by 
the kidney and enter tumor by penetrating the leaky vasculature. Such a small size will 
also be effective to penetrate into the cancer cells. 
Table 4.1 The average size and size distribution of the micelles 





Docetaxel-loaded TPGS micelles 8.98±0.53 0.318±0.042 
TPGS-cisplatin prodrug micelles 8.48±0.38 0.351±0.045 







Figure 4.3 TEM images of micelles. A: TPGS micelles; B: docetaxel-loaded TPGS 
micelles; C: TPGS-cisplatin micelles; D: docetaxel-loaded TPGS-cisplatin micelles 
 
Drug load 
The cisplatin load of TPGS-cisplatin prodrug micelles is defined as weight percentage 
of cisplatin in the micelles. It can be determined by ICP-MS through analyzing the 
content of platinum in the sample. The theoretically maximal drug load can be 
achieved when every TPGS molecule conjugates with one cisplatin molecule and it can 
be calculated to be around 15% w/w. The actual drug load was measured to be 
4.95±0.27% w/w (mean±SD, n=3). It indicates a high drug load which is higher than 
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some recent cisplatin delivery system and even higher than some nanoparticle 
encapsulation system [262, 272]. Such a drug load result demonstrates that the 
TPGS-cisplatin prodrug micelles will be an effective delivery system for cisplatin. 
The docetaxel load of docetaxel-loaded TPGS-cisplatin prodrug micelles is defined as 
weight percentage of docetaxel in the micelles. It was tested with HPLC and showed 
to be 2.82±0.64% (mean±SD, n=3). 
Surface chemistry 
The conjugation and distribution of cisplatin in the micelles were demonstrated with 
x-ray photoelectron spectroscopy (XPS). Wide scan and the binding energy of Pt 4f are 
shown in Figure 4.4. The lower curve represents TPGS micelles and the upper curve 
represents the TPGS-cisplatin prodrug micelles. In the two samples, the Pt 4f signal 
can be only from cisplatin. There is no detectable level of cisplatin in the TPGS 
micelles. Therefore, the appearance of Pt signal in TPGS-cisplatin prodrug micelles 
shows the successful conjugation of the prodrug. It also indicates that the cisplatin is 




Figure 4.4 Representative X-ray photoelectron spectroscopy (XPS) spectrum of 
widescan spectrum and Pt 4f peaks (the inset) from the TPGS micelles (lower curve), 
and TPGS-cisplatin prodrug micelles (upper curve). 
 
Critical micelle concentration (CMC) of TPGS-cisplatin prodrug micelles 
The critical micelle concentration (CMC) of TPGS-cisplatin prodrug micelles is 
determined using fluorescence technology. Pyrene with a determined concentration is 
used as fluorescent probe and different concentrations of TPGS-cisplatin prodrug 
solutions are prepared. When the concentration of TPGS-cisplatin prodrug is higher 
than its CMC, micelles will be formed and pyrene will be encapsulated inside the 
hydrophobic core. The change of the environment of pyrene, from polar to non-polar, 
leads to a red shift in the excitation spectra. The CMC of TPGS-cisplatin prodrug 
micelles can be obtained by plotting the I336/I332 ratio of each curve in the excitation 
spectra versus log concentration of the prodrug. The maximum change in the slope 
represents the formation of TPGS-cisplatin prodrug micelles. It can be seen from 
Figure 4.5, the CMC of TPGS-cisplatin prodrug is about 5.01±0.35 mg/L. Such a low 
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CMC indicates that the micelles will keep stable even at a very low concentration in 
blood. 
 
Figure 4.5 Plot of the fluorescence intensity ratio of I336/I332 as a function of 
TPGS-cisplatin prodrug concentration. 
 
4.3.4 In vitro drug release 
The in vitro cisplatin release profile of TPGS-cisplatin prodrug micelles in 120 h is 
shown in Figure 4.6. It is obtained by recording the platinum content at different time 
points through ICP-MS. The sustained release of cisplatin is due to the hydrolysis of 
ester bond in TPGS-cisplatin prodrug. It can be seen that the release rates of 
TPGS-cisplatin prodrug micelles in the solutions of pH=5.5 and pH=7.4 are almost the 
same at the first 12 h, which released 50.18% of total cisplatin at pH=5.5 and 49.53% 
of it at pH=7.4 respectively. It means that the hydrolyzed rates at different pH are very 
close at first 12 h. An initial burst of release can be observed because of the relatively 
high concentration of cisplatin in the micelles and some degree of hydrolysis has begun 





















cancer cells effectively. After that, a moderate release is represented which ensures the 
ability of the micelles to sustained treatment of the cancer cells. During this process 
(from 24 h to 120 h), the micelles show a higher release rate in acid environment at 
pH=5.5 than that at pH=7.4. The reason is that the acid environment will accelerate the 
hydrolysis of ester bond. This result will prevent the total drug release in bloodstream 
and promote the drug release in endosomes or lysosomes in cancer cells. It reveals that 
after 120 h the TPGS-cisplatin prodrug micelles release 87.04% of the total amount at 
pH=5.5 and 70.83% at pH=7.4. It shows that though ester bond may not the best choice 
for PH sensitive release, it improve the release of cisplatin in acid environment instead 
of neutral environment. 
 
Figure 4.6 Cumulative release profile of cisplatin from TPGS-cisplatin prodrug 





































4.3.5 In vitro cellular uptake: confocal microscopy study 
The internalization of the TPGS-cisplatin prodrug micelles into HepG2 cancer cells is 
visualized through confocal laser scanning microscopy (CLSM). The TPGS-cisplatin 
prodrug micelles are loaded with coumarin-6 as model cargo and the two kinds of cells 
are cultured with 0.125 mg/mL micelles for 2 h. The fluorescence of coumarin-6 
loaded micelles is detected and the results are shown in Figure 4.7. Figure 4.7A is FITC 
channel showing the green fluorescence from coumarin-6 loaded TPGS-cisplatin 
prodrug micelles in HepG2 cells. Figure 4.7B is PI channel showing the red 
fluorescence from PI stained nuclei. Figure 4.7C is merged channels of FITC and PI. 
From the Figure, it can be seen that obviously green fluorescence is detected in the 
cytoplasma. It means that the TPGS-cisplatin prodrug micelles are able to penetrate 
into the cells effectively through endocytosis due to its small size. Therefore, the 
TPGS-cisplatin prodrug micelles can be a good delivery platform for other drugs or 
imaging agents for multimodality treatment and theranostics. 
 
Figure 4.7 Confocal laser scanning microscopy (CLSM) images show the 
internalization of TPGS-cisplatin prodrug micelles in cells (2 h incubation). (A): 
FITC channels showing the green fluorescence from coumarin-6 loaded 
TPGS-cisplatin prodrug micelles distributed in cytoplasm. (B): PI channels showing 
the red fluorescence from propidium iodide stained nuclei. (C): Merged channels of 
FITC and PI channels. (A), (B) and (C): HepG2 cells were used. 
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4.3.6 In vitro cellular uptake: quantitative study 
The cellular uptake of TPGS-cisplatin prodrug micelles is compared with cisplatin and 
cisplatin-PEG prodrug at the same cisplatin concentration in HepG2 cells using 
ICP-MS. Cisplatin-PEG was used as a standard form of cisplatin prodrug to compare 
with TPGS-cisplatin prodrug micelles and show the advantage of prodrug micelles for 
cellular uptake. It shows in figure 4.8 that after 0.5 h, the cellular uptake efficiency of 
cisplatin, cisplatin -PEG prodrug and TPGS-cisplatin prodrug micelles were measured 
to be 3.31±0.21 %, 0.21±0.023 % and 7.65±0.075 % respectively, well after 2h, they 
were measured to be 8.02±0.29 %, 0.83±0.062 % and 18.73±1.10 % respectively. The 
results reveal that neither cisplatin nor cisplatin-PEG prodrug can penetrate into the 
cancer cells as efficiently as TPGS-cisplatin prodrug micelles. High uptake efficiency 
is obtained through forming TPGS-cisplatin prodrug micelles. Therefore, 





Figure 4.8 Cellular uptake efficiency of cisplatin, cisplatin-PEG prodrug and 
TPGS-cisplatin prodrug micelles in HepG2 cells after 0.5 h and 2 h incubation 
respectively at 37ºC. Data represent mean ± SD, n=3. 
4.3.7 In vitro cytotoxicity of TPGS-cisplatin prodrug micelles 
The cytotoxicity of TPGS-cisplatin prodrug micelles was demonstrated first with a 
cancer cell line HepG2. The cells were incubated for 24, 48 and 72 h with the micelles 
of different loaded cisplatin concentrations at 25, 2.5, 0.25, 0.025 μg/mL. Its 
anti-cancer effect was examined by comparing with original cisplatin at the same 
concentrations and incubation time. The results are shown in Figure 4.9. We 
normalized the cell viability to the group of cells without any treatment. For cisplatin, 
after 24 h incubation at the concentrations of 25, 2.5, 0.25, and 0.025μg /mL, the cell 
viability is found to be 12.23±2.76%, 58.23±1.76%, 91.42±2.77% and 100.35±2.35% 
respectively. Instead, at the four designed drug concentrations, the cell viability 
decreased to 8.42±3.01%, 35.22±1.40%, 77.12±1.37%, and 91.45±1.24% after 48 h 
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incubation and 0.99±0.37%, 16.59±2.01%, 52.38±1.92%, 78.68±7.01% after 72h 
incubation respectively. While, for TPGS-cisplatin prodrug micelles at the equivalent 
drug concentration, the cell viability was measured to be 5.70±0.55%, 55.71±2.83%, 
77.14±6.12% and 95.87±1.12% after 24 h treatment; 4.54±1.39%, 37.58±2.63%, 
67.30±1.06% and 84.28±2.23% after 48 h treatment; 0.52±0.42%, 20.64±2.66%, 
43.71±3.01% and 50.65±1.24% after 72 h treatment, respectively. It can be seen that as 
the incubation time and concentration increase, the cell viability decreases obviously. 
Besides, after conjugation to TPGS and formation of prodrug micelles, instead of 
reducing the anti-cancer effect, cisplatin shows better anti-cancer effects than the 
original cisplatin for HepG2 cancer cells. Such increased anti-cancer effects may be 
due to the advantages of nanomedicine [110]. Formulation of cisplatin into prodrug 
micelles will lead to higher drug load, more desirable release of drugs as well as higher 
cellular uptake. Besides, it has been demonstrated that TPGS also shows some 
anti-cancer effect (Chapter 3). All of these reasons lead to a higher efficacy of 
TPGS-cisplatin prodrug micelles than that of the original cisplatin. The results can be 
further ensured by calculating the IC50 value, which is defined as the drug 
concentration needed to kill 50% of the incubated cells in a designated time period. 
From Table 4.2, it can be seen that the IC50 of the original cisplatin is 3.95, 0.98 and 
0.19 μg/mL for 24, 48, and 72 h respectively. The IC50 of TPGS-cisplatin decreases to 
be 1.36, 0.51 and 0.08μg/mL after the same incubation time, i.e. a 65.6%, 48.0% and 
57.9% decrease for the TPGS-cisplatin prodrug micelles formulation. The results 
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imply that TPGS-cisplatin prodrug micelles are more effective than original cisplatin 
for cancer therapy. 
 
Figure 4.9 The diagrams of HepG2 cell viability at various drug concentrations after 
24 h, 48 h and 72 h treatment. Data represent mean ± SD, n=6. 
 
Table 4.2 IC50 of cisplatin and TPGS-Cisplatin prodrug micelles after 24, 48, 72 h 
incubation with HepG2 cells at 37°C. 
Incubation time (h) 
IC50 (μg/mL) 
HepG2 Hepatocarcinoma Cells 
Cisplatin TPGS-Cisplatin prodrug micelles 
24 3.95 1.36 
48 0.98 0.51 




4.3.8 Anti-cancer effect of docetaxel-loaded TPGS-cisplatin prodrug micelles 
The anti-cancer effect of docetaxel-loaded TPGS-cisplatin prodrug micelles was 
evaluated in SK-BR-3 cancer cells by testing the IC50 of the cells treated by the 
micelles after 24, 48 and 72 hours. The result was compared with the IC50 of 
SK-BR-3 cells treated by docetaxel-loaded TPGS micelles and TPGS-cisplatin 
prodrug micelles to demonstrate the enhanced anti-cancer effect of the dual-drug 
multimodality treatment. The cell viability of different treatments was shown in 
Figure 4.10 and their IC50 was calculated. In Table 4.3, it can be seen that the IC50 of 
docetaxel-loaded TPGS micelles is 0.20, 0.10 nd 0.11 μg/mL for 24, 48, and 72 h, 
respectively. The IC50 of TPGS-cisplatin prodrug micelles is 0.15, 0.09 and 0.10 
μg/mL for 24, 48, and 72 h, respectively. The IC50 of docetaxel-loaded TPGS-cisplatin 
prodrug micelles is 0.10, 0.06 and 0.01 μg/mL for 24, 48, and 72 h, respectively. The 
result revealed that the dual-drug multimodality treatment could further improve the 
anti-cancer efficiency of TPGS-cisplatin prodrug micelles. When using micelles as 
the nano delivery system, the dual-drug multimodality treatment was superior to 





Figure 4.10 Cell viability of SK-BR-3 treated with docetaxel-loaded TPGS micelles, 
TPGS-cisplatin prodrug micelles and docetaxel-loaded TPGS-cisplatin prodrug 
micelles after 24h, 48h and 72 h. 
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Table 4.3 IC50 of SK-BR-3 cells treated by docetaxel-loaded TPGS micelles, 
TPGS-cisplatin prodrug micelles and docetaxel-loaded TPGS-cisplatin prodrug 
micelles after 24, 48, 72 h incubation at 37°C. 










24 0.20 0.15 0.10 
48 0.10 0.09 0.06 
72 0.11 0.10 0.01 
 
4.4 Conclusions 
This research developed a vitamin E TPGS prodrug micelle strategy for hydrophilic 
and hydrophobic drug formulation for high drug loading and high cellular uptake in 
comparison with the traditional double emulsion strategy. Cisplatin was chosen as a 
model hydrophilic drug, which was first conjugated to vitamin E TPGS as a prodrug. 
TPGS-Cisplatin micelles were then synthesized and characterized. Docetaxel was 
also loaded into the core of the micelles as hydrophobic drug. Such a prodrug micelle 
system showed good potential to deliver hydrophilic cisplatin and hydrophobic 
docetaxel with a low critical micelle concentration (CMC) of 5.01 mg/L, a high drug 
load, and a pH-controlled release of cisplatin. The IC50 value showed the advantage of 
the prodrug micelle formulation compared with the drug itself, which was found to 
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decrease from 3.95 μg/mL of cisplatin to 1.36 μg/mL of the TPGS-cisplatin prodrug 
micelles after 24 hour cultured in HepG2 hepatocarcinoma cells. Moreover, loading 
of docetaxel in the TPGS-cisplatin prodrug micelle core led to enhanced anti-cancer 












Chapter 5: Targeted Co-Delivery of Docetaxel, Cisplatin and 
Herceptin by Vitamin E TPGS-Cisplatin Prodrug 
Nanoparticles for Multimodality Treatment of Cancer 
5.1 Introduction 
Cancer is the first leading cause of death in developing countries and the second 
leading cause of death in developed countries. One in eight deaths in the world is due to 
cancer. It is reported that the global burden is expected to grow to 21.4 million new 
cancer cases and 13.2 million cancer deaths by 2030 (American Cancer Society: Global 
Cancer Facts & Figures 2
nd
 Edition). In spite of great effort, there has been no 
significant progress in cancer treatment in the past decades. It is unlikely that any 
magic anticancer drug can be discovered in the next few years to cure the cancer, since 
the problems in drug delivery such as low drug tolerance, no specificity, multidrug 
resistance, undesired pharmacokinetics and biodistribution would be always there. 
Instead, multimodality treatment can be expected to have increased efficacy compared 
to any single treatment in the current practice. Nanomedicine can provide a functional 
platform for multimodality treatment. 
It has been reported in several cases in clinics that combination chemotherapy 
(chemotherapy by more than one anticancer drugs) will effectively overcome the drug 
resistance for mono chemotherapy, improve their response rate and even lead to 
synergistic effect. For example, taxanes are combined with doxorubicin and a 94% 
response rate was reported in chemotherapy-naive patients with metastatic disease 
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[273]. There is a clinical trial showing that paclitaxel/doxorubicin could be 
significantly more active than paclitaxel alone [274]. In a trial of combination of 
docetaxel and cisplatin for advanced epithelial ovarian cancer, an overall clinical 
response rate of 69% and median progression-free survival of 12 months were reported 
[275]. Combining chemotherapy with other therapeutic methods for multimodality 
treatment such as radiotherapy, immunotherapy, thermotherapy and gene therapy will 
further improve the therapeutic efficacy of chemotherapy. For example, trastuzumab 
(herceptin), a biological therapy agent, was shown to have at least additive cytotoxic 
effects with taxanes [276, 277]. The interaction with docetaxel appears to be 
synergistic. Some clinical trials have combined docetaxel, cisplatin and herceptin for 
breast cancer therapy. In one trial, it was shown that such a combination is feasible and 
active in T2 HER2-overexpressing breast cancer patients in terms of complete response, 
partial response and manageable toxicities [278]. In another trial, combination of these 
three agents as primary systemic therapy for HER2-positive locally advanced breast 
cancer achieved a 4-year progression-free survival rate of 81% and overall survival rate 
of 86% [279]. 
Unfortunately, most anticancer drugs have difficulties in formulation due to their 
problems in solubility, permeability and stability. Considered multimodality treatment 
for cancer, such problem will be magnified due to the nature of the multiple agents 
involved in the treatment. For example, Taxotere®, the clinical formulation of 
docetaxel, is formulated in polysobate 80, which has been found to cause serious side 
effects including hypersensitivity reactions, nephrotoxicity, cardiotoxicity and 
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neurotoxicity [121]. Cisplatin is poorly soluble in organic solvents and partially soluble 
in water such that it is difficult to be well dispersed in the plasma [257]. Nanomedicine 
may provide a good platform to overcome the problems in drug formulation, which is 
defined as application and further development of nanotechnology to solve problems in 
medicine, i.e. to diagnose, treat and prevent diseases in cellular and molecular level. 
With the help of nanocarriers such as prodrugs, micelles, liposomes, nanoparticles of 
biodegradable polymers, nanohydrogels and dendrimers, the various therapeutic agents 
could be loaded efficiently to realize sustained and controlled delivery. [213, 248, 280]. 
Furthermore, nanomedicine will help to improve the efficacy of multimodality 
treatment due to its size effect and surface property, which might lead to passive and 
active targeting for agents accumulation in tumor [109, 259, 281]. 
In this article, we will prove the concept of nanomedicine-mediated multimodality 
treatment by co-encapsulation of cisplatin, docetaxel and herceptin in vitamin E 
TPGS-cisplatin prodrug nanoparticles. Vitamin E TPGS or simply TPGS is short for 
d-alpha-tocopheryl polyethylene glycol 1000 succinate, which is a water-soluble 
derivative of natural vitamin E, i.e., a PEGylated Vitamin E. It has an amphiphilic 
structure comprising of lipophilic alkyl tail and hydrophilic polar head portion. TPGS 
is a molecular biomaterial applicable that has found wide application in development 
of the various nanocarriers of high performance [131, 132, 282, 283]. The advantages 
of TPGS-cisplatin prodrug micelles have been reported (Chapter 4). It has been shown 
that such a prodrug system could deliver hydrophilic drug with high drug load, 
pH-responsive drug release, high cellular uptake and enhanced anticancer efficacy. It is 
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believed that TPGS-cisplatin based nanomedicine would be a practical platform for 
multimodality treatment.  
In this paper, TPGS-cisplatin prodrug nanoparticles were synthesized to co-deliver 
both cisplatin and docetaxel. Poly(lactide)-TPGS (PLA-TPGS) and carboxyl 
group-terminated TPGS (TPGS-COOH) copolymer blend were added to stabilize the 
nanoparticles. Herceptin was conjugated onto the TPGS-cisplatin prodrug 
nanoparticles, which is a humanized monoclonal antibody, targeting the extracellular 
domain of human epidermal growth factor receptor 2 (HER2) [284]. About 20%-30% 
of the breast cancer patients are diagnosed as HER2 positive. It has been used as a 
targeting ligand for nanocarrier drug delivery systems as well as a biological 
therapeutic agent for HER2-overexpresssing breast cancer [115-117].  
We showed in this research that the herceptin conjugated TPGS-cisplatin prodrug 
nanoparticles could achieve quantitative control of the ratio of the two drugs by simply 
varying the feeding ratio of docetaxel and TPGS-cisplatin prodrug in the nanoparticle 
formulation process. A pH-sensitive controlled release of cisplatin and docetaxel and 
the synergistic effect of cisplatin and docetaxel could be achieved. An optimal 
cisplatin:docetaxel ratio was also determined. The efficacy of multimodality treatment 
by docetaxel, cisplatin and herceptin loaded nanoparticles was evaluated in vitro with 
breast cancer cell lines of low, moderate and high HER2 overexpression. 
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5.2 Materials and methods 
5.2.1 Materials 
PLA-TPGS [285, 286], TPGS-COOH [287] and TPGS-cisplatin prodrug (Chapter 4) 
were synthesized according to previous papers. Herceptin (21 mg/mL, 4.76 mL) was 
purchased from National Cancer Centre (Singapore). Docetaxel (anhydrous, 99.56% 
purity) was obtained from Shanghai Jinhe Bio-Technology Co. Ltd (Shanghai, China). 
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS, C33O5H54(CH2CH2O)23) 
was from Eastman Chemical Company (Tennessee, USA). Lactide 
(3,6-dimethyl-1,4-dioxane-2,5-dione, C6H8O4), cis-diammineplatinum (II) dichloride, 
succinic anhydride, N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine 
(DMAP), N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), 
N-Hydroxysuccinimide (NHS), dimethyl sulfoxide (DMSO), Tetrahydrofuran (THF), 
stannous octoate (Sn(OOCC7H15)2), coumarin-6, phosphate buffered saline (PBS, pH 
7.4), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsin-EDTA solution and propidium iodide (PI) were all purchased from 
Sigma-Aldrich (St. Louise, MO, USA). Tween-80 was from ICN Biomedicals, Inc. 
(OH, USA). Fetal bovine serum (FBS) was purchased from Gibco Life Technologies 
(AG, Switzerland). Penicillin-streptomycin solution was from Invitrogen. Dulbecco’s 
Modified Eagle’s Medium (DMEM) was purchased from Thermo Scientific Hyclone 
(South Logan, USA). MCF7 breast cancer cells, SK-BR-3 breast cancer cells, NIH3T3 
fibroblast cells were obtained from American Type Culture Collection (ATCC, USA).  
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All solvents used in this study were HPLC grade. Water was treated with the Milli-Q 
Plus System from Millipore Corporation (Bedford, USA). 
5.2.2 Preparation of TPGS-cisplatin prodrug nanoparticles (TCP NPs) and 
herceptin-conjugated TPGS-cisplatin prodrug nanoparticles (HTCP NPs) 
PLA-TPGS were firstly synthesized and characterized. The details can be found from 
our earlier publications, for example [16], where a complete list of references for 
PLA-TPGS and TPGS-COOH synthesis and characterization can be found. 
TPGS-cisplatin prodrug nanoparticles (TCP NPs) were prepared by the 
nanoprecipitation method. Briefly, weighed amount of PLA-TPGS, TPGS-COOH, 
TPGS-cisplatin prodrug with a ratio of 5:1:10, and docetaxel of 4 wt% (TCP2.6 NPs), 1 
wt% (TCP0.7 NPs) and 0.2 wt% (TCP0.1 NPs) of the TPGS-cisplatin weight were 
dissolved in the THF with polymer concentration of 10 mg/mL. The solution was 
added drop-wise into ultrapure water with an oil-water ratio of 1:2 under vigorous 
stirring. After 3 h, the suspension was filtered with filter paper to remove the 
unformulated docetaxel. The filtrate was washed and centrifuged twice at 15,000 rpm 
for 30 min at 4 ºC. The same procedure was applied to synthesize the fluorescent 
coumarin-6 loaded TCP NPs with docetaxel replaced by 0.1 wt% coumatin-6.  
Herceptin was then conjugated to the surface of the nanoparticles to form the HTCP 
NPs by previously established method [116]. Briefly, before conjugation, the carboxyl 
group on particle surface (from TPGS-COOH) was first converted to amine group by 
conjugating TPGS-COOH and ethylenediamine by carbodiimide chemistry with the 
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assistance of EDC and NHS in a buffer solution (pH 8.4). Then, herceptin carboxyl 
group was conjugated to the amine group of nanoparticles by carbodiimide chemistry 
with the assistance of EDC and NHS in a buffer solution (pH 9.2). 
5.2.3 Characterization of TCP NPs and HTCP NPs 
Size and size distribution of the TCP NPs and HTCP NPs were measured by the 
dynamic light scattering (DLS) (90 plus particle size analyzer, Brookhaven Instruction 
Corporation, TX, USA). The samples were prepared by diluting the nanoparticles 
suspension with deionized water to a count rate of 300-500 kcps and sonicated for 5 
min before measurement. 
Zeta potentials of the TCP NPs and HTCP NPs were measured by Doppler anemometry 
(zeta plus analyzer, Brookhaven Corporation, USA). Samples were prepared by 
diluting the nanoparticles suspension until slightly opaque in a PDMS cuvette. The 
data were obtained as the average of five measurements. 
Docetaxel load was determined by high performance liquid chromatography (HPLC, 
Agilent LC1100, Agilent, Tokyo, Japan) with absorption peak at 230 nm. The method 
was described in 3.2.4 “Drug Encapsulation Efficiency”. 
Cisplatin load is defined as weight percentage of cisplatin in the TCP NPs and HCP 
NPs. It was analyzed with ICP-MS (Agilent ICP-MS 7500 Series). The method was 
described in 4.2.5 “Drug load”. 
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Herceptin load was tested with Bradford assay. Standard protocol of Bradford assay 
was used. Briefly, 50 mL of Herceptin solution was mixed with 1.5 mL Bradford 
reagent and incubated for 15 min before measuring absorption at 590 nm using a 
UV-Vis spectrophotometer (UV-1601, Shimadzu, Japan). 
Nanoparticles surface morphology was imaged by the field emission scanning electron 
microscopy (FESEM, JSM-6700F, JEOL, Japan) at an accelerating voltage of 10 kV. 
Before loading to the instrument chamber, samples were coated with platinum by 
JFC-1300 platinum coater (JEOL, Tokyo, Japan) for 30 s at 30 mA. The shape and 
surface morphology of the particles were also investigated by field emission 
transmission electron microscope (FETEM, JEM-2200FS, JEOL, Japan), in which the 
nanoparticles suspension was dropped onto the surface of copper grid with carbon film 
and dried at room temperature. 
Surface chemistry of nanoparticles was analyzed by X-ray photoelectron spectroscopy 
(XPS, Kratos Ultra DLD, Shimadzu, Japan) under fixed transmission mode with pass 
energy of 80 mV and the binding energy ranged from 0 to 1100 eV. 
5.2.4 In vitro drug release 
The TCP NPs and HTCP NPs were dispersed in buffers with different pH values 
(pH=7.4 or pH=5) containing 0.1% v/v Tween-80 and 5 mL of each one was placed in a 
dialysis bag (molecular mass cut-off 2 kDa). The dialysis bags were incubated in 20 
mL buffer (pH = 7.4 or pH = 5) containing 0.1% (v/v) Tween-80 at 37 °C with gentle 
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shaking at 90 rpm. The incubation buffer was collected and replaced by fresh 
incubation buffer at every designated time points. The collected buffer including the 
released drugs was separated into two tubes and freeze-dried. One was used to measure 
the released docetaxel by HPLC following the same procedure of docetaxel load test; 
the other was used to measure the released cisplatin by ICP-MS following the same 
procedure of cisplatin load test. Experiments were conducted in triplicate and results 
were presented as mean±standard deviation SD.  
5.2.5 Cell culture 
NIH3T3 fibroblast cells, MCF7 breast cancer cells and SK-BR-3 breast cancer cells 
were cultured using Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% FBS and 1% penicillin-streptomycin solution in 25 mL cell culture flask. Cells 
were cultivated in an incubator at 37 °C with 5% carbon dioxide. 
5.2.6 In vitro cellular uptake: confocal microscopy study 
The method was described in 3.2.7. 
5.2.7 In vitro cytotoxicity 
NIH3T3 cells, MCF7 cells and SK-BR-3 cells were seeded in 96-well transparent 
plates (Costar, IL, USA) at 5×10
3
 cells/well (0.1 mL) and after 12 h, the medium was 
replaced by nanoparticles suspensions with designated concentrations for 24 h. The 
nanoparticles were sterilized with UV irradiation overnight before the experiment. Cell 
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viability was measured using MTT assay standard protocol. 
5.2.8 Statistical analysis 
Data were expressed as the means with 95% confidence intervals. Statistical tests were 
performed with the Student ’s t test. For all tests, P values less than 0.05 were 
considered to be statistically significant. All statistical tests were two-tailed. 
5.3 Results and discussion 
5.3.1 Design of TPGS-cisplatin prodrug nanoparticles (TCP NPs) and herceptin 
conjugated TPGS-cisplatin prodrug nanoparticles (HTCP NPs) 
In our design, TPGS-cisplatin prodrug was synthesized first. In order to form stable 
prodrug nanoparticles, PLA-TPGS was added as an adjuvant matrix material. 
TPGS-COOH was also used to provide surface functional group for herceptin 
conjugation. All the component materials and docetaxel were dissolved in the organic 
solvent and the nanoprecipitation method was applied to form TPGS-cisplatin prodrug 
nanoparticles (Figure 5.1), which was designated as TCP NPs. These TCP NPs with 
carboxyl groups on surface were then transformed to amine groups by ethylenediamine 
and EDC/NHS at pH 8.2. Herceptin was conjugated on the surface to form 
herceptin-conjugated TPGS-cisplatin prodrug nanoparticles, which was designated as 







Figure 5.1 Schematic illustration of the formulation of docetaxel-loaded 
TPGS-cisplatin prodrug nanoparticles (TCP NPs) and herceptin-conjugated, 
docetaxel loaded TPGS-cisplatin prodrug nanoparticles (HTCP NPs). 
 
5.3.2 Characterization of TCP NPs and HTCP NPs 
Nanoparticle size, size distribution, and zeta potential 
Before herceptin conjugation, three formulations of TCPs of different docetaxel to 
cisplatin weight ratio (2.6:1, 0.7:1, and 0.1:1) are synthesized, and named as TCP2.6, 
TCP0.7, and TCP0.1 (Table 5.1). The sizes of all formulations are above 100 nm and 
below 200 nm, which are suitable for efficient drug delivery via intravenous injection, 
because nanoparticles bigger than 10 nm could escape renal clearance and smaller than 
200 nm have the capability of penetrating through the leaky vasculature [112]. It can be 
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concluded from the three formulations that the hydrodynamic diameter of 
nanoparticles increases with the increase of ratio of docetaxel versus cisplatin. The 
polydispersity indexes (PDI) of all the three formulations are around 0.13, which 
indicate narrow size distribution. Surface charges of the nanoparticles are reflected by 
zeta potential. The zeta potentials of the three formulations of TCPs range from -15 to 
-30, which guarantee sufficient colloidal stability and less toxicity for normal cells than 
positive charged nanoparticles. Numerous studies have shown that high magnitude of 
zeta potentials (positive or negative) may have detrimental effects on blood 
circulation time. -15 - -30 mV seem to be appropriate values with consideration 
between colloidal stability and blood clearance. 
Table 5.1 Characterization of docetaxel-loaded TPGS-cisplatin prodrug nanoparticles 
(TCP NPs) of the various docetaxel versus cisplatin ratios. 














TCP2.6 160.0±9.6 0.133±0.017 -28.1±0.6 10.3±0.2 4.0±0.1 14.3 2.6 
TCP0.7 146.3±8.6 0.131±0.025 -17.7±0.9 2.8±0.4 4.3±0.08 7.1 0.7 
TCP0.1 133.0±5.4 0.130±0.014 -16.7±0.4 0.6±0.1 4.6±0.04 5.2 0.1 
 
We select TCP2.6 for further loading of herceptin. After herceptin conjugation, the 
hydrodynamic diameter of TCP2.6 increases from 160.0±9.6 nm to 187.4±2.4 nm. The 
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polydispersity of HTCP2.6 is 0.114±0.008 which is similar to that of TCP2.6, 
suggesting that nanoparticles still have a uniform size after the conjugation reaction. 
The zeta potential of HTCP2.6 (-25.7±1.4) is slightly more positive than that of 
TCP2.6 (-28.1±0.6), because herceptin (pI = 9.2) has an overall positive charge in the 
ultrapure water (Table 5.2). 
 
Table 5.2 Characterization of herceptin-conjugated, docetaxel-loaded TPGS-cisplatin 
prodrug nanoparticles (HTCP NPs) 









HTCP2.6 187.4±2.4 0.114±0.008 -25.7±1.4 9.0±0.5 3.5±0.1 73.1±5.8 
 
Surface morphology  
The size and surface morphology of the nanoparticles were assessed using FESEM and 
FETEM. Figure 5.2 shows an example of TCP2.6 NPs. It can be seen from the FESEM 
image that the nanoparticles are generally spheres with smooth surfaces. The size 
ranges from 100 nm to 200 nm with narrow distribution, which is in good agreement 
with the result obtained from DLS. TEM shows basically the particle size and 
morphology, which were found no significant difference among the various samples 





Figure 5.2 (A) Field emission scanning electron microscopy (FESEM) image of 
docetaxel loaded TPGS-cisplatin prodrug nanoparticles (TCP2.6 NPs) of 
docetaxel:cisplatin=2.6. (B) Field emission transmission electron microscopy 
(FETEM) image of herceptin-conjugated, docetaxel loaded TPGS-cisplatin prodrug 
nanoparticles of docetaxel:cisplatin=2.6 (HTCP2.6 NPs). 
 
We have noticed that such a nanoparticle system might not be stable with three 
different drugs encapsulated together. We found by TEM, however, that there has been 
no significant changes were observed in the size and morphology of the nanoparticles 
after 2 weeks of storage.  
Therapeutic agents load 
Drug load is defined as the weight of drug (μg) per mg of the drug-loaded nanoparticles. 
The docetaxel load and cisplatin load measured by HPLC and ICP-MS are shown in 
Table 5.1. The docetaxel load for TCP2.6, TCP0.7, and TCP0.1 are 10.3±0.2 μg/mg, 
2.8±0.4 μg/mg, and 0.6±0.1 μg/mg, respectively. In addition, the cisplatin load for 
TCP2.6, TCP0.7, and TCP0.1 are 4.0±0.1 μg/mg, 4.3±0.08 μg/mg, and 4.6±0.04 
μg/mg, respectively. The experiment and result show that the drug load can be easily 
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controlled by varying the feeding concentration of docetaxel and TPGS-cisplatin 
prodrug. As a consequence, their ratio can be precisely controlled. The capability of 
loading the two drugs with adjustable ratio shows that this delivery system is flexible in 
multimodality treatment for cancer. 
We then loaded herceptin by conjugating it to TCP2.6 to form HTCP NPs. The 
docetaxel load and cisplatin load of HTCP NPs are 9.0±0.5 μg/mg and 3.5±0.1 μg/mg, 
respectively, showing insignificant change compared with the drug load of TCP2.6 
NPs. The herceptin load is measured with Bradford assay to be 73.1±5.8 μg/mg (Table 
5.2). 
Surface chemistry 
Surface chemistry of TCP NPs and HTCP NPs was analyzed by X-ray photoelectron 
spectroscopy (XPS). Figure 5.3A shows the peaks of platinum (Pt) 4f for both TCP NPs 
and PLA-TPGS/TPGS-COOH NPs. In the two samples, the Pt 4f signal can be only 
detected from cisplatin. There is no detectable level of Pt in the 
PLA-TPGS/TPGS-COOH NPs. The appearance of Pt signal in TCP NPs indicates that 
cisplatin is successfully loaded into the nanoparticles and most of it distributes on the 
surface of the nanoparticles. It demonstrates that TPGS-cisplatin prodrug nanoparticles 
could be formed and both hydrophilic and hydrophobic drugs could be loaded and 







Figure 5.3 X-ray photoelectron spectroscopy (XPS) spectrum. (A) Pt 4f peaks from 
docetaxel-loaded TPGS-cisplatin prodrug nanoparticles (TCP NPs) and 
PLA-TPGS/TPGS-COOH NPs. (B) N 1s peaks from herceptin-conjugated, docetaxel 
loaded TPGS-cisplatin prodrug nanoparticles (HTCP NPs) and docetaxel-loaded 
TPGS-cisplatin prodrug nanoparticles (TCP NPs). 
 
TCP NPs were further conjugated with herceptin to form HTCP NPs for multimodality 
treatment and targeted delivery. The peaks of nitrogen (N) 1s for both TCP NPs and 
HTCP NPs are shown in Figure 5.3B. Nitrogen signal can be detected either from 
docetaxel or herceptin. Lower curve indicates that no detectable level of docetaxel 
appears on the surface of TCP NPs. Hence, the nitrogen peak in the upper curve should 
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389 391 393 395 397 399 401 403 
HTCP NPs 
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be contributed by herceptin alone. Such result indicates that docetaxel would be 
encapsulated into the hydrophobic core of TCP NPs and herceptin was successfully 
loaded onto the surface of HTCP NPs. 
5.3.3 In vitro drug release profile 
The in vitro drug release profiles of TCP NPs and HTCP NPs at different release 
buffers in 144 h are shown in Figure 5.4. The sustained release of conjugated cisplatin 
from the prodrug nanoparticles is due to the hydrolysis of ester bond in TPGS-cisplatin 
prodrug. Its cumulative release curve was obtained by recording the released platinum 
content in the buffer at different time points through ICP-MS and was shown in Figure 
5.4A. It can be seen that there is an initial burst release of 13.33±0.09% for TCP NPs at 
pH=7.4, 19.46±0.13% for TCP NPs at pH=5, 14.30±0.04% for HTCP NPs at pH=7.4 
and 15.49±0.08% for HTPC NPs at pH=5 in the first 12 h. The initial burst happened 
probably due to the relatively high concentration of cisplatin at the surface of TCP NPs 
and HTCP NPs at the beginning and the occurrence of certain degree of hydrolysis in 
advance. After 144 h, the cumulative release reached 36.14±0.15% for TCP NPs at 
pH=7.4, 44.27±0.10% for TCP NPs at pH=5, 36.28±0.11% for HTCP NPs at pH=7.4 
and 41.67±0.07% for HTPC NPs at pH=5. When compared the curves obtained at 
different pH values, it indicates that acidic environment will accelerate the release rate 
of cisplatin due to the faster hydrolysis of ester bond in the prodrug nanoparticles. Such 
result will prevent the total cisplatin release in bloodstream and promote its release in 
endosomes or lysosomes in cancer cells. When compared the curves of TCP NPs and 
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HTCP NPs, it shows that the release rates are almost the same at pH=7.4 and slightly 
faster for TCP NPs at pH=5. The result reveals that conjugation of herceptin has little 
influence on the release of cisplatin due to the structure of the prodrug nanoparticles 
which keeps cisplatin prodrug located at the outer layer of the nanoparticles. 
 
Figure 5.4 Cumulative release profiles of docetaxel-loaded TPGS-cisplatin prodrug 
nanoparticles (TCP NPs) and herceptin-conjugated, docetaxel-loaded TPGS-cisplatin 
prodrug nanoparticles (HTCP NPs) at pH=7.4 and pH=5 buffers. (A) Cisplatin release 
profile. (B) Docetaxel release profile. Data represent mean ± SD, n = 3, p<0.05. 
 
The release profiles of encapsulated docetaxel were tested with HPLC and shown in 
Figure 5.4B. The burst release in the first 12 h was tested to be 23.24±0.57% for TCP 
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NPs at pH=7.4, 59.97±3.46% for TCP NPs at pH=5, 16.23±0.89% for HTCP NPs at 
pH=7.4 and 33.21±2.55% for HTPC NPs at pH=5, whereas after 144 h it was tested to 
be 26.31±0.22%, 79.65±0.62%, 19.76±0.11% and 51.34±0.33%, respectively. The 
neutral or acidic environment shows significant effect on the release of docetaxel. The 
reason might be that the emergence of cisplatin on the surface of the nanoparticles 
produces large hindrance for the diffusion of docetaxel so that only little docetaxel (less 
than 30%) diffuses out from TCP NPs or HTCP NPs at pH=7.4 after 144h. Meanwhile, 
following the accelerated release of cisplatin in acidic environment which 
demonstrated in Fig. 4A, the release rate of docetaxel was largely increased. At pH=5, 
the final docetaxel release reached more than 50% for both TCP NPs and HTCP NPs in 
144 h. It is worth noting that the effect of acidic environment on docetaxel release is 
magnified by the pH-related cisplatin release at the outer layer. Such release 
characterization would make maximum accumulation of docetaxel in tumor instead of 
bloodstream. When compared the release curves between TCP NPs and HTCP NPs at 
both pH=7.4 and pH=5, the emergence of herceptin shows larger influence for 
docetaxel release than that for cisplatin release. The reason might attribute to the 
hydrophobicity of docetaxel. The increase of hydrophilicity and sterical hindrance of 
the nanoparticle surface after conjugation of herceptin greatly delay the release rate of 
docetaxel which is encapsulated in the hydrophobic core of HTCP NPs.  
5.3.4 In vitro cellular uptake: confocal microscopy study 
Cell internalizations of TCP NPs and HTCP NPs are investigated on NIH3T3, MCF7, 
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and SK-BR-3 cell lines. NIH3T3 is a HER2 non-expressing fibroblast cell line which 
is selected as negative control group for HER2 reception in breast cancer cells. 
MCF-7 is a HER2 moderately-expressing breast cancer cell line, while SK-BR-3 is a 
HER2 over-expressing breast cancer cell line [116, 288]. The confocal images are 
shown in Figure 5.5, in which Image A, B, and C are NIH3T3, MCF7, and SK-BR-3 
cells incubated with coumarin-6 loaded TCP NPs, respectively; while Image D,E, and 
F are NIH3T3, MCF7, and SK-BR-3 cells incubated with coumarin-6 loaded HTCP 
NPs, respectively. Green fluorescence is obtained from the FITC channel (green, 
excitation wavelength 495 nm, emission wavelength 520 nm), which represent 
coumarin-6 loaded TCP NPs or HTCP NPs. Red fluorescence is obtained from the 
propidium iodide (PI, red) channel, which shows PI stained nuclei  (excitation 
wavelength 535 nm, emission wavelength 617 nm). It can be observed from the images 
that PI stained nuclei are circumvented by green fluorescence, which indicate that the 
green fluorescent dye coumarin-6 loaded nanoparticles are internalized into cell 
cytoplasm. The results demonstrate that the both TCP NPs and HTCP NPs could 
interact with cells and being internalized to deliver their cargo to target sites. 
Furthermore, the green fluorescent intensity is an indication of the level of particle 
internalization into cells, because the same concentration of nanoparticles is incubated 
with cells for the same period of time, and the images are taken under the same exciting 
laser intensity from the same confocal microscope. When compared the intensity 
among different cell lines with different HER2 expression levels in Figure 5.5, the 
green fluorescent intensity in image F is much higher than other images, meanwhile the 
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increase of green fluorescent intensity from A to D, B to E is not as high as that from C 
to F, showing that conjugation of herceptin on TCP NPs surface promotes cell 
internalization into HER2 over-expressed breast cancer cells probably through a 
receptor-mediated endocytosis mechanism. 
 
Figure 5.5 Confocal laser scanning microscopy (CLSM) images. (A), (B) and (C): 
NIH3T3, MCF7, and SK-BR-3 cells incubated with coumarin-6 loaded 
TPGS-cisplatin prodrug nanoparticles (TCP NPs); (D), (E) and (F): NIH3T3, MCF7, 
and SK-BR-3 cells incubated with herceptin-conjugated, coumarin-6-loaded 
TPGS-cisplatin prodrug nanoparticles (HTCP NPs). 
 
5.3.5 In vitro cytotoxicity of TCP NPs  
The efficacy of TCP NPs with different ratios of docetaxel versus cisplatin were first 
tested on SK-BR-3 breast cancer cells and compared with Taxotere
®
 or cisplatin 
individually after 24 h treatment. The total drug concentration was fixed to be 0.5, 0.05, 





) to minimum (only cisplatin). It shows in Figure 5.6 that at the designated 
total drug concentrations of 0.5, 0.05, 0.005 μg/mL, the cell viability was found to be 
88.62±6.65%, 101.56±4.20% and 108.20±2.83% for cisplatin; 61.76±1.53%, 
72.13±3.59% and 93.73±2.87% for Taxotere
®
; 60.13±2.94%, 67.39±4.81% and 
100.57±3.20% for TCP0.1; 50.38±1.88%, 56.95±1.87% and 79.59±4.01% for TCP0.7; 
45.16±2.79%, 52.24± 1.27% and 72.16±2.09% for TCP2.6, respectively. It can be 
seen that Taxotere
®
 shows better therapeutic efficacy than cisplatin for SK-BR-3 
cancer cells. When combining these two therapeutic agents together, all the three 
formulations with different drug ratios show enhanced anticancer effect than single 
use of the two drugs at the same total drug concentration. Furthermore, it shows that 
there is an optimized ratio to achieve the highest cancer cell toxicity for 
multimodality treatment. In this case, TCP2.6 (docetaxel:cisplatin=2.6) is the best 
ratio to maximum the efficacy of both drugs and to achieve the synergistic effect. The 
results indicate that quantitative control of the ratio of combination agents could 
promote the current efficacy of cancer treatment. Meanwhile, fewer drugs will be 




Figure 5.6 SK-BR-3 cell viability after 24 h incubation with Taxotere
®
, cisplatin, and 
docetaxel-loaded TPGS-cisplatin prodrug nanoparticles (TCP NPs) with the various 
docetaxel (DCL) versus cisplatin (CisPt) ratios at the various total drug 
concentrations of 0.5, 0.05 and 0.005 μg/mL. Data represent mean ± SD, n=6, p<0.05 
 
The efficacy could be compared more clearly from the IC50 after 24 h incubation in 
Table 5.3, which is defined as the total drug concentration needed to kill 50% of cells 
in a designated time period. It was found that all the combination chemotherapy 
showed better efficacy than mono chemotherapy, and the IC50 decreased from 0.87 
μg/mL for Taxotere®, a commercial formulation of docetaxel, and 4.03 μg/mL for 
cisplatin, to 0.12 μg/mL of docetaxel plus 0.045 μg/mL of cisplatin for TCP2.6 which 
is better than other TCP NPs with different drug ratios. To show the synergistic effect, 
a physical mixture of 0.63 μg/mL of Taxotere® plus 1.12 μg/mL of cisplatin at the 
docetaxel versus cisplatin ratio of 2.6 should be required to kill 50% of cancer cells, 




Table 5.3 IC50 of Taxotere
®
, cisplatin and docetaxel-loaded TPGS-cisplatin prodrug 





 Cisplatin  Docetaxel+Cisplatin  
TCP0.1 TCP0.7 TCP2.6 
SK-BR-3 0.87 4.03 0.044+0.34 0.13+0.20 0.12+0.045 
a. IC50: concentration of total drugs to kill 50% of cancer cells 
 
5.3.6 In vitro cytotoxicity of HTCP NPs  
TCP2.6 NPs was further conjugated with herceptin (HTCP NPs) for multimodality 
treatment. The efficacy after 24 h treatment was tested on NIH3T3, MCF7 and 
SK-BR-3 cell lines, which were used as HER2 non-expressing fibroblast cell line, 
HER2 moderate-expressing breast cancer cell line and HER2 over-expressing breast 
cancer cell line, respectively. It shows in Figure 5.7 that at the designated total drug 
concentrations of 0.5, 0.05, 0.005 μg/mL, the cell viability was found to be 
46.06±3.50%, 63.83±3.91% and 75.80±23.45% for NIH3T3 cells; 49.19±1.63%, 
54.77±2.99% and 64.65±1.94% for MCF7 cells; 34.26±1.70%, 45.11±3.00% and 
60.69±4.34% for SK-BR-3 cells, respectively. It can be seen that the efficacy of 
HTCP NPs was further improved than that of TCP2.6 NPs for SK-BR-3 cancer cells. 
When compared among the different cell lines, it demonstrated that HTCPs NPs 




Figure 5.7 NIH3T3, MCF7 and SK-BR-3 cell viability after 24 h incubation with 
herceptin-conjugated, docetaxel-loaded TPGS-cisplatin prodrug nanoparticles (HTCP 
NPs) with docetaxel (DCL) versus cisplatin (CisPt) ratio of 2.6 at the various total 
drug concentrations of 0.5, 0.05 and 0.005 μg/mL. Data represent mean ± SD, n=6, 
p<0.05. 
 
The efficacy could also be shown with the IC50 after 24 h incubation in Table 5.4. The 
table is shown to clearly compare the drugs used in different cell lines and to 
demonstrate the targeting and therapy effect of herceptin. It was found that the IC50 
further decreased to be 0.0201 μg/mL of docetaxel plus 0.00780 μg/mL of cisplatin 
plus 0.1629 μg/mL of herceptin for HTCP NPs for SK-BR-3 cancer cells. While, for 
HER2 non-expressing or moderate-expressing cells, the IC50 was tested to be 0.225 
μg/mL of docetaxel plus 0.0875 μg/mL of cisplatin plus 1.827 μg/mL of herceptin, or 
0.227 μg/mL of docetaxel plus 0.0882 μg/mL of cisplatin plus 1.842 μg/mL of 
herceptin, indicating that high therapeutic efficacy and low side effect could be 
achieved with such system for HER2 positive cancer therapy. The experiment played 
on three different cell lines with different HER2 expression showed that with herceptin 
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as active targeting ligand, the nanoparticles are able to kill cancer cells at very low 
concentrations, while they are safe to normal cells with low HER2 expression at the 
same concentrations. 
 
Table 5.4 IC50 of herceptin-conjugated, docetaxel loaded TPGS-cisplatin prodrug 
nanoparticles (HTCP NPs) with NIH3T3 cells, MCF7 cells and SK-BR-3 cells after 
24 h incubation. 
  Docetaxel+Cisplatin+Herceptin  





0.225+0.0875+1.827 0.227+0.0882+1.842 0.0201+0.00780+0.1629 
a. IC50: concentration of total drugs to kill 50% of cancer cells 
5.4 Conclusions 
We developed a drug delivery system of herceptin-conjugated vitamin E 
TPGS-cisplatin prodrug nanoparticles (HTCP NPs) for co-delivery of docetaxel, 
cisplatin and herceptin for targeted multimodality treatment of breast cancer of HER2 
overexpression, which showed a pH-sensitive release of cisplatin and docetaxel. The 
HTCP NPs of high, moderate and low docetaxel versus cisplatin ratio were prepared by 
the nanoprecipitation method and their therapeutic effects were evaluated in vitro in 
close comparison with Taxotere
®
 and cisplatin. The TPGS-cisplatin prodrug NPs 
formulation (TCP NPs) showed much better therapeutic efficacy than each of the two 
original drugs alone, and the TCP NPs of high docetaxel versus cisplatin ratio were 
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found to have better efficacy than those of moderate and low docetaxel versus cisplatin 
ratio. The targeting effects of the HTCP NPs were shown by a much lower IC50 value of 
the formulated drugs for SK-BR-3 cells of high HER2 overexpression than those for 
NIH3T3 cells and MCF7 cells of no or low HER2 overexpression. The same design of 
TPGS prodrug nanoparticles can be applied for targeted co-delivery of other 










Chapter 6: Multimodality Treatment of Cancer with Herceptin 
Conjugated, Thermomagnetic Iron Oxides and Docetaxel 
Loaded Nanoparticles of Biodegradable Polymers 
6.1 Introduction 
The current treatment of cancer mainly includes surgery followed by 
radiotherapy and/or chemotherapy, and other emerging modalities such as 
immunotherapy, gene therapy, thermal therapy, photodynamic therapy. It is 
clear, however, that although successful in certain degree, those single 
modalities each could hardly provide so far complete treatment due to their dose 
limitation and the resistance of cancer cells to the modality. It is thus reasonable 
to combine two or more of those modalities to take their advantages and avoid 
their disadvantages, and most likely, to achieve synergistic effects of 1+1>2. 
For example, chemotherapy is efficient for certain types of cancer in practice. 
Chemotherapy, however, has problems in side effects, which are caused by lack 
of drug targeting, the resistance of cancer cells to, and the problems in solubility, 
permeability and stability of, the anticancer drugs [121]. Recent development of 
nanomedicine has brought hope to realize sustained, controlled and targeted 
delivery of anticancer drugs by the various nanocarriers including prodrugs, 
micelles, liposomes, solid lipid nanoparticles and nanoparticles of 
biodegradable polymers [109, 248, 289, 290]. Nevertheless, chemotherapy 
itself is confined by the maximum tolerance of the drug, which can be enhanced 
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in combination with other modalities such as thermal therapy and 
immunotherapy. The former will increase the response of the cancer cells to the 
anticancer drug and the latter can increase the defense ability of our body, both 
resulting in less dose for the same therapeutic effects or same dose with much 
higher therapeutic effects and less side effects. We thus developed in this 
research a system of herceptin-conjugated, thermomagnetic iron oxides and 
docetaxel loaded nanoparticles of biodegradable polymers for a combinatory 
treatment of chemotherapy, thermotherapy and immunotherapy to demonstrate 
the concept of multimodality treatment of cancer. A quantitative analysis is also 
developed to justify the synergistic effects among those modalities. 
In this research, docetaxel is used as a model anticancer agent. docetaxel 
(N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl) is a new generation of 
taxanes, which has higher patient reaction rate and lower side effect than 
Paclitaxel for treatment of a wide spectrum of cancer such as breast cancer, 
ovarian cancer, small and non-small cell lung cancer, head/neck cancer [291, 
292]. Both of paclitaxel and docetaxel act by binding to microtubules and 
inhibiting microtubule depolymerization to free tubulin. As a result, the 
equilibrium within the microtubule system is disrupted, leading to mitotic arrest 
in the G2M phase of the cell cycle and ultimately to cell death [293].  
Herceptin (Trastuzumab®) is a humanized monoclonal antibody, which targets 
the extracellular domain of human epidermal growth factor receptor (HER)-2 
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[284]. It has been developed, approved and used clinically as a biological 
therapy for the treatment of HER-2-overexpressing breast cancer [294]. Breast 
cancer is the top occurring type of cancer in women. Among the breast cancer 
patients, 20% to 30% are diagnosed as HER-2 positive, which are associated 
with poor disease-free survival and resistance to certain chemotherapeutic 
agents [295]. Herceptin exerts its antitumor effect through multiple mechanisms, 
including blockage of survival signaling pathways, reduction of angiogenesis, 
antibody-dependent cellular toxicity, inhibition of HER2 extracellular domain 
cleavage, and hindrance of DNA repair [193]. However, after receiving 
herceptin monotherapy, most of the patients of initial response develop 
resistance within one year. Combination of herceptin with chemotherapeutic 
agents such as docetaxel, vinorelbine, cisplatin, carboplatin, or paclitaxel has 
achieved highest pooled response rates [194]. Besides, herceptin has been used 
as a targeting ligand for nanocarrier drug delivery systems, attributing to its 
ability to bind HER-2 receptor and to lead to subsequent receptor mediated 
endocytosis [115]. It has been shown that herceptin decorated nanoparticles 
achieved higher cellular uptake efficiency and thus cytotoxicity of the 
formulated drug in vitro, suggesting an enhanced therapeutic efficacy [116, 
296]. 
Superparamagnetic iron oxides (IOs, Fe3O4) are used in this research as 
hyperthermia therapy agent. Hyperthermia is a kind of heat therapy which 
makes body tissue exposed to high temperatures. It has been shown that high 
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temperature, usually above 42 °C, can damage and kill cancer cells, while cause 
minimal injury to normal tissues [297]. Iron oxides are often used as 
hyperthermia agent because of their high biocompatibility and their heat 
response to the applied magnetic field [199]. When exposing iron oxides to an 
alternating magnetic field at a specified frequency, it can produce enough heat 
for cancer treatment due to its high specific absorption rate (SAR) [199, 200]. 
Encapsulation of iron oxides in a nano delivery system will help them 
accumulate inside the cancer cells with passive and active targeting mechanism 
[201, 202]. Therefore, local hyperthermia can be realized to reduce the heat 
injury to healthy cells. However, cancer cells may present thermotolerance due 
to the existence of a class of heat-shock proteins (HSPs) [203]. Hyperthermia 
will increase the expression of HSPs in cancer cells, which leads to higher 
resistance to hyperthermia therapy. To further enhance its efficacy, 
hyperthermia therapy is often used together with chemotherapy [204, 205]. It 
has been shown that mild hyperthermia between 39 °C and 43 °C will enhance 
the cytotoxicity of the chemotherapy agents including docetaxel and paclitaxel 
[206, 207]. In addition, some HSPs inhibitor drugs can also help to enhance the 
efficacy of hyperthermia therapy [208]. 
In our earlier research, nanoparticles of mixed copolymers of 
poly(lactide)-d-alpha-tocopheryl polyethylene glycol succinate (PLA-TPGS) 
and  carboxyl group terminated TPGS (PLA-TPGS/TPGS-COOH 
nanoparticles) have been shown advantages in drug delivery, which resulted in 
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higher level of drug encapsulation and loading efficiency for hydrophobic 
agents (docetaxel, IOs or quantum dots), more desirable controlled release rate, 
higher cellular uptake efficiency, and thus therapeutic/imaging effects, in 
comparison with those of the US FDA approved biodegradable polymers such 
as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) and 
poly(caprolactone) (PCL) [130, 298]. The carboxyl group terminated TPGS, i.e. 
TPGS-COOH, is used to provide carboxyl group for herceptin conjugation 
[116]. Besides, TPGS as a molecular material has been found to have certain 
anti-cancer (Chapter 3). 
We synthesized in this research herceptin-conjugated nanoparticles of 
PLA-TPGS/TPGS-COOH copolymer blend for co-encapsulation of docetaxel 
and IOs to demonstrate the concept of multimodal treatment of cancer, which 
combines chemotherapy, hyperthermic therapy and biological therapy. We shall 
show that the multimodal treatment has great advantages versus each of the 
single modal therapy and synergistic effects among those therapies can be 
achieved, which will result in much better therapeutic effects and less side 
effects. The three therapeutic agents were successfully loaded in the designated 
nanoparticles to form multimodality treatment nanoparticles (MMNPs). 
Optimization of loading ratio among the three agents was investigated to 
achieve the best design. The docetaxel release profile from the MMNPs in vitro 
was assessed with consideration of the hyperthermia effect. SK-BR-3 breast 
cancer cells, which are of high HER2 expression, were used as model cancer 
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cells to show the efficacy of multimodality treatment in vitro. Hyperthermia 
therapy was conducted on living cells directly after culture with the MMNPs at 
the designated particle concentration. Meanwhile, the relevant single modality 
and the dual modality treatment nanoparticles were also synthesized and their 
therapeutic effects were investigated in comparison with the MMNPs.  
6.2 Materials and methods. 
6.2.1 Materials 
PLA-TPGS was synthesized via ring-opening polymerization as previously reported 
[285]. TPGS-COOH was activated by succinic anhydride as described previously 
[299]. Iron oxides of 10 nm were synthesized according to previous paper [300]. 
Herceptin (21 mg/mL, 4.76 mL) was purchased from National Cancer Centre, 
Singapore. Docetaxel (anhydrous, 99.56% purity) was obtained from Shanghai Jinhe 
Bio-Technology Co. Ltd, China. Lactide (3,6-dimethyl-1,4-dioxane-2,5-dione, 
C6H8O4) was purchased from Aldrich. Vitamin E TPGS (D-a-tocopheryl polyethylene 
glycol 1000 succinate, C33O5H54(CH2CH2O)23) was from Eastman Chemical Company, 
USA. Succinic anhydride, 4-(Dimethylamino)pyridine (DMAP), stannous octoate 
(Sn(OOCC7H15)2), Tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), coumarin-6, 
phosphate buffered saline (PBS, pH 7.4), ethylenediamine, Bradford reagent, 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), 
N-Hydroxysuccinimide (NHS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay, trypsin-ethylenediaminetetraacetic acid (EDTA) and 
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40,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (St. 
Louise, MO, USA). Ethanol was obtained from VWR Singapore Pte Ltd. Tween-80 
was from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was from USB Corporation 
(OH, USA). Fetal bovine serum (FBS) and penicillin-streptomycin solution were 
provided by Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) was 
purchased from Thermo Scientific Hyclone (South Logan, USA). SK-BR-3 breast 
cancer cells were obtained from American Type Culture Collection (ATCC). Water was 
treated with the Milli-Q Plus System (Millipore Corporation, Bedford, USA). 
6.2.2 Synthesis of multimodality treatment nanoparticles (MMNPs) 
The docetaxel and iron oxides loaded PLA-TPGS/TPGS-COOH nanoparticles were 
prepared by the nanoprecipitation method as mentioned in our earlier publication [201]. 
Briefly, weighted amount of PLA-TPGS and TPGS-COOH with a ratio of 2:1, 
docetaxel of 10 wt% of the total polymer amount, and iron oxides with the various 
designated weight ratios to docetaxel were dissolved in the THF with polymer 
concentration of 10 mg/mL. The solution was added drop-wise into ultrapure water 
with an oil-water ratio of 1:2 under vigorous stirring. After 3 h, the suspension was 
filtered with filter paper to remove the unencapsulated docetaxel and iron oxides. The 
filtrate was washed and centrifuged twice at 15,000 rpm for 30 min at 4 ºC. The same 
procedure was applied to synthesize the fluorescent coumarin-6 and iron oxides loaded 




Herceptin was then conjugated to the surface of the nanoparticles to form the MMNPs 
by previously established method [301]. Briefly, before conjugation, the carboxyl 
group on particle surface (from TPGS-COOH) was first converted to amine group by 
conjugating TPGS-COOH and ethylenediamine by carbodiimide chemistry with the 
assistance of EDC and NHS in a buffer solution (PH 8.4). Then, herceptin carboxyl 
group was conjugated to the amine group of nanoparticles by carbodiimide chemistry 
with the assistance of EDC and NHS in a buffer solution (PH 9.2). 
6.2.3 Characterization of multimodality treatment nanoparticles (MMNPs) 
Size and size distribution of the MMNPs were measured by the dynamic light 
scattering (DLS) (90 plus particle size analyzer, Brookhaven Instruction Corporation, 
TX, USA). The samples were prepared by diluting the nanoparticles suspension with 
deionized water to a count rate of 300-500 kcps and sonicated for 5 min before 
measurement. 
Zeta potentials of the MMNPs were measured by Doppler anemometry (zeta plus 
analyzer, Brookhaven Corporation, USA). Samples were prepared by diluting the 
nanoparticles suspension until slightly opaque in a PDMS cuvette. The data were 
obtained as the average of five measurements. 
Docetaxel load was determined by high performance liquid chromatography (HPLC, 
Agilent LC1100, Agilent, Tokyo, Japan) with absorption peak at 230 nm. The method 
was described in 3.2.4. 
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Iron oxides load was analyzed with ICP-MS (Agilent ICP-MS 7500 Series). A 
designated amount of freeze-dried MMNPs was put in a glass test tube. 2 mL of 
concentrated nitric acid was added. The tube was then heated to 90 °C for 4 h and the 
samples were analyzed using ICP-MS (Agilent ICP-MS 7500 Series) after sufficient 
dilution with milli-Q water. The analysis of samples was done in comparison with the 
ICP-MS standard (Sigma). 
Herceptin load was tested with Bradford assay. Standard protocol of Bradford assay 
was used. The method was decribed in 5.2.3. 
Nanoparticles surface morphology was imaged by the field emission scanning electron 
microscopy (FESEM, JSM-6700F, JEOL, Japan) at an accelerating voltage of 10 kV. 
Before loading to the instrument chamber, samples were coated with platinum by 
JFC-1300 platinum coater (JEOL, Tokyo, Japan) for 30 s at 30 mA. The shape and 
surface morphology of the particles were also investigated by field emission 
transmission electron microscope (FETEM, JEM-2200FS, JEOL, Japan), in which the 
nanoparticles suspension was dropped onto the surface of copper grid with carbon film 
and dried at room temperature. 
Surface chemistry of nanoparticles was analyzed by X-ray photoelectron spectroscopy 
(XPS, Kratos Ultra DLD, Shimadzu, Japan) under fixed transmission mode with pass 
energy of 80 mV and the binding energy ranged from 0 to 1100 eV. 
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6.2.4 Magnetic property and hyperthermia study 
The hysteresis curve of iron oxides (IOs) and multimodality treatment nanoparticles 
(MMNPs) were determined using a vibrating sample magnetometer (VSM, Lakeshore 
7300 Series, USA). Dried sample of known mass was taken in non-magnetic aluminum 
sheet. The sample was subjected to varying magnetic field at room temperature and the 
magnetization was measured. 
Hyperthermia study of MMNPs was done with a RF generator (EASYHEAT-5060, 
Ameritherm) operating at 240 kHz frequency. In brief, 1 mL MMNPs with a Fe 
concentration of 2 mg/mL was subjected to an AMF (43 kA•m-1, 240 kHz). 
Temperature changes were then recorded using a fiber thermocouple. The specific 
absorption rate (SAR) is obtained using the equation: 
                
where C is the specific heat of the medium (Cwater = 4.18 J•g
-1o
C
-1), ΔT/Δt is the initial 
slope of the time-dependent temperature curve and mFe is the weight fraction of Fe in 
the medium. 
6.2.5 In vitro drug release 
The multimodality treatment nanoparticles (MMNPs) were dispersed in PBS (0.1 M, 
pH 7.4) containing 0.1% v/v Tween-80, which improves the solubility of docetaxel in 










shaker shaking at 120 rpm in a water bath at 37 °C and 42 °C. At designated time 
intervals, the tube of the suspension was centrifuged at 15,000 rpm for 20 min. The 
pellet was drained and resuspended in fresh medium to continue the drug release 
process. The drug released in the supernatant was extracted by DCM and transferred in 
the same mobile phase as used in measuring drug load. After the evaporation of DCM, 
docetaxel quantity was determined by HPLC. The error bars were obtained from 
triplicate samples. 
6.2.6 Cell culture 
SK-BR-3 breast cancer cells were cultured using Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin solution in 25 
mL cell culture flask. Cells were cultivated in an incubator at 37 °C with 5% carbon 
dioxide. 
6.2.7.Cellular uptake of multimodality treatment nanoparticles (MMNPs) 
The method was described in 3.2.7. 
6.2.8 In vitro hyperthermia therapy 
After reaching confluence, cells were detached, counted, and seeded in 6-well plate 
(Costar, IL, USA) at 1×10
6
 cells/mL concentration. After 12 h incubation, the medium 
was replaced by the nanoparticles suspension, i.e. the nanoparticles suspended in the 
cell culture medium, at the designated nanoparticles concentrations. The cells were 
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then incubated for 24 h. After that, the cells were detached and placed back into the 
nanoparticles suspension, which was then exposed to 42 kA/m alternating electric 
current field at 240 kHz frequency for a designated time period. The cells were then 
seeded and recovered in 96 well plates with fresh medium for 12 h for further MTT 
assay test. 
6.2.9 In vitro cytotoxicity 
SK-BR-3 cells were seeded in 96-well transparent plates (Costar, IL, USA) at 5×10
3
 
cells/well (0.1 mL) and after 12 h, the medium was replaced by nanoparticles 
suspensions with designated concentrations for 24 h and changed to fresh one for 
another 12 h. The nanoparticles were sterilized with UV irradiation overnight before 
the experiment. Cell viability was measured using MTT assay standard protocol. 
6.3 Results 
6.3.1 Synthesis of multimodality treatment nanoparticles (MMNPs) 
The structure of multimodality treatment nanoparticles (MMNPs) is shown in 
schematic Figure 6.1. A PLA-TPGS/TPGS-COOH copolymer blend was chosen as the 
nanoparticles matrix material. The TPGS-COOH was used to provide carboxyl group 
on the nanoparticles surface to conjugate the biological therapy agent herceptin, which 
is also used as a targeting ligand. The weight ratio of PLA-TPGS:TPGS-COOH is 2:1, 
which is an optimized ratio to get relatively high drug load, high nanoparticles yield 
and high herceptin conjugation amount according to our previous study [301]. 
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Chemotherapy agent docetaxel and hyperthermia agent superparamagnetic iron oxides 
nanoparticles (Fe3O4) were loaded in the polymeric matrix of the nanoparticles, which 
were prepared by the nanoprecipitation method. The IOs/docetaxel ratio was optimized 
and reported in the following section. After the formation of the MMNPs, their surface 
with carboxyl group was first converted to amine group and then conjugated with the 
biological therapy agent herceptin by carbodiimide chemistry with assistance of EDC 
and NHS in a buffer solution (PH =9.2, isoelectric point of herceptin). 
 
Figure 6.1 Schematic illustration of the structure of multimodality treatment 
nanoparticles (MMNPs). 
 
6.3.2 Optimization of iron oxides:docetaxel ratio 
The loading ratio of the two agents, iron oxides (IOs) and docetaxel (DCL) was 
optimized. The drug amount was fixed to one tenth of the polymer weight. The ratio of 
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IOs:DCL was designated to be 1:2, 1:1, 2:1 and 5:1. Nanoparticles size, size 
polydispersity, zeta potential, iron load and drug load were accessed and listed in Table 
6.1, from which it can be seen that the size of the MMNPs of the various IOs:DCL 
ratios varies from 80 to 150 nm with polydispersity less than 0.25, indicating a narrow 
size distribution. Zeta potential is around -30 mV, which is caused by the negative 
charge of the nanoparticles surface with carboxyl group. Its absolute value increases a 
bit with higher iron load. Also, Iron load amount increases as the IOs:DCL ratio 
increased but decreases when the IOs:DCL ratio is as high as 5:1. Drug load amount 
increases with higher IOs:DCL ratio but begins to decrease with the IOs:DCL ratio of 
2:1. It can be seen that when the ratio of IOs:DCL is as high as 5:1, both the iron and the 
drug load amount become very low. The reason is that such a high IOs concentration 
will lead to undesired dispersion of hydrophobic phase in water, which will lead to 
form some ultra large particles and will be filtered away.  
Table 6.1 Optimization of loading ratio between iron oxides (IOs) and docetaxel 
(DCL). 
IOs:DCL NPs size (nm) Polydispersity Zeta Potential 
(mV) 
Fe load (μg/mg) Drug load (μg/mg) 
1:2 81.82±10.04 0.139±0.014 -31.00±0.46 41.04±5.77 20.42±0.15 
1:1 70.45±1.642 0.234±0.034 -29.79±1.44 108.43±6.17 34.03±0.22 
2:1 105.30±11.21 0.159±0.013 -27.42±1.35 261.82±9.11 31.96±0.09 




Therefore, The IOs:DCL ratio of 2:1 was selected to form multimodality treatment 
nanoparticles in this article. The IOs load can be further observed directly by the results 
of TEM, which is shown in Figure 6.2. 
 
Figure 6.2 Field emission transmission electron microscopy (FETEM) image of iron 
oxides (IOs) and docetaxel (DCL) loaded PLA-TPGS/TPGS-COOH nanoparticles 
under different IOs and DCL ratio: (A) 1:2; (B) 1:1; (C) 2:1; (D) 5:1. 
 
6.3.3 Characterization of multimodality treatment nanoparticles (MMNPs) 
The multimodality treatment nanoparticles (MMNPs) were synthesized. The agent 
loading amount of IOs, DCL and herceptin was measured by ICP-MS, HPLC and 
Bradford assay, respectively. The results were listed in Table 6.2. The size, PDI and 
zeta potential of the MMNPs were found to be 155.2±0.17 nm, 0.195±0.004 and 
-18.6±1.2 mV respectively. The size and zeta potential showed certain increase 
compared with the IOs and DCL loaded nanoparticles before herceptin conjugation.  
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Table 6.2 Characterizations of multimodality treatment nanoparticles (MMNPs). 
 
Surface chemistry of the MMNPs before and after herceptin conjugation was examined 
using X-ray photoelectron spectroscopy (XPS) (Figure 6.3A). The lower curve 
represents the MMNPs before herceptin loading, while the upper curve represents the 
MMNPs after herceptin conjugation onto the nanoparticles surface. It can be seen from 
the inset, which highlights the signal at the position corresponding to the binding 
energy of nitrogen 1s (N 1s), that nitrogen signal appears after herceptin conjugation. 
Nitrogen signal can be detected either from docetaxel or herceptin. Lower curve 
indicates that no detectable level of docetaxel appears on the nanoparticles surface. 
Hence, the nitrogen peak in the upper curve should be contributed by herceptin alone.  
















Figure 6.3 Characterizations of multimodality treatment nanoparticles (MMNPs). (A) 
X-ray photoelectron spectroscopy (XPS) spectrum of widescan spectrum and N 1S 
peaks (the inset) from the MMNPs before conjugation with herceptin (lower curve), 
and MMNPs (upper curve). (B) Field emission scanning electron microscopy 
(FESEM) image of MMNPs. (C) Field emission transmission electron microscopy 
(FETEM) image of MMNPs. 
 
Surface morphology of the MMNPs was observed by field emission scanning 
electronmicroscope (FESEM). It can be seen from this image (Figure 6.3B) that the 
MMNPs are spherical with smooth surface. The size is ranging from 100 nm to 200 nm 
with narrow size distribution, which is in good agreement with the size measured by 
DLS.  
The transmission electron microscope (TEM) image of the MMNPs is shown in Figure 
6.3C. Loading of iron oxides into the multimodality treatment nanoparticles (MMNPs) 
was visualized. The image shows that iron oxides are distributed in the polymeric 
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matrix of the MMNPs, indicating successful loading of the hyperthermia agent. 
6.3.4. Magnetic property and hyperthermia study 
The magnetic property of iron oxides (IOs) and multimodality treatment 
PLA-TPGS/TPGS-COOH nanoparticles (MMNPs) was recorded with a vibrating 
sample magnetometer (VSM). Their hysteresis M-H curves are shown in Figure 6.4A. 
The amount of magnetization of IOs and the MMNPs is shown against the varying 
magnetic field. The saturation magnetization (σs) was determined to be 61.4 and 21.1 
emu/g of Fe3O4 for IOs and MMNPs, respectively. The decrease of σs for MMNPs is 
due to the encapsulation of the PLA-TPGS/TPGS-COOH matrix and the herceptin 
conjugation. However, the zero coercivity and remanence of the M-H curves indicate 
that encapsulation and modification will not affect the superparamagnetism of the IOs 








Figure 6.4 (A) Hysteresis curve of original iron oxides (IOs) and multimodality 
treatment nanoparticles (MMNPs). (B) Hyperthermia study showing the 
time-dependent temperature rise of MMNPs with Fe concentration of 2 mg/mL and 
DI water on exposure to 42 kA/m alternating current field at 240 kHz frequency.  
 
In order to evaluate the effect of the MMNPs in hyperthermia applications, the 
magnetic heating characterization was carried out using an induction heating system 
(Ambrell, Easy Heat, 4.2-10 kW). In the measurements, 1 mL MMNPs dispersion with 
Fe concentration of 2 mg/mL was used and subjected to an AMF (43 kA/m, 240 kHz). 
Temperature change was then recorded. DI water was used as a control to demonstrate 
the thermo effect of the MMNPs. The result is shown in Figure 6.4B, in which the time 

























whereas the temperature for the DI water increased only less than 5 °C during the same 
process. The specific absorption rate (SAR) value of the MMNPs is calculated to be 
146 Watt/g. Such a high SAR value indicates that the MMNPs will perform well for 
hyperthermia therapy. Their in vitro hyperthermia therapy effect will be demonstrated 
in the following section. 
6.3.5 In vitro drug release 
The accumulative release profiles of the chemotherapeutic agent docetaxel from the 
multimodality treatment nanoparticles (MMNPs) at normal body temperature (37
o
C) 
and hyperthermia temperature (42
o
C) in 120 h are shown in Figure 6.5. It can be seen 
from this graph that there is an initial burst release in the first 12 h, during which 





C, respectively. The burst release phenomenon could attribute to drugs loaded 
near the surface of the MMNPs. In the following hours, docetaxel was released from 
the nanoparticles in a sustained manner. After 120 h, the accumulative drug release is 





respectively. Generally, compared to the single modality chemotherapy nanoparticles, 
the release rate is slower for the MMNPs. This could be due to the hydrophobic 
interaction between docetaxel and iron oxides nanoparticles such that the drug 
diffusion is hindered due to interaction with IOs. In addition, it can be noticed from the 




C accelerated drug release. 
This is an advantage of the MMNPs, because faster drug release in tumor site could be 
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triggered by alternating magnetic field, while premature release in blood stream is 
minimized. 
 
Figure 6.5 Cumulative release profile of multimodality treatment nanoparticles 
(MMNPs) at different temperatures. Data represent mean ± SD, n = 3. 
 
6.3.6 Cellular uptake of multimodality treatment nanoparticles (MMNPs) 
Cellular uptake efficiency of the multimodality treatment nanoparticles (MMNPs) by 
SK-BR-3 cells after 2 h incubation was qualitatively evaluated using confocal laser 
scanning microscope (CLSM), and quantitatively measured by a microplate reader. It 
has been demonstrated in the literature that herceptin could be used as a targeting 
ligand for the breast cancer cells of human epidermal growth factor receptor type 2 
(HER2) overexpression. Here we compare the cellular uptake efficiency between the 
MMNPs with or without herceptin conjugation to show that the herceptin-conjugated 
































6.6A and Figure 6.6B shows the confocal images of SK-BR-3 cells incubated with the 
MMNPs with or without herceptin conjugation, respectively. The green fluorescence 
represents coumarin-6 loaded MMNPs, while the red fluorescence represents nuclei 
stained by propidium iodide (PI). It can be seen from those images that PI stained 
nuclei are circumvented by the coumarin-6 loaded MMNPs, indicating that the 
MMNPs have been internalized into the cytoplasm of SK-BR-3 cells. In comparison 
between the two types of confocal images, it could be observed that the green 
fluorescence intensity in Figure 6.6B is much higher than that in Figure 6.6A, 
indicating a higher cellular uptake efficiency of the herceptin conjugated MMNPs. The 
result shows that not only could the herceptin function as a biological therapeutic agent, 
but also as a targeting ligand to enhance the internalization of the MMNPs into the 
HER2 receptor overexpressed cancer cells. Indeed, the dual functions of the biological 




Figure 6.6 Cellular uptake efficiency of multimodality treatment nanoparticles 
(MMNPs) in SK-BR-3 cells. (A) and (B) confocal laser scanning microscopy (CLSM) 
images of MMNPs without herceptin and MMNPs for 2 h incubation in SK-BR-3 
respectively. (C) Quantitative study of cellular uptake efficiency of MMNPs without 
herceptin and MMNPs after 0.5 h and 2 h incubation respectively at 37ºC. Data 
represent mean ± SD, n=6. 
 
The internalization of the MMNPs with or without herceptin conjugation into the 
SK-BR-3 cells was also quantitatively assessed by the fluorescent mode of microplate 
reader. The result is shown in Figure 6.6C. After 0.5 h incubation, 20.72±1.33% of the 
MMNPs without herceptin conjugation and 26.70±0.73% of the MMNPs with 
herceptin conjugation are internalized into the SK-BR-3 cells; while after 2 h 
incubation, 23.86±1.08% of the MMNPs without herceptin conjugation and 
30.00±0.26% of the MMNPs with herceptin conjugation are internalized into the 
SK-BR-3 cells, respectively. The results indicate that during the first two hours, the 
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MMNPs showed time-dependent cellular uptake. In addition, compared to the MMNPs 
without herceptin conjugation, the MMNPs with herceptin conjugation demonstrated 
28.86% and 25.73% increase in cellular uptake after 0.5 h and 2 h incubation, 
respectively. It quantitatively confirms the qualitative observation in confocal imaging.  
6.3.7 In vitro therapeutic efficiency of multimodality treatment nanoparticles 
(MMNPs) 
We employ the SK-BR-3 breast cancer cell line, which is of high HER2 overexpression, 
as an in vitro model of cancer to investigate the therapeutic efficiency of the 
multimodality treatment nanoparticles (MMNPs) versus the various single or dual 
modality treatment NPs with a focus on the synergistic effects of the various 
combinations of the individual single modality treatment NPs. To do so, we would like 
to expand the concept of IC50, the so-called half maximal inhibitory drug concentration, 
which is defined as the concentration of the drug in a formulation that is required to kill 
50% of the cancer cells in a designated time period, say for 24 hours. To make the in 
vitro therapeutic efficiency quantitatively comparable among the various single, dual 
and multiple modality treatments by the nanoparticles formulation of the various 
therapeutic agents such as docetaxel for chemotherapy, herceptin for biological therapy 
and IOs for hyperthermia therapy, we shall use the NPs IC50, i.e. the nanoparticles 
concentration of any treatment that is needed to kill 50% of the cancer cells in a 
designated time period. The new concept of NPs IC50 will bring great convenience in 
comparison of the multimodality treatment NPs with the mixture of the individual 
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single treatment NPs. For example, the great advantage of the MMNPs of the loading 
ratio of docetaxel:herceptin:IOs=n1:n2:n3 can be confirmed if the NPs IC50 of the 
MMNPs is found much smaller than that of the physical mixture of the three kinds of 
single modality treatment NPs at the ratio of n1/n:n2/n:n3/n, where n=n1+n2+n3, in the 
same time period, say for 24 hours. 
We thus synthesized seven types of PLA-TPGS/TPGS-COOH NPs, which include the 
docetaxel-, herceptin, IOs-loaded PLA-TPGS/TPGS-COOH NPs for the single 
modality treatment of chemotherapy, biological therapy and hyperthermia therapy, 
which are called DCL-NPs, Her-NPs and IOs-NPs, respectively; the docetaxel and 
herceptin–loaded, IOs+herceptin-loaded, herceptin+IOs-loaded 
PLA-TPGS/TPGS-COOH NPs for the dual modality treatment of the combined 
chemotherapy and biological therapy, hyperthermia therapy and biological therapy,  
chemotherapy and hyperthermia therapy, which are called DOX+Her-NPs, 
IOs+Her-NPs and DCL+IOs-NPs, respectively; as well as the herceptin conjugated, 
docetaxel and IOs-loaded PLA-TPGSA.TPGS-COOH NPs for the multimodality 
treatment, which are called MMNPs. In order to make the therapeutic efficiency 
quantitatively comparable among these seven treatments, we suggest fix the loading 
ratio of docetaxel:herceptin:iron oxides, which is designated in this research to be 1:2:7, 
in the MMNPs and control the loading ratio of the three therapeutic agents (docetaxel, 
herceptin, IOs) in the seven treatments to be the same as that in the MMNPs according 
to Table 6.2.  
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Two control experiments were conducted firstly. The SK-BR-3 cells without any 
treatment were exposed to 42 kA/m alternating current field at 240 kHz frequency for 
20 min and 30 min respectively and recovered for 12 h. The cell viability was measured 
to be 96.23±3.36% and 95.59±4.83% respectively (Figure 6.7A), which indicates that 
almost all the cells are still alive under the various conditions of alternating current 
field. It can thus be concluded that such an alternating current field will not contribute 
to cell mortality. The SK-BR-3 cells were then incubated with the IOs-loaded 
PLA-TPGS/TPGS-COOH nanoparticles (IOs-NPs) at the NPs concentrations of 0.86, 
0.086, 0.0086 and 0.00086 mg/mL for 24 h with no exposure to any alternating current 
field. The cell viability was found to be 96.67±2.11%, 98.38±1.35%, 98.61±7.42% and 
97.12±0.72% respectively (Figure 6.7B). This result demonstrated that the IOs-NPs 
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Figure 6.7 (A) SK-BR-3 cell viability after 20 min and 30 min exposure to 42 kA/m 
alternating current field at 240 kHz frequency without any nanoparticles incubation 
and incubated in fresh medium for 12 h. Data represent mean ± SD, n=6. (B) 
SK-BR-3 cell viability after incubation with different concentrations of iron oxides 
nanoparticles (IOs-NPs) for 24 h. Data represent mean ± SD, n=6. 
 
The viability of the SK-BR-3 cells incubated with the MMNPs at various 
concentrations of 0.86, 0.086, 0.0086 and 0.00086 mg/mL was then systematically 
investigated in comparison with the viability of the SK-BR-3 cells treated with the 
various single modality treatment nanoparticles and dual modality treatment 
nanoparticles at the same NPs concentrations. The cell viability values for each 
treatment are shown in Figure 6.8. It shows the SK-BR-3 cell viability as the vertical 
axis versus the various modality treatments as one, and the various NPs concentration 
as another, of the two horizontal axes. It can be concluded from Figure 6.8 that the 
multimodality treatment NPs showed superior in vitro therapeutic efficacy than any 
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Figure 6.8 SK-BR-3 cell viability of different treatment methods at various 
concentrations of nanoparticles after 24 h incubation and recovered in fresh medium 
for 12 h. Data shown were taken average from six repeats, SD/Mean×100% < 8%. 
  
Such an advantage of the multimodality treatment can be further demonstrated 
quantitatively by employing the NPs IC50 of each treatment, which is listed in Table 6.3. 
It shows that for DCL-NPs, Her-NPs and IOs-NPs, the NPs IC50 is 4.17, 6.66 and 0.84 
mg/mL for 24 h incubation, respectively. It can be seen that these single modality 
treatment NPs formulations are not efficient with such high NPs concentration needed 
to kill 50% cancer cells in 24 hours. As for the dual modality treatment NPs of 
DCL+Her-NPs, IOs+Her-NPs and DCL+IOs-NPs, the NPs IC50 is getting lower to be 
1.28, 0.19 and 0.010 mg/mL respectively, which indicates that a significant increase in 
the in vitro therapeutic effect has been achieved for each of the dual modality treatment 
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NPs, especially those with hyperthermia therapy involved. Finally, the NPs IC50 for the 
multimodality treatment nanoparticles MMNPs, which combine chemotherapy, 
biological therapy and hyperthermia therapy, was found dramatically decreased to be 
0.0011 mg/mL, that must be achieved due to the synergistic effects among the various 
modalities. 
Table 6.3 NPs IC50 of different modality therapy with docetaxel loaded nanoparticles 
for chemo therapy (Chemo), herceptin-conjugated nanoparticles for biological 
therapy (Bio), iron oxides loaded nanoparticles for hyperthermia therapy (Thermo), 
docetaxel loaded and herceptin-conjugated nanoparticles for chemotherapy and 
biological therapy (Chemo+Bio), iron oxides loaded and herceptin-conjugated 
nanoparticles for hyperthermia therapy and biological therapy (Thermo+Bio), 
docetaxel and iron oxides loaded nanoparticles for chemotherapy and hyperthermia 
therapy (Chemo+Thermo), docetaxel and iron oxides loaded herceptin-conjugated 
nanoparticles for multimodality treatment (Chemo+Thermo+Bio). 
 Single modality treatment Dual modality treatment Multimodality 
treatment 




























 NPs IC50: the concentration of nanoparticles at which 50% of cancer cells were killed 
after 24 hour treatment 
 
To compare the synergistic effects, we compare the NPs IC50 of the dual or multiple 
treatment NPs IC50 with that of the physical mixture of the corresponding single 
modality treatment NPs at the same loading ratio as that in the MMNPs. For example, 
to kill 50% cancer cells in the designated 24 hours, 0.52 mg/mL DCL-NPs plus 0.74 
mg/mL IOs-NPs, a total amount of 1.26 mg/mL NPs would have been needed for a 
physical mixture of the two single modality treatment DCL-NPs and IOs-NPs at the 
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given ratio 1:7, while in fact only 0.010 mg/mL was found to be needed for the dual 
modality treatment NPs, which is 126 fold more effective than the physical mixture of 
the corresponding single modality treatment NPs at the same ratio of 1:7. The dual 
modality treatment NPs thus demonstrated great advantages versus the corresponding 
single modality treatment NPs. 
It can be further seen from Table 6.3 that the MMNPs could achieve even better 
synergistic effects than the dual modality treatments. It can be found that to kill 50% of 
the SK-BR-3 cells in 24 hours, 0.42 mg/mL DCL-NPs plus 1.33 mg/mL Her-NPs plus 
0.59 mg/mL IOs-NPs, a total NPs concentration of 2.34 mg/mL, would have been 
needed for the treatment of a physical mixture of the DCL-NPs, Her-NPs and IOs-NPs 
at the 1:2:7 weight ratio, while only 0.0011 mg/mL was actually needed for the 
MMNPs to obtain the same in vitro therapeutic efficiency, which is 2127 fold more 
efficient than the physical mixture of the corresponding single modality treatments. We 
can thus conclude that the multimodal modality treatment NPs could achieve even 
better synergistic effects in comparison with the individual single modality treatment 




Figure 6.9 SK-BR-3 cell viability after 24 h treatment with different concentrations of 
multimodality treatment nanoparticles (MMNPs) and exposure to 42 kA/m 
alternating current field at 240 kHz frequency for hyperthermia therapy for different 
time. Data represent mean ± SD, n=6. 
 
The time interval for the hyperthermia therapy is another important parameter to 
determine the therapeutic effects of the multimodality treatment. Figure 6.9 shows the 
SK-BR-3 cell viability after 24 h treatment with the multimodality treatment 
nanoparticles (MMNPs) at the various MMNPs concentrations and exposed to 42 
kA/m alternating current field at 240 kHz frequency for hyperthermia therapy for 10, 
20 and 30 min respectively. It can be concluded from Figure 6.9 that the in vitro 
therapeutic effect of such multimodality treatment for the HER2 positive breast cancer 
is dependent on the MMNPs concentration, the higher the better, as well as on the 
hyperthermia treatment time, the longer the better. Its efficiency is quantitatively 
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Table 6.4 NPs IC50 of multimodality treatment under different hyperthermia time. 
MMNPs 10 min 20 mn 30 min 
NPs IC50
a
 (mg/mL) 0.0016 0.0011 0.00045 
a. NPs IC50: concentration of nanoparticles to kill 50% of cancer cells. 
 
6.4 Discussion 
In this paper, a strategy of multimodality treatment for cancer is suggested, which is 
realized by co-encapsulation of the corresponding therapeutic agents in the 
nanoparticles of biodegradable polymers to promote a synergistic effect among the 
various individual modality treatments for high efficiency and low side effects. We did 
a series of proof-of-concept experiments through various combinations of 
chemotherapy, hyperthermia therapy and biological therapy by co-encapsulation of the 
corresponding therapeutic agents in the PLG-TPGS/TPGS-COOH nanoparticles. The 
SK-BR-3 cancer cells of high HER2 overexpression were used as an in vitro model of 
the HER2-positive breast cancer. The final results demonstrated that due to the 
synergistic effects among the various single modality treatments, the multimodality 
treatment could achieve the best treatment efficiency over the various single modality 
or dual modality treatment. 
One expect of the synergistic effect may be accomplished via combination of 
chemotherapy and hyperthermia therapy. Each of the nanoparticle formulations for 
chemotherapy and for hyperthermia therapy showed obvious cytotoxicity for the 
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cancer cells. For a combination of these two modality treatments, the NPs IC50 of 
DCL+IOs-NPs (0.30 μg/mL) decreases significantly compared with that for the NPs 
IC50 of DCL-NPs (>100 μg/mL) and IOs-NPs (24.17 μg/mL), i.e. a decrease of more 
than 99.7% for chemotherapy and 98.8% for hyperthermia therapy, indicating that 
synergistic effect is achieved. First possible reason of such synergistic effect may be 
that hyperthermia can accelerate the drug release from the nanoparticles, which will 
lead to higher concentration of docetaxel in cancer cells. Such reason is supported by 
the cumulative release profile in Figure 6.5. Another reason may be that hyperthermia 
can lead to reoxygenation of the cancer cells. Experiments revealed that when tumors 
are heated up between 39 °C and 43 °C, which is called mild hyperthermia, it will lead 
to enhanced oxygen delivery and decreased oxygen consumption. Such changes will 
make tumor reoxygenated, which can last for 24 h after heating [53]. It has been 
demonstrated that hypoxia plays an important role in chemoresistance. Therefore, the 
improvement of tumor oxygenation may increase a positive response of tumors to 
chemotherapy [54]. Thus, hyperthermia will make tumors more sensitive to 
chemotherapy.  
Another expect of the synergistic effect is the interaction between docetaxel and 
herceptin. It has been shown that the NPs IC50 of both DCL-NPs and Her-NPs are 
above 100 μg/mL. However, the NPs IC50 of their combination is only 37.01 μg/mL for 
DCL+Her-NPs, i.e. a decrease of more than 63.0% for both of single modality 
treatment. Such synergistic effect is achieved first due to the active targeting effect of 
herceptin. Herceptin, as an anti-HER2 antibody, can be used as a targeting ligand for 
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HER2 overexpressed breast cancers. In this work, it increases the cellular uptake 
efficiency of MMNPs (Figure 6.6), therefore higher concentration of docetaxel will be 
accumulated in the SK-BR-3 cells. Moreover, several clinical studies have 
demonstrated the synergistic interaction between docetaxel and herceptin [194, 302]. 
For example, a randomized Phase II trial divided 186 patients into three groups: (1) one 
group treated with docetaxel alone; 2) one crossed over to receive trastuzumab after 
progressing docetaxel; and 3) one received docetaxel/trastuzumab first-line 
combination. The result shows that the median durations of overall survival were 16.6, 
30.3 and 31.2 months, respectively [303]. Though the mechanism of such synergistic 
effect between docetaxel and herceptin remains unclear, the results from clinical trials 
provided rationale for our chemo+bio dual modality treatment by  our Her+DCL-NPs.  
Although there is little report in the literature that is concerned with the synergistic 
effect between the herceptin biological therapy and the IOs hyperthermia therapy, 
several herceptin conjugated nanoparticles or liposomes have been synthesized for 
enhanced hyperthermia therapy, which have achieved strong better therapeutic effects 
[304, 305]. Our result shows strong synergistic effect between the bio and the thermo 
therapies. The NPs IC50 for the Her+IOs-NPs achieved 94.6% decrease than the 
Her-NPs and 77.8% than the IOs-NPs although the mechanism for such a synergistic 
effects needs to be further studied. 
Finally, it can be noticed that the multimodal treatment developed in this research by 
co-encapsulation of docetaxel, herceptin and IOs in the PLA-TPGS/TPGS-COOH NPs 
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did not show any antagonistic effect.  
6.5 Conclusions 
We developed a nanoparticle system for multimodality treatment of cancer, which 
formulated docetaxel for chemotherapy, herceptin for biotherapy and targeting, and 
iron oxides for hyperthermia therapy in nanoparticles of PLS-TPGS/TPGS-COOH 
copolymer blend, which are denoted as MMNPs,/ zit is shown that the MMNPs 
achieved a significantly higher therapeutic than the various combination of the 
corresponding individual modality treatment and the dual modality treatments due to 
the synergistic effects among the chemo, bio, and thermo therapies. We also developed 
a method by employing the concept of NPs IC50 to quantitatively investigate the 
synergistic effects, in which the treatment of lower NPs IC50 in the designated time is 
considered more efficient in comparison between the multimodality treatment NPs and 
the physical mixture of the corresponding single modality treatment under the same 
loading ratio of the therapeutic agents.  We demonstrated by employing the SK-BR-3 
cell line as an in vitro model of the HER2-positive breast cancer, the MMNPs can be an 
excellent carrier for co-encapsulation of the various single modality treatment agents 
such as docetaxel for chemotherapy, herceptin for biotherapy and targeting, and iron 






Chapter 7: Conclusions and Recommendations 
7.1 Conclusions 
The main body of this thesis includes four works. In the first work, we developed a 
micelle system with a newly synthesized TPGS2k polymer, which showed lower 
critical micelle concentration (CMC) of 0.0219 mg/mL compared with 0.2 mg/mL for 
traditional micelles with TPGS involved. We found that TPGS itself could have 
anti-cancer effect and TPGS micelles could be considered as both delivery system 
and therapeutic agent. The micelle system achieved sustained and controlled drug 
delivery with docetaxel, used as a model hydrophobic anti-cancer drug. The TPGS2k 
micelles were further conjugated to folic acid (FA) for targeted drug delivery. The 
docetaxel loaded TPGS2k micelles with and without FA conjugation were found of 
desired size and size distribution, high drug encapsulation efficiency and favorable 
drug release. In vitro studies using MCF-7 cancer cells demonstrated high cellular 
uptake of the formulated drug for TPGS2k micelles. The targeting effect for the 
FA-conjugated TPGS2k micelles was also demonstrated. The IC50 value was 103.4, 
1.280 and 0.1480 μg/mL for MCF-7 cancer cells after 24, 48, and 72 h treatment with 
Taxotere
®
, respectively, which was greatly decreased to be 0.526, 0.251 and 0.233 
μg/mL, i.e. a 99.5%, 80.4% decrease and 57.5% increase for the TPGS2k micelle 
formulation, and further decreased to be 0.1780, 0.1520 and 0.1140 μg/mL, i.e. a 
99.8%, 88.1% and 23.0% decrease for the folic acid conjugated micelles, respectively. 
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A synergistic effect between TPGS2k and docetaxel was also achieved. The present 
work represents a new concept in the design of drug delivery systems - the carrier 
materials of the drug delivery system are made to also have therapeutic effects and to 
promote a synergistic interaction with the formulated drug for multimodality treatment 
of cancer.  
In the second work, we further synthesized TPGS-cisplatin prodrugs to form 
docetaxel-loaded prodrug micelles for dual-drug multimodality treatment. We 
demonstrated that the nano delivery system could successfully co-deliver both 
hydrophilic and hydrophobic drug with a low CMC of 5.01 mg/L, a high hydrophilic 
drug load of 4.95% (w/w), a pH-responsive cisplatin release kinetics, and higher 
cellular uptake in comparison with the original cisplatin and the TPGS-cisplatin 
prodrug itself. The cell viability experiment showed great enhancement of the 
cisplatin chemotherapy by this prodrug micelle system, of which the IC50 value 
reduced from 3.95, 0.98, 0.19 for cisplatin to 1.36, 0.51, 0.08 μg/m for the TPGS 
prodrug micelle formulation after 24, 48, 72 hours culture with the HepG2 
hepatocarcinoma cells, respectively. Furthermore, such platform was also used to 
encapsulate docetaxel for co-delivery of hydrophilic and hydrophobic drugs. The 
improved anti-cancer effect by the dual-drug multimodality treatment was evaluated 
in SK-BR-3 cancer cells by comparing its cell viability and IC50 with single 
drug-loaded TPGS micelles. The system represents novel hybrid nanocarriers which 
can better achieve the purpose of co-delivery of both hydrophobic and hydrophilic 
agents for dual-drug multimodality treatment. 
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In the third work, we developed a nanocarrier system of herceptin-conjugated 
nanoparticles of D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate 
(TPGS)-cisplatin prodrug (HTCP NPs) for targeted co-delivery of cisplatin, docetaxel 
and herceptin for multimodality treatment of breast cancer of high human epidermal 
growth factor receptor 2 (HER2) overexpression. Co-polymers poly(lactic 
acid)-TPGS (PLA-TPGS) and carboxyl group-terminated TPGS (TPGS-COOH) were 
also added in the polymeric matrix to stabilize the prodrug nanoparticles and to 
facilitate herceptin conjugation. The HTCP NPs of high, moderate and low docetaxel 
versus cisplatin ratio were prepared by the nanoprecipitation method, which showed a 
pH-sensitive release for both anti-cancer drugs. The therapeutic effects of HTCP NPs 
were evaluated in vitro and compared with Taxotere
®
 and cisplatin. The HTCP NPs of 
high docetaxel versus cisplatin ratio were found to have better efficacy than those of 
moderate and low docetaxel versus cisplatin ratio. The targeting effects of the HTCP 
NPs were demonstrated by a much lower IC50 value of 0.0201+0.00780+0.1629 
μg/mL of docetaxel+cisplatin+herceptin for SK-BR-3 cells, which are of high HER2 
overexpression, than that of 0.225+0.0875+1.827 μg/mL for NIH3T3 cells, which are 
of low HER2 overexpression, after 24 h incubation. The same design of TPGS 
prodrug nanoparticles can also be applied for targeted co-delivery of other 
hydrophilic and hydrophobic agents. 
In the fourth work, We developed a system of nanoparticles of 
poly(lactide)-D--tocopheryl polyethylene glycol succinate (PLA-TPGS) and 
carboxyl group-terminated TPGS (TPGS-COOH) copolymer blend for multimodality 
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treatment of cancer, which formulated docetaxel for chemotherapy, herceptin for 
biotherapy and targeting, and iron oxides (IOs) for hyperthermia therapy, which are 
denoted as MMNPs. It is demonstrated that the MMNPs achieved a significantly 
higher therapeutic effects than the various combination of the corresponding individual 
modality treatment NPs and the dual modality treatment NPs due to the synergistic 
effects among the chemo, bio, and thermo therapies. We further developed a method by 
employing the concept of NPs IC50, the concentration of the agent-, or agents-loaded 
nanoparticles that is needed to kill 50% of the cancer cells, to quantitatively access the 
synergistic effects of the multimodality treatment. It is shown by employing the 
SK-BR-3 cell line as an in vitro model of the HER2-positive breast cancer that the NPs 
IC50 is  0.42 mg/mL DCL-NPs plus 1.33 mg/mL Her-NPs plus 0.59 mg/mL IOs-NPs, a 
total NPs concentration of 2.34 mg/mL for the treatment of a physical mixture of the 
DCL-NPs, Her-NPs and IOs-NPs at the 1:2:7 weight ratio, while it is only 0.0011 
mg/mL for the MMNPs for 24 hours, which is 2130 fold more efficient than the 
physical mixture of the corresponding single modality treatments.  
7.2 Recommendations 
Though it is unlikely to discover some magic drugs to cure cancer in the next few years, 
we are striving to prolong the life of cancer patients. To improve current efficacy of 
cancer therapy, nanomedicine for multimodality treatment of cancer has been 
proposed and demonstrated in this PhD work. However, the works mostly focus on 
the design and synthesis of novel delivery systems and the proof-of-concept study of 
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their synergistic anti-cancer effect in vitro. Therefore, in vivo study and clinical trials 
are recommended for all the above works to further confirm the efficacy of 
nanomedicine for multimodality treatment of cancer. Besides, whether the synergistic 
anti-cancer effect will produce systematic toxicity to normal organs is important and 
recommended for further study.  
In addition, one of the most important factors leading to the ineffectiveness of various 
cancer treatments is the developed resistance of cancer cells. The various available 
therapies would be much more effective at much lower dose if the corresponding 
siRNA could be successfully co-delivered by nanocarriers. Theoretically, siRNA 
could be designed to silence any gene of known sequence with a high potency that 
only a few molecules could induce a robust response to. In addition, siRNA is only 
involved in post-transcriptional process, which reduces the risk of possible adverse 
gene alterations [122]. Therefore, for each modality treatment, it is recommended to 
combine with the corresponding siRNA to fight against the resistance. In fact, it can 
become a standard strategy for future cancer therapy: formulating multimodality 
therapeutic agents in one nano delivery system and conjugating the corresponding 
siRNAs to decrease the cell resistance to the treatments. For example, when we 
combine docetaxel and iron oxides for chemo- and thermo- multimodality treatment, 
Bcl-2 siRNA or MRP-1 siRNA and HSP90 siRNA can be also loaded into the 
nanocarriers for better anti-cancer effect. 
Nanoimmunotherpay is another promising area of cancer treatment. It is believed that 
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if our immune system can be fully stimulated to fight against cancer, cancer will be 
curable. Unfortunately, cancer suppresses the body’s immune system and, thus, can 
spread so quickly that any treatment is inefficient. Tumor cells may secrete a number 
of immunosuppressive factors which makes our immune system unable to recognize 
the tumor [192, 306]. Therefore, to achieve successful cancer immunotherapy, we 
should on the one hand activate the T-cell responses; on the other hand inhabit the 
immunosuppression. Different agents will be involved for immuno-multimodality 
treatment and nano delivery systems for efficient delivery of these proteins or small 
molecules are deserved to be studied. Moreover, combining immunotherapy with 
other therapies, such as chemotherapy, may promote synergistic effect for more 
efficient cancer therapy. 
It is believed that immunotherapy and gene therapy are promising in cancer treatment 
and their combination with other therapies provides possibility to cure cancer. 
Nanomedicine for multimodality treatment of cancer will be a fantastic platform. 
Studies within these areas will be strongly recommended. 
Additionally, cancer stem cell hypothesis has been demonstrated in many experiments 
recently. Cancer stem cell shows extreme resistance to cancer treatment, thus single 
modality treatment may not be strong enough to kill these cells. Multimodality 
treatment will be required for cancer stem cell therapy. Besides, as cancer stem cells 
only form a small population in solid tumor, how to efficiently deliver therapeutic 
agents to these cells will be a painful problem. Nano delivery systems which directly 
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target to these cells should be studied and developed for cancer stem cell therapy. For 
example, all breast cancer stem cells have a surface protein marker called CD44, 
along with very low levels or no levels of two markers called CD24 and lin. Nano 
delivery systems targeting CD44 may achieve targeted delivery of therapeutic agents 
for breast cancer stem cells. The study towards nanomedine for multimodality 














[1] Y. Mi, Y.J. Guo, S.S. Feng, Nanomedicine for multimodality treatment of cancer, 
Nanomedicine-Uk, 7 (2012) 1791-1794. 
[2] B. Alberts, Molecular biology of the cell, 5th ed., Garland Science, New York, 
2008. 
[3] P.S. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, Nat Med, 
12 (2006) 895-904. 
[4] C.L. Chaffer, R.A. Weinberg, A Perspective on Cancer Cell Metastasis, Science, 
331 (2011) 1559-1564. 
[5] P.B. Gupta, C.L. Chaffer, R.A. Weinberg, Cancer stem cells: mirage or reality?, Nat 
Med, 15 (2009) 1010-1012. 
[6] M.F. Clarke, M.W. Becker, Stem cells: The real culprits in cancer?, Sci Am, 295 
(2006) 52-59. 
[7] M.F. Clarke, A self-renewal assay for cancer stem cells, Cancer Chemoth Pharm, 56 
(2005) S64-S68. 
[8] T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, Stem cells, cancer, and cancer 
stem cells, Nature, 414 (2001) 105-111. 
[9] N.Y. Frank, T. Schatton, M.H. Frank, The therapeutic promise of the cancer stem 
cell concept, J Clin Invest, 120 (2010) 41-50. 
[10] M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, D.L. Jones, J. 
Visvader, I.L. Weissman, G.M. Wahl, Cancer stem cells--perspectives on current status 
and future directions: AACR Workshop on cancer stem cells, Cancer Res, 66 (2006) 
9339-9344. 
[11] F. Ishikawa, S. Yoshida, Y. Saito, A. Hijikata, H. Kitamura, S. Tanaka, R. 
Nakamura, T. Tanaka, H. Tomiyama, N. Saito, M. Fukata, T. Miyamoto, B. Lyons, K. 
Ohshima, N. Uchida, S. Taniguchi, O. Ohara, K. Akashi, M. Harada, L.D. Shultz, 
Chemotherapy-resistant human AML stem cells home to and engraft within the 
bone-marrow endosteal region, Nat Biotechnol, 25 (2007) 1315-1321. 
[12] M.H. Frank, T. Schatton, G.F. Murphy, N.Y. Frank, K. Yamaura, A.M. 
Waaga-Gasser, M. Gasser, Q. Zhan, S. Jordan, L.M. Duncan, C. Weishaupt, R.C. 
Fuhlbrigge, T.S. Kupper, M.H. Sayegh, Identification of cells initiating human 
198 
 
melanomas, Nature, 451 (2008) 345-U311. 
[13] C. Heeschen, P.C. Hermann, S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, M. 
Guba, C.J. Bruns, Distinct populations of cancer stem cells determine tumor growth 
and metastatic activity in human pancreatic cancer, Cell Stem Cell, 1 (2007) 313-323. 
[14] R. De Maria, A. Eramo, L. Ricci-Vitiani, A. Zeuner, R. Pallini, F. Lotti, G. Sette, E. 
Pilozzi, L.M. Larocca, C. Peschle, Chemotherapy resistance of glioblastoma stem cells, 
Cell Death Differ, 13 (2006) 1238-1241. 
[15] J.C. Chang, X.X. Li, M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, M.F. Wu, 
S.G. Hilsenbeck, A. Pavlick, X.M. Zhang, G.C. Chamness, H. Wong, J. Rosen, 
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy, J Natl Cancer I, 
100 (2008) 672-679. 
[16] S.J. Dylla, L. Beviglia, I.K. Park, C. Chartier, J. Raval, L. Ngan, K. Pickell, J. 
Aguilar, S. Lazetic, S. Smith-Berdan, M.F. Clarke, T. Hoey, J. Lewicki, A.L. Gurney, 
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following 
Chemotherapy, Plos One, 3 (2008). 
[17] J.N. Rich, S.D. Bao, Q.L. Wu, R.E. McLendon, Y.L. Hao, Q. Shi, A.B. 
Hjelmeland, M.W. Dewhirst, D.D. Bigner, Glioma stem cells promote radioresistance 
by preferential activation of the DNA damage response, Nature, 444 (2006) 756-760. 
[18] M.F. Clarke, M. Diehn, R.W. Cho, N.A. Lobo, T. Kalisky, M.J. Dorie, A.N. Kulp, 
D.L. Qian, J.S. Lam, L.E. Ailles, M.Z. Wong, B. Joshua, M.J. Kaplan, I. Wapnir, F.M. 
Dirbas, G. Somlo, C. Garberoglio, B. Paz, J. Shen, S.K. Lau, S.R. Quake, J.M. Brown, 
I.L. Weissman, Association of reactive oxygen species levels and radioresistance in 
cancer stem cells, Nature, 458 (2009) 780-U123. 
[19] S.K. Carter, Surgery Plus Adjuvant Chemotherapy - a Review of Therapeutic 
Implications .1. Breast-Cancer, Cancer Chemoth Pharm, 4 (1980) 147-163. 
[20] B.A. Chabner, T.G. Roberts, Timeline - Chemotherapy and the war on cancer, Nat 
Rev Cancer, 5 (2005) 65-72. 
[21] L.E. Gaspar, M.S. Ding, A Review of Intensity-Modulated Radiation Therapy, 
Curr Oncol Rep, 10 (2008) 294-299. 
[22] A. Chakravarti, S.E. Noda, T. Lautenschlaeger, M.R. Siedow, D.R. Patel, A. 
El-Jawahri, Y. Suzuki, J.S. Loeffler, M.R. Bussiere, Technological Advances in 




[23] C.J. Ryan, G. Wilding, Angiogenesis inhibitors - New agents in cancer therapy, 
Drug Aging, 17 (2000) 249-255. 
[24] Y.F. Hui, R.J. Ignoffo, Angiogenesis inhibitors - A promising role in cancer 
therapy, Cancer Pract, 6 (1998) 60-62. 
[25] S.G. Eckhardt, Angiogenesis inhibitors as cancer therapy, Hosp Pract, 34 (1999) 
63-+. 
[26] A.M. Thielen, S. Kuenzli, J.H. Saurat, Cutaneous adverse events of biological 
therapy for psoriasis: Review of the literature, Dermatology, 211 (2005) 209-217. 
[27] D.E.J.G.J. Dolmans, D. Fukumura, R.K. Jain, Photodynamic therapy for cancer, 
Nat Rev Cancer, 3 (2003) 380-387. 
[28] M.B. Vrouenraets, G.W.M. Visser, G.B. Snow, G.A.M.S. van Dongen, Basic 
principles, applications in oncology and improved selectivity of photodynamic therapy, 
Anticancer Res, 23 (2003) 505-522. 
[29] J. van der Zee, Heating the patient: a promising approach?, Ann Oncol, 13 (2002) 
1173-1184. 
[30] M. Schlemmer, L.H. Lindner, S. Abdel-Rahman, R.D. Issels, Principles, 
technology and indication of hyperthermia and part body hyperthermia, Radiologe, 44 
(2004) 301-+. 
[31] G.U. Dachs, G.J. Dougherty, I.J. Stratford, D.J. Chaplin, Targeting gene therapy to 
cancer: A review, Oncol Res, 9 (1997) 313-325. 
[32] E. Check, Gene-therapy trials to restart following cancer risk review, Nature, 434 
(2005) 127-127. 
[33] A. Khatri, C. Tang, P.J. Russell, R. Martiniello-Wilks, J.E.J. Rasko, Concise 
Review: Nanoparticles and Cellular Carriers-Allies in Cancer Imaging and Cellular 
Gene Therapy?, Stem Cells, 28 (2010) 1686-1702. 
[34] I. Mellman, G. Coukos, G. Dranoff, Cancer immunotherapy comes of age, Nature, 
480 (2011) 480-489. 
[35] Z. Zhang, Y. Guo, S.S. Feng, Nanoimmunotherapy: application of nanotechnology 
for sustained and targeted delivery of antigens to dendritic cells, Nanomedicine (Lond), 
7 (2012) 1-4. 
[36] S.A. Rosenberg, J.C. Yang, N.P. Restifo, Cancer immunotherapy: moving beyond 
200 
 
current vaccines, Nature medicine, 10 (2004) 909-915. 
[37] I. Melero, A.M. Grimaldi, J.L. Perez-Gracia, P.A. Ascierto, Clinical Development 
of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination, 
Clin Cancer Res, 19 (2013) 997-1008. 
[38] S.D. Blackburn, H. Shin, W.N. Haining, T. Zou, C.J. Workman, A. Polley, M.R. 
Betts, G.J. Freeman, D.A.A. Vignali, E.J. Wherry, Coregulation of CD8(+) T cell 
exhaustion by multiple inhibitory receptors during chronic viral infection, Nature 
immunology, 10 (2009) 29-37. 
[39] M.A. Curran, W. Montalvo, H. Yagita, J.P. Allison, PD-1 and CTLA-4 
combination blockade expands infiltrating T cells and reduces regulatory T and 
myeloid cells within B16 melanoma tumors, P Natl Acad Sci USA, 107 (2010) 
4275-4280. 
[40] P. Yu, J.C. Steel, M.L. Zhang, J.C. Morris, T.A. Waldmann, Simultaneous 
Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor 
Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model, 
Clin Cancer Res, 16 (2010) 6019-6028. 
[41] A.J.M. van den Eertwegh, J. Versluis, H.P. van den Berg, S.J.A.M. Santegoets, 
R.J.A. van Moorselaar, T.M. van der Sluis, H.E. Gall, T.C. Harding, K. Jooss, I. Lowy, 
H.M. Pinedo, R.J. Scheper, A.G.M. Stam, B.M.E. von Blomberg, T.D. de Gruijl, K. 
Hege, N. Sacks, W.R. Gerritsen, Combined immunotherapy with 
granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate 
cancer cells and ipilimumab in patients with metastatic castration-resistant prostate 
cancer: a phase 1 dose-escalation trial, Lancet Oncology, 13 (2012) 509-517. 
[42] R.A. Madan, M. Mohebtash, P.M. Arlen, M. Vergati, M. Rauckhorst, S.M. 
Steinberg, K.Y. Tsang, D.J. Poole, H.L. Parnes, J.J. Wright, W.L. Dahut, J. Schlom, J.L. 
Gulley, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in 
metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, Lancet 
Oncology, 13 (2012) 501-508. 
[43] E.C.M. Zeestraten, F.M. Speetjens, M.J.P. Welters, S. Saadatmand, L.F.M. 
Stynenbosch, R. Jongen, E. Kapiteijn, H. Gelderblom, H.W. Nijman, A.R.P.M. 
Valentijn, J. Oostendorp, L.M. Fathers, J.W. Drijfhout, C.J.H. van de Velde, P.J.K. 
Kuppen, S.H. van der Burg, C.J.M. Melief, Addition of interferon-alpha to the 
p53-SLP (R) vaccine results in increased production of interferon-gamma in 
vaccinated colorectal cancer patients: A phase I/II clinical trial, Int J Cancer, 132 (2013) 
1581-1591. 
[44] A.A. Tarhini, J. Cherian, S.J. Moschos, H.A. Tawbi, Y.L. Shuai, W.E. Gooding, C. 
201 
 
Sander, J.M. Kirkwood, Safety and Efficacy of Combination Immunotherapy With 
Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma, J Clin 
Oncol, 30 (2012) 322-328. 
[45] C.G. Drake, Combination immunotherapy approaches, Ann Oncol, 23 (2012) 
41-46. 
[46] L. Zitvogel, G. Kroemer, Anticancer immunochemotherapy using adjuvants with 
direct cytotoxic effects, J Clin Invest, 119 (2009) 2127-2130. 
[47] T. De Pas, M. Giovannini, M. Rescigno, C. Catania, F. Toffalorio, G. Spitaleri, A. 
Delmonte, M. Barberis, L. Spaggiari, P. Solli, G. Veronesi, F. De Braud, Vaccines in 
non-small cell lung cancer: Rationale, combination strategies and update on clinical 
trials, Crit Rev Oncol Hemat, 83 (2012) 432-443. 
[48] E. Quoix, R. Ramlau, V. Westeel, Z. Papai, A. Madroszyk, A. Riviere, P. 
Koralewski, J.L. Breton, E. Stoelben, D. Braun, D. Debieuvre, H. Lena, M. Buyse, M.P. 
Chenard, B. Acres, G. Lacoste, B. Bastien, A. Tavernaro, N. Bizouarne, J.Y. Bonnefoy, 
J.M. Limacher, Therapeutic vaccination with TG4010 and first-line chemotherapy in 
advanced non-small-cell lung cancer: a controlled phase 2B trial, Lancet Oncology, 12 
(2011) 1125-1133. 
[49] Y. Kimura, J. Tsukada, T. Tomoda, H. Takahashi, K. Imai, K. Shimamura, M. 
Sunamura, Y. Yonemitsu, S. Shimodaira, S. Koido, S. Homma, M. Okamoto, Clinical 
and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination 
With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma, 
Pancreas, 41 (2012) 195-205. 
[50] T.K. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pflugfelder, R. 
Gonzalez-Iglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. 
Trachsel, H.D. Menssen, D. Neri, C. Garbe, A Dose-Escalation and Signal-Generating 
Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the 
Therapy of Patients with Metastatic Melanoma, Clin Cancer Res, 17 (2011) 
7732-7742. 
[51] M. Ramos-Suzarte, P. Lorenzo-Luaces, N.G. Lazo, M.L. Perez, J.L. Soriano, 
C.E.V. Gonzalez, I.M. Hernadez, Y.A. Albuerne, B.P. Moreno, E.S. Alvarez, I.P. 
Callejo, J. Alert, J.A. Martell, Y.S. Gonzalez, Y.S. Gonzalez, H.A. De la Vega, E.B. 
Ruiz-Garcia, T. Crombet-Ramos, Treatment of malignant, non-resectable, epithelial 
origin esophageal tumors with the humanized anti-epidermal growth factor antibody 
nimotuzumab combined with radiation therapy and chemotherapy, Cancer biology & 
therapy, 13 (2012) 600-605. 
[52] J.M. Dong, S.G. Zhao, G.Y. Huang, Q. Liu, NADPH oxidase-mediated generation 
202 
 
of reactive oxygen species is critically required for survival of undifferentiated human 
promyelocytic leukemia cell line HL-60, Free Radical Res, 38 (2004) 629-637. 
[53] J.R. Oleson, Robertson,Eugene Special Lecture Hyperthermia from the Clinic to 
the Laboratory - a Hypothesis, Int J Hyperther, 11 (1995) 315-322. 
[54] Z. Vujaskovic, C.W. Song, Physiological mechanisms underlying heat-induced 
radiosensitization, Int J Hyperther, 20 (2004) 163-174. 
[55] O. Sandre, C. Sanson, O. Diou, J. Thevenot, E. Ibarboure, A. Soum, A. Brulet, S. 
Miraux, E. Thiaudiere, S. Tan, A. Brisson, V. Dupuis, S. Lecommandoux, Doxorubicin 
Loaded Magnetic Polymersomes: Theranostic Nanocarriers for MR Imaging and 
Magneto-Chemotherapy, Acs Nano, 5 (2011) 1122-1140. 
[56] A.M. Westermann, G.J. Wiedemann, E. Jager, D. Jager, D.M. Katschinski, A. 
Knuth, P.Z. Vorde Sive Vording, J.D. Van Dijk, J. Finet, A. Neumann, W. Longo, A. 
Bakhshandeh, C.L. Tiggelaar, W. Gillis, H. Bailey, S.O. Peters, H.I. Robins, A 
Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and 
etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft 
tissue sarcoma, Oncology, 64 (2003) 312-321. 
[57] C. Schroeder, C. Gani, U. Lamprecht, C.H. von Weyhern, M. Weinmann, M. 
Bamberg, B. Berger, Pathological complete response and sphincter-sparing surgery 
after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced 
rectal cancer compared with radiochemotherapy alone, International journal of 
hyperthermia : the official journal of European Society for Hyperthermic Oncology, 
North American Hyperthermia Group, 28 (2012) 707-714. 
[58] V. Kouloulias, G. Plataniotis, J. Kouvaris, C. Dardoufas, C. Gennatas, N. 
Uzunoglu, C. Papavasiliou, L. Vlahos, Chemoradiotherapy combined with 
intracavitary hyperthermia for anal cancer: feasibility and long-term results from a 
phase II randomized trial, American journal of clinical oncology, 28 (2005) 91-99. 
[59] A.M. Westermann, E.L. Jones, B.C. Schem, E.M. van der Steen-Banasik, P. Koper, 
O. Mella, A.L. Uitterhoeve, R. de Wit, J. van der Velden, C. Burger, C.L. van der Wilt, 
O. Dahl, L.R. Prosnitz, J. van der Zee, First results of triple-modality treatment 
combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients 
with stage IIB, III, and IVA cervical carcinoma, Cancer, 104 (2005) 763-770. 
[60] A. Westermann, O. Mella, J. Van Der Zee, E.L. Jones, E. Van Der Steen-Banasik, P. 
Koper, A.L. Uitterhoeve, R. De Wit, J. Van Der Velden, C. Burger, B.C. Schem, C. Van 
Der Wilt, O. Dahl, L.R. Prosnitz, H. Van Tinteren, Long-term survival data of triple 
modality treatment of stage IIB-III-IVA cervical cancer with the combination of 
radiotherapy, chemotherapy and hyperthermia - an update, International journal of 
203 
 
hyperthermia : the official journal of European Society for Hyperthermic Oncology, 
North American Hyperthermia Group, 28 (2012) 549-553. 
[61] Z. Vujaskovic, D.W. Kim, E. Jones, L. Lan, L. McCall, M.W. Dewhirst, O. 
Craciunescu, P. Stauffer, V. Liotcheva, A. Betof, K. Blackwell, A phase I/II study of 
neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced 
breast cancer, International journal of hyperthermia : the official journal of European 
Society for Hyperthermic Oncology, North American Hyperthermia Group, 26 (2010) 
514-521. 
[62] K.E. Tschoep-Lechner, V. Milani, F. Berger, N. Dieterle, S. Abdel-Rahman, C. 
Salat, R.D. Issels, Gemcitabine and cisplatin combined with regional hyperthermia as 
second-line treatment in patients with gemcitabine-refractory advanced pancreatic 
cancer, Int J Hyperther, 29 (2013) 8-16. 
[63] R. Wessalowski, H. Kruck, H. Pape, T. Kahn, R. Willers, U. Gobel, Hyperthermia 
for the treatment of patients with malignant germ cell tumors: a phase I/II study in ten 
children and adolescents with recurrent or refractory tumors, Cancer, 82 (1998) 
793-800. 
[64] R.D. Issels, Hyperthermia adds to chemotherapy, Eur J Cancer, 44 (2008) 
2546-2554. 
[65] S. Lindquist, E.A. Craig, The heat-shock proteins, Annual review of genetics, 22 
(1988) 631-677. 
[66] R. Suto, P.K. Srivastava, A mechanism for the specific immunogenicity of heat 
shock protein-chaperoned peptides, Science, 269 (1995) 1585-1588. 
[67] V. Milani, E. Noessner, S. Ghose, M. Kuppner, B. Ahrens, A. Scharner, R. Gastpar, 
R.D. Issels, Heat shock protein 70: role in antigen presentation and immune 
stimulation, International journal of hyperthermia : the official journal of European 
Society for Hyperthermic Oncology, North American Hyperthermia Group, 18 (2002) 
563-575. 
[68] R. Stone, T. Willi, Y. Rosen, O.T. Mefford, F. Alexis, Targeted magnetic 
hyperthermia, Therapeutic delivery, 2 (2011) 815-838. 
[69] L. Zhao, J. Tang, S.S. Feng, Nanothermotherapy by high performance magnetic 
nanoparticles, Nanomedicine (Lond), 5 (2010) 1305-1308. 
[70] C.S. Kumar, F. Mohammad, Magnetic nanomaterials for hyperthermia-based 




[71] M. Hu, J.Y. Chen, Z.Y. Li, L. Au, G.V. Hartland, X.D. Li, M. Marquez, Y.N. Xia, 
Gold nanostructures: engineering their plasmonic properties for biomedical 
applications, Chem Soc Rev, 35 (2006) 1084-1094. 
[72] P.K. Jain, X.H. Huang, I.H. El-Sayed, M.A. El-Sayed, Noble Metals on the 
Nanoscale: Optical and Photothermal Properties and Some Applications in Imaging, 
Sensing, Biology, and Medicine, Accounts Chem Res, 41 (2008) 1578-1586. 
[73] E. Boisselier, D. Astruc, Gold nanoparticles in nanomedicine: preparations, 
imaging, diagnostics, therapies and toxicity, Chem Soc Rev, 38 (2009) 1759-1782. 
[74] E.S. Day, J.G. Morton, J.L. West, Nanoparticles for thermal cancer therapy, 
Journal of biomechanical engineering, 131 (2009) 074001. 
[75] N.W.S. Kam, M. O'Connell, J.A. Wisdom, H.J. Dai, Carbon nanotubes as 
multifunctional biological transporters and near-infrared agents for selective cancer 
cell destruction, P Natl Acad Sci USA, 102 (2005) 11600-11605. 
[76] A.R. Burke, R.N. Singh, D.L. Carroll, J.C.S. Wood, R.B. D'Agostino, P.M. Ajayan, 
F.M. Torti, S.V. Torti, The resistance of breast cancer stem cells to conventional 
hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy, 
Biomaterials, 33 (2012) 2961-2970. 
[77] R. Kerbel, J. Folkman, Clinical translation of angiogenesis inhibitors, Nat Rev 
Cancer, 2 (2002) 727-739. 
[78] P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases, Nature, 407 
(2000) 249-257. 
[79] J. Folkman, Opinion - Angiogenesis: an organizing principle for drug discovery?, 
Nat Rev Drug Discov, 6 (2007) 273-286. 
[80] J. Folkman, Angiogenesis, Annu Rev Med, 57 (2006) 1-18. 
[81] M. Kamrava, M.B. Bernstein, K. Camphausen, J.W. Hodge, Combining radiation, 
immunotherapy, and antiangiogenesis agents in the management of cancer: the Three 
Musketeers or just another quixotic combination?, Molecular bioSystems, 5 (2009) 
1262-1270. 
[82] N. Ferrara, R.S. Kerbel, Angiogenesis as a therapeutic target, Nature, 438 (2005) 
967-974. 
[83] G. Gasparini, R. Longo, M. Fanelli, B.A. Teicher, Combination of antiangiogenic 
therapy with other anticancer therapies: Results, challenges, and open questions, J Clin 
205 
 
Oncol, 23 (2005) 1295-1311. 
[84] E.L. Mayer, S.J. Isakoff, G. Klement, S.R. Downing, W.Y. Chen, K. Hannagan, R. 
Gelman, E.P. Winer, H.J. Burstein, Combination antiangiogenic therapy in advanced 
breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic 
chemotherapy, with correlative platelet proteomics, Breast Cancer Res Tr, 136 (2012) 
169-178. 
[85] H.A. Burris, A. Dowlati, R.A. Moss, J.R. Infante, S.F. Jones, D.R. Spigel, K.T. 
Levinson, D. Lindquist, S.D. Gainer, M.M. Dar, A.B. Suttle, H.A. Ball, A.R. Tan, 
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given 
Every 21 Days in Patients with Advanced Solid Tumors, Molecular cancer therapeutics, 
11 (2012) 1820-1828. 
[86] A.A. Garcia, H. Hirte, G. Fleming, D.Y. Yang, D.D. Tsao-Wei, L. Roman, S. 
Groshen, S. Swenson, F. Markland, D. Gandara, S. Scudder, R. Morgan, H. Chen, H.J. 
Lenz, A.M. Oza, Phase II clinical trial of bevacizumab and low-dose metronomic oral 
cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and 
princess Margaret hospital phase II consortia, J Clin Oncol, 26 (2008) 76-82. 
[87] E. Van Cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausova, T. Macarulla, P. 
Ruff, G.A. van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, J. Polikoff, A. Tellier, 
R. Castan, C. Allegra, Addition of Aflibercept to Fluorouracil, Leucovorin, and 
Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With 
Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, 
J Clin Oncol, 30 (2012) 3499-3506. 
[88] L.E. Kandalaft, D.J. Powell, C.L. Chiang, J. Tanyi, S. Kim, M. Bosch, K. Montone, 
R. Mick, B.L. Levine, D.A. Torigian, C.H. June, G. Coukos, Autologous lysate-pulsed 
dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo 
co-stimulated T cells in recurrent ovarian cancer, Oncoimmunology, 2 (2013). 
[89] A. Fabi, M. Russillo, G. Ferretti, G. Metro, C. Nistico, P. Papaldo, F. De Vita, G. 
D'Auria, A. Vidiri, D. Giannarelli, F. Cognetti, Maintenance bevacizumab beyond 
first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone 
receptor-positive metastatic breast cancer: efficacy in combination with hormonal 
therapy, Bmc Cancer, 12 (2012). 
[90] I. Baldea, A.G. Filip, Photodynamic Therapy in Melanoma - an Update, Journal of 
Physiology and Pharmacology, 63 (2012) 109-118. 
[91] S.B. Brown, E.A. Brown, I. Walker, The present and future role of photodynamic 
therapy in cancer treatment, Lancet Oncology, 5 (2004) 497-508. 
206 
 
[92] M.F. Zuluaga, N. Lange, Combination of photodynamic therapy with anti-cancer 
agents, Curr Med Chem, 15 (2008) 1655-1673. 
[93] P. Agostinis, K. Berg, K.A. Cengel, T.H. Foster, A.W. Girotti, S.O. Gollnick, S.M. 
Hahn, M.R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. 
Nowis, J. Piette, B.C. Wilson, J. Golab, Photodynamic Therapy of Cancer: An Update, 
Ca-Cancer J Clin, 61 (2011) 250-281. 
[94] J.S. Friedberg, R. Mick, J. Stevenson, J. Metz, T. Zhu, J. Buyske, D.H. Sterman, 
H.I. Pass, E. Glatstein, S.M. Hahn, A phase I study of foscan-mediated photodynamic 
therapy and surgery in patients with mesothelioma, Annals of Thoracic Surgery, 75 
(2003) 952-959. 
[95] C.E. Thomas, A. Ehrhardt, M.A. Kay, Progress and problems with the use of viral 
vectors for gene therapy, Nat Rev Genet, 4 (2003) 346-358. 
[96] F. McCormick, Cancer gene therapy: Fringe or cutting edge?, Nat Rev Cancer, 1 
(2001) 130-141. 
[97] J.A. Roth, R.J. Cristiano, Gene therapy for cancer: What have we done and where 
are we going?, J Natl Cancer I, 89 (1997) 21-39. 
[98] J.P. DeVincenzo, The promise, pitfalls and progress of RNA-interference-based 
antiviral therapy for respiratory viruses, Antivir Ther, 17 (2012) 213-225. 
[99] M. Izquierdo, Short interfering RNAs as a tool for cancer gene therapy, Cancer 
Gene Ther, 12 (2005) 217-227. 
[100] B.L. Davidson, P.B. McCray, Current prospects for RNA interference-based 
therapies, Nat Rev Genet, 12 (2011) 329-340. 
[101] S.L. Ginn, I.E. Alexander, M.L. Edelstein, M.R. Abedi, J. Wixon, Gene therapy 
clinical trials worldwide to 2012 an update, J Gene Med, 15 (2013) 65-77. 
[102] D. Haussecker, The Business of RNAi Therapeutics in 2012, Molecular therapy. 
Nucleic acids, 1 (2012) e8. 
[103] T. Satoh, B.S. Teh, T.L. Timme, W.Y. Mai, Y. Gdor, N. Kusaka, T. Fujita, C.K. 
Pramudji, M.T. Vlachaki, G. Ayala, T. Wheeler, R. Amato, B.J. Miles, D. Kadmon, E.B. 
Butler, T.C. Thompson, Enhanced systemic T-cell activation after in situ gene therapy 
with radiotherapy in prostate cancer patients, Int J Radiat Oncol, 59 (2004) 562-571. 
[104] K.J. Chang, T. Reid, N. Senzer, S. Swisher, H. Pinto, N. Hanna, A. Chak, R. 
Soetikno, Phase I evaluation of TNFerade biologic plus chemoradiotherapy before 
207 
 
esophagectomy for locally advanced resectable esophageal cancer, Gastrointest 
Endosc, 75 (2012) 1139-+. 
[105] J.R. Hecht, J.J. Farrell, N. Senzer, J. Nemunaitis, A. Rosemurgy, T. Chung, N. 
Hanna, K.J. Chang, M. Javle, M. Posner, I. Waxman, A. Reid, R. Erickson, M. Canto, 
A. Chak, G. Blatner, M. Kovacevic, M. Thornton, EUS or percutaneously guided 
intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line 
treatment of locally advanced pancreatic cancer: a phase I/II study, Gastrointest Endosc, 
75 (2012) 332-338. 
[106] N.A. Habib, C.E. Sarraf, R.R. Mitry, R. Havlik, J. Nicholls, M. Kelly, G.C. 
Vernon, D. Gueret-Wardle, R. El-Masry, H. Salama, R. Ahmed, N. Michail, E. Edward, 
S.L. Jensen, E1B-deleted adenovirus (dl1520) gene therapy for patients with primary 
and secondary liver tumors, Hum Gene Ther, 12 (2001) 219-226. 
[107] F.R. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I.F. Tannock, L. Romel, M. Gore, 
J. Ironside, R.H. MacDougall, C. Heise, B. Randlev, A.M. Gillenwater, P. Bruso, S.B. 
Kaye, W.K. Hong, D.H. Kirn, A controlled trial of intratumoral ONYX-015, a 
selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in 
patients with recurrent head and neck cancer, Nature medicine, 6 (2000) 879-885. 
[108] C. Hesdorffer, J. Ayello, M. Ward, A. Kaubisch, L. Vahdat, C. Balmaceda, T. 
Garrett, M. Fetell, R. Reiss, A. Bank, K. Antman, Phase I trial of retroviral-mediated 
transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing 
high-dose chemotherapy and autologous stem-cell transplantation, J Clin Oncol, 16 
(1998) 165-172. 
[109] M.E. Davis, Z. Chen, D.M. Shin, Nanoparticle therapeutics: an emerging 
treatment modality for cancer, Nat Rev Drug Discov, 7 (2008) 771-782. 
[110] S.S. Feng, L.Y. Zhao, Z.P. Zhang, G. Bhakta, K.Y. Win, Y.C. Dong, S. Chien, 
Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of 
biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo, 
Chem Eng Sci, 62 (2007) 6641-6648. 
[111] C.W. Gan, S. Chien, S.S. Feng, Nanomedicine: Enhancement of 
Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle 
Formulation, Curr Pharm Design, 16 (2010) 2308-2320. 
[112] D. Peer, J.M. Karp, S. Hong, O.C. FaroKHzad, R. Margalit, R. Langer, 
Nanocarriers as an emerging platform for cancer therapy, Nat Nanotechnol, 2 (2007) 
751-760. 
[113] Y. Mi, J. Zhao, S.S. Feng, Vitamin E TPGS prodrug micelles for hydrophilic drug 
208 
 
delivery with neuroprotective effects, International journal of pharmaceutics, 438 
(2012) 98-106. 
[114] K.Y. Win, S.S. Feng, Effects of particle size and surface coating on cellular 
uptake of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials, 
26 (2005) 2713-2722. 
[115] Y. Mi, Y.T. Liu, Y.J. Guo, S.S. Feng, Herceptin (R)-conjugated nanocarriers for 
targeted imaging and treatment of HER2-positive cancer, Nanomedicine-Uk, 6 (2011) 
311-312. 
[116] J. Zhao, Y. Mi, Y.T. Liu, S.S. Feng, Quantitative control of targeting effect of 
anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable 
copolymer blend, Biomaterials, 33 (2012) 1948-1958. 
[117] Y. Mi, K. Li, Y. Liu, K.Y. Pu, B. Liu, S.S. Feng, Herceptin functionalized 
polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide 
nanoparticles for tumor cell sorting and detection, Biomaterials, 32 (2011) 8226-8233. 
[118] C.W. Gan, S.S. Feng, Transferrin-conjugated nanoparticles of 
Poly(lactide)-D-alpha-Tocopheryl polyethylene glycol succinate diblock copolymer 
for targeted drug delivery across the blood-brain barrier, Biomaterials, 31 (2010) 
7748-7757. 
[119] Y.T. Liu, K. Li, J. Pan, B. Liu, S.S. Feng, Folic acid conjugated nanoparticles of 
mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of 
Docetaxel, Biomaterials, 31 (2010) 330-338. 
[120] Y. Mi, J. Zhao, S.S. Feng, Targeted co-delivery of docetaxel, cisplatin and 
herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality 
treatment of cancer, J Control Release, (2013). 
[121] S.S. Feng, S. Chien, Chemotherapeutic engineering: Application and further 
development of chemical engineering principles for chemotherapy of cancer and other 
diseases, Chem Eng Sci, 58 (2003) 4087-4114. 
[122] J. Zhao, Y. Mi, S.S. Feng, siRNA-based nanomedicine, Nanomedicine (Lond), 8 
(2013) 859-862. 
[123] H.A. Meng, M. Liong, T.A. Xia, Z.X. Li, Z.X. Ji, J.I. Zink, A.E. Nel, Engineered 
Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and 
P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line, Acs Nano, 
4 (2010) 4539-4550. 
209 
 
[124] S. Sengupta, D. Eavarone, I. Capila, G.L. Zhao, N. Watson, T. Kiziltepe, R. 
Sasisekharan, Temporal targeting of tumour cells and neovasculature with a nanoscale 
delivery system, Nature, 436 (2005) 568-572. 
[125] J. Yang, C.H. Lee, H.J. Ko, J.S. Suh, H.G. Yoon, K. Lee, Y.M. Huh, S. Haam, 
Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic 
therapeutic effects on breast cancer, Angew Chem Int Ed Engl, 46 (2007) 8836-8839. 
[126] T.M. Sun, J.Z. Du, Y.D. Yao, C.Q. Mao, S. Dou, S.Y. Huang, P.Z. Zhang, K.W. 
Leong, E.W. Song, J. Wang, Simultaneous Delivery of siRNA and Paclitaxel via a 
"Two-in-One" Micelleplex Promotes Synergistic Tumor Suppression, Acs Nano, 5 
(2011) 1483-1494. 
[127] T. Lammers, V. Subr, K. Ulbrich, P. Peschke, P.E. Huber, W.E. Hennink, G. 
Storm, Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using 
prototypic polymeric drug carriers, Biomaterials, 30 (2009) 3466-3475. 
[128] S.X. Huang, K. Shao, Y. Liu, Y.Y. Kuang, J.F. Li, S. An, Y.B. Guo, H.J. Ma, C. 
Jiang, Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for 
Combination Therapy of Antiangiogenesis and Apoptosis, Acs Nano, 7 (2013) 
2860-2871. 
[129] Y.G. Wang, T.Y. Yang, X. Wang, W.B. Dai, J.C. Wang, X.A. Zhang, Z.Q. Li, Q.A. 
Zhang, Materializing sequential killing of tumor vasculature and tumor cells via 
targeted polymeric micelle system, J Control Release, 149 (2011) 299-306. 
[130] Z.P. Zhang, X.L. Yang, S.S. Feng, Copolymer technology for advanced 
nanomedicine, Nanomedicine-Uk, 6 (2011) 583-587. 
[131] Z.P. Zhang, S.W. Tan, S.S. Feng, Vitamin E TPGS as a molecular biomaterial for 
drug delivery, Biomaterials, 33 (2012) 4889-4906. 
[132] Y. Mi, Y.T. Liu, S.S. Feng, Formulation of Docetaxel by folic acid-conjugated 
D-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) 
micelles for targeted and synergistic chemotherapy, Biomaterials, 32 (2011) 
4058-4066. 
[133] H. Wang, Y. Zhao, Y. Wu, Y.L. Hu, K.H. Nan, G.J. Nie, H. Chen, Enhanced 
anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic 
methoxy PEG-PLGA copolymer nanoparticles, Biomaterials, 32 (2011) 8281-8290. 
[134] H. Wang, Y. Wu, R.F. Zhao, G.J. Nie, Engineering the Assemblies of Biomaterial 
Nanocarriers for Delivery of Multiple Theranostic Agents with Enhanced Antitumor 
Efficacy, Adv Mater, 25 (2013) 1616-1622. 
210 
 
[135] Z. Wang, W.K. Chui, P.C. Ho, Nanoparticulate Delivery System Targeted to 
Tumor Neovasculature for Combined Anticancer and Antiangiogenesis Therapy, 
Pharm Res-Dordr, 28 (2011) 585-596. 
[136] Z. Wang, P.C. Ho, A nanocapsular combinatorial sequential drug delivery system 
for antiangiogenesis and anticancer activities, Biomaterials, 31 (2010) 7115-7123. 
[137] R.S. Chang, M.S. Suh, S. Kim, G. Shim, S. Lee, S.S. Han, K.E. Lee, H. Jeon, 
H.G. Choi, Y. Choi, C.W. Kim, Y.K. Oh, Cationic drug-derived nanoparticles for 
multifunctional delivery of anticancer siRNA, Biomaterials, 32 (2011) 9785-9795. 
[138] H. Fan, Q.D. Hu, F.J. Xu, W.Q. Liang, G.P. Tang, W.T. Yang, In vivo treatment of 
tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and 
therapeutic gene pTRAIL, Biomaterials, 33 (2012) 1428-1436. 
[139] M.J. Shieh, C.Y. Hsu, L.Y. Huang, H.Y. Chen, F.H. Huang, P.S. Lai, Reversal of 
doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells, J 
Control Release, 152 (2011) 418-425. 
[140] C. Conte, F. Ungaro, G. Maglio, P. Tirino, G. Siracusano, M.T. Sciortino, N. 
Leone, G. Palma, A. Barbieri, C. Arra, A. Mazzaglia, F. Quaglia, Biodegradable 
core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine 
inspired by combination therapy for cancer, J Control Release, 167 (2013) 40-52. 
[141] H. Cho, T.C. Lai, G.S. Kwon, Poly(ethylene 
glycol)-block-poly(epsilon-caprolactone) micelles for combination drug delivery: 
Evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft 
models of ovarian cancer, J Control Release, 166 (2013) 1-9. 
[142] H.C. Shin, A.W.G. Alani, H. Cho, Y. Bae, J.M. Kolesar, G.S. Kwon, A 3-in-1 
Polymeric Micelle Nanocontainer for Poorly Water-Soluble Drugs, Mol Pharmaceut, 8 
(2011) 1257-1265. 
[143] J. Zhao, Y. Mi, S.S. Feng, Targeted co-delivery of docetaxel and siPlk1 by 
herceptin-conjugated vitamin E TPGS based immunomicelles, Biomaterials, 34 (2013) 
3411-3421. 
[144] C.F. Zheng, M.B. Zheng, P. Gong, J.Z. Deng, H.Q. Yi, P.F. Zhang, Y.J. Zhang, P. 
Liu, Y.F. Ma, L.T. Cai, Polypeptide cationic micelles mediated co-delivery of docetaxel 
and siRNA for synergistic tumor therapy, Biomaterials, 34 (2013) 3431-3438. 
[145] Q.L. Hu, W. Li, X.R. Hu, Q.D. Hu, J. Shen, X. Jin, J. Zhou, G.P. Tang, P.K. Chu, 
Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and 
paclitaxel via supramolecular micellar assembly, Biomaterials, 33 (2012) 6580-6591. 
211 
 
[146] C.L. Peng, M.J. Shieh, M.H. Tsai, C.C. Chang, P.S. Lai, Self-assembled 
star-shaped chlorin-core poly(c-caprolactone)-poly(ethylene glycol) diblock 
copolymer micelles for dual chemo-photodynamic therapies, Biomaterials, 29 (2008) 
3599-3608. 
[147] C.L. Peng, P.S. Lai, F.H. Lin, S.Y.H. Wu, M.J. Shieh, Dual chemotherapy and 
photodynamic therapy in an HT-29 human colon cancer xenograft model using 
SN-38-loaded chlorin-core star block copolymer micelles, Biomaterials, 30 (2009) 
3614-3625. 
[148] D. Zucker, A.V. Andriyanov, A. Steiner, U. Raviv, Y. Barenholz, 
Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and 
vincristine: relating structure and pharmacokinetics to therapeutic efficacy, J Control 
Release, 160 (2012) 281-289. 
[149] Y.F. Zhang, J.C. Wang, D.Y. Bian, X. Zhang, Q. Zhang, Targeted delivery of 
RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for 
tumor therapy: In vitro and in vivo studies, Eur J Pharm Biopharm, 74 (2010) 467-473. 
[150] S.H. Kang, H.J. Cho, G. Shim, S. Lee, S.H. Kim, H.G. Choi, C.W. Kim, Y.K. Oh, 
Cationic Liposomal Co-delivery of Small Interfering RNA and a MEK Inhibitor for 
Enhanced Anticancer Efficacy, Pharm Res-Dordr, 28 (2011) 3069-3078. 
[151] Y. Wang, M. Saad, R.I. Pakunlu, J.J. Khandare, O.B. Garbuzenko, O.B. 
Garbuzenko, A.A. Vetcher, V.A. Soldatenkov, V.P. Pozharov, T. Minko, Nonviral 
nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible 
factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor, Clin 
Cancer Res, 14 (2008) 3607-3616. 
[152] Y.T. Ko, C. Falcao, V.P. Torchilin, Cationic Liposomes Loaded with Proapoptotic 
Peptide D-(KLAKLAK)(2) and Bcl-2 Antisense Oligodeoxynucleotide G3139 for 
Enhanced Anticancer Therapy, Mol Pharmaceut, 6 (2009) 971-977. 
[153] W.J. Xiao, X.A. Chen, L. Yang, Y.Q. Mao, Y.Q. Wei, L.J. Chen, Co-delivery of 
doxorubicin and plasmid by a novel FGFR-mediated cationic liposome, International 
journal of pharmaceutics, 393 (2010) 119-126. 
[154] M.M. Yallapu, M. Jaggi, S.C. Chauhan, Design and engineering of nanogels for 
cancer treatment, Drug discovery today, 16 (2011) 457-463. 
[155] A.V. Kabanov, S.V. Vinogradov, Nanogels as Pharmaceutical Carriers: Finite 
Networks of Infinite Capabilities, Angew Chem Int Edit, 48 (2009) 5418-5429. 
[156] Z.Y. Qian, S.Z. Fu, S.S. Feng, Nanohydrogels as a prospective member of the 
212 
 
nanomedicine family, Nanomedicine-Uk, 8 (2013) 161-164. 
[157] M.H. Smith, L.A. Lyon, Multifunctional Nanogels for siRNA Delivery, Accounts 
Chem Res, 45 (2012) 985-993. 
[158] D.C. Gonzalez-Toro, J.H. Ryu, R.T. Chacko, J.M. Zhuang, S. Thayumanavan, 
Concurrent Binding and Delivery of Proteins and Lipophilic Small Molecules Using 
Polymeric Nanogels, J Am Chem Soc, 134 (2012) 6964-6967. 
[159] L.L. Zhao, L.J. Zhu, F.Y. Liu, C.Y. Liu, Shan-Dan, Q. Wang, C.L. Zhang, J.L. Li, 
J.G. Liu, X.Z. Qu, Z.Z. Yang, pH triggered injectable amphiphilic hydrogel containing 
doxorubicin and paclitaxel, International journal of pharmaceutics, 410 (2011) 83-91. 
[160] A.R. Menjoge, R.M. Kannan, D.A. Tomalia, Dendrimer-based drug and imaging 
conjugates: design considerations for nanomedical applications, Drug discovery today, 
15 (2010) 171-185. 
[161] C.C. Lee, J.A. MacKay, J.M.J. Frechet, F.C. Szoka, Designing dendrimers for 
biological applications, Nature biotechnology, 23 (2005) 1517-1526. 
[162] L.A. Han, R.Q. Huang, J.F. Li, S.H. Liu, S.X. Huang, C. Jiang, Plasmid 
pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using 
peptide-conjugated polyamidoamine dendrimer, Biomaterials, 32 (2011) 1242-1252. 
[163] I.H. Lee, S. An, M.K. Yu, H.K. Kwon, S.H. Im, S. Jon, Targeted 
chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates, J Control 
Release, 155 (2011) 435-441. 
[164] H.L. Wong, R. Bendayan, A.M. Rauth, Y.Q. Li, X.Y. Wu, Chemotherapy with 
anticancer drugs encapsulated in solid lipid nanoparticles, Advanced drug delivery 
reviews, 59 (2007) 491-504. 
[165] A.J. Almeida, E. Souto, Solid lipid nanoparticles as a drug delivery system for 
peptides and proteins, Advanced drug delivery reviews, 59 (2007) 478-490. 
[166] K.H. Bae, J.Y. Lee, S.H. Lee, T.G. Park, Y.S. Nam, Optically Traceable Solid 
Lipid Nanoparticles Loaded with siRNA and Paclitaxel for Synergistic Chemotherapy 
with In situ Imaging, Adv Healthc Mater, 2 (2013) 576-584. 
[167] D. Sutaria, B.K. Grandhi, A. Thakkar, J. Wang, S. Prabhu, Chemoprevention of 
pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, 




[168] M. Mahmood, A. Karmakar, A. Fejleh, T. Mocan, C. Iancu, L. Mocan, D.T. Iancu, 
Y. Xu, E. Dervishi, Z.R. Li, A.R. Biris, R. Agarwal, N. Ali, E.I. Galanzha, A.S. Biris, 
V.P. Zharov, Synergistic enhancement of cancer therapy using a combination of carbon 
nanotubes and anti-tumor drug, Nanomedicine-Uk, 4 (2009) 883-893. 
[169] L. Wang, J.J. Shi, H.L. Zhang, H.X. Li, Y. Gao, Z.Z. Wang, H.H. Wang, L.L. Li, 
C.F. Zhang, C.Q. Chen, Z.Z. Zhang, Y. Zhang, Synergistic anticancer effect of RNAi 
and photothermal therapy mediated by functionalized single-walled carbon nanotubes, 
Biomaterials, 34 (2013) 262-274. 
[170] L. Wang, M.Y. Zhang, N. Zhang, J.J. Shi, H.L. Zhang, M. Li, C. Lu, Z.Z. Zhang, 
Synergistic enhancement of cancer therapy using a combination of docetaxel and 
photothermal ablation induced by single-walled carbon nanotubes, Int J Nanomed, 6 
(2011) 2641-2652. 
[171] W. Zhang, Z.Y. Guo, D.Q. Huang, Z.M. Liu, X. Guo, H.Q. Zhong, Synergistic 
effect of chemo-photothermal therapy using PEGylated graphene oxide, Biomaterials, 
32 (2011) 8555-8561. 
[172] J. You, R. Zhang, G.D. Zhang, M. Zhong, Y. Liu, C.S. Van Pelt, D. Liang, W. Wei, 
A.K. Sood, C. Li, Photothermal-chemotherapy with doxorubicin-loaded hollow gold 
nanospheres: A platform for near-infrared light-trigged drug release, J Control Release, 
158 (2012) 319-328. 
[173] H.C. Huang, Y. Yang, A. Nanda, P. Koria, K. Rege, Synergistic administration of 
photothermal therapy and chemotherapy to cancer cells using polypeptide-based 
degradable plasmonic matrices, Nanomedicine-Uk, 6 (2011) 459-473. 
[174] W.S. Kuo, Y.T. Chang, K.C. Cho, K.C. Chiu, C.H. Lien, C.S. Yeh, S.J. Chen, 
Gold nanomaterials conjugated with indocyanine green for dual-modality 
photodynamic and photothermal therapy, Biomaterials, 33 (2012) 3270-3278. 
[175] K.C. Barick, S. Singh, N.V. Jadhav, D. Bahadur, B.N. Pandey, P.A. Hassan, 
pH-Responsive Peptide Mimic Shell Cross-Linked Magnetic Nanocarriers for 
Combination Therapy, Adv Funct Mater, 22 (2012) 4975-4984. 
[176] Y. Xu, A. Karmakar, W.E. Heberlein, T. Mustafa, A.R. Biris, A.S. Biris, 
Multifunctional Magnetic Nanoparticles for Synergistic Enhancement of Cancer 
Treatment by Combinatorial Radio Frequency Thermolysis and Drug Delivery, Adv 
Healthc Mater, 1 (2012) 493-501. 
[177] Y. Chen, Y. Gao, H.R. Chen, D.P. Zeng, Y.P. Li, Y.Y. Zheng, F.Q. Li, X.F. Ji, X. 
Wang, F. Chen, Q.J. He, L.L. Zhang, J.L. Shi, Engineering Inorganic 
Nanoemulsions/Nanoliposomes by Fluoride-Silica Chemistry for Efficient 
214 
 
Delivery/Co-Delivery of Hydrophobic Agents, Adv Funct Mater, 22 (2012) 
1586-1597. 
[178] H.Y. Liu, D. Chen, L.L. Li, T.L. Liu, L.F. Tan, X.L. Wu, F.Q. Tang, 
Multifunctional Gold Nanoshells on Silica Nanorattles: A Platform for the 
Combination of Photothermal Therapy and Chemotherapy with Low Systemic Toxicity, 
Angew Chem Int Edit, 50 (2011) 891-895. 
[179] H.Y. Liu, T.L. Liu, X.L. Wu, L.L. Li, L.F. Tan, D. Chen, F.Q. Tang, Targeting 
Gold Nanoshells on Silica Nanorattles: a Drug Cocktail to Fight Breast Tumors via a 
Single Irradiation with Near-Infrared Laser Light, Adv Mater, 24 (2012) 755-+. 
[180] S. Shen, H.Y. Tang, X.T. Zhang, J.F. Ren, Z.Q. Pang, D.G. Wang, H.L. Gao, Y. 
Qian, X.G. Jiang, W.L. Yang, Targeting mesoporous silica-encapsulated gold nanorods 
for chemo-photothermal therapy with near-infrared radiation, Biomaterials, 34 (2013) 
3150-3158. 
[181] M. Ma, H.R. Chen, Y. Chen, X. Wang, F. Chen, X.Z. Cui, J.L. Shi, Au capped 
magnetic core/mesoporous silica shell nanoparticles for combined 
photothermo-/chemo-therapy and multimodal imaging, Biomaterials, 33 (2012) 
989-998. 
[182] W.J. Fang, S.H. Tang, P.X. Liu, X.L. Fang, J.W. Gong, N.F. Zheng, Pd 
Nanosheet-Covered Hollow Mesoporous Silica Nanoparticles as a Platform for the 
Chemo-Photothermal Treatment of Cancer Cells, Small, 8 (2012) 3816-3822. 
[183] M.B. Zheng, C.X. Yue, Y.F. Ma, P. Gong, P.F. Zhao, C.F. Zheng, Z.H. Sheng, P.F. 
Zhang, Z.H. Wang, L.T. Cai, Single-Step Assembly of DOX/ICG Loaded 
Lipid-Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination 
Therapy, Acs Nano, 7 (2013) 2056-2067. 
[184] P.M. Valencia, E.M. Pridgen, B. Perea, S. Gadde, C. Sweeney, P.W. Kantoff, N.H. 
Bander, S.J. Lippard, R. Langer, R. Karnik, O.C. Farokhzad, Synergistic cytotoxicity 
of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles, 
Nanomedicine (Lond), 8 (2013) 687-698. 
[185] S. Aryal, C.M. Hu, L. Zhang, Polymeric nanoparticles with precise ratiometric 
control over drug loading for combination therapy, Mol Pharm, 8 (2011) 1401-1407. 
[186] N. Kolishetti, S. Dhar, P.M. Valencia, L.Q. Lin, R. Karnik, S.J. Lippard, R. 
Langer, O.C. Farokhzad, Engineering of self-assembled nanoparticle platform for 




[187] K. Nam, H.Y. Nam, P.H. Kim, S.W. Kim, Paclitaxel-conjugated PEG and 
arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug 
and gene, Biomaterials, 33 (2012) 8122-8130. 
[188] H. Xiao, W. Li, R. Qi, L. Yan, R. Wang, S. Liu, Y. Zheng, Z. Xie, Y. Huang, X. 
Jing, Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer 
and more efficacious combination therapy, J Control Release, 163 (2012) 304-314. 
[189] H.H. Xiao, H.Q. Song, Q. Yang, H.D. Cai, R.G. Qi, L.S. Yan, S. Liu, Y.H. Zheng, 
Y.B. Huang, T.J. Liu, X.B. Jing, A prodrug strategy to deliver cisplatin(IV) and 
paclitaxel in nanomicelles to improve efficacy and tolerance, Biomaterials, 33 (2012) 
6507-6519. 
[190] H.L. Lu, W.J. Syu, N. Nishiyama, K. Kataoka, P.S. Lai, Dendrimer 
phthalocyanine-encapsulated polymeric micelle-mediated photochemical 
internalization extends the efficacy of photodynamic therapy and overcomes 
drug-resistance in vivo, J Control Release, 155 (2011) 458-464. 
[191] K.J. Son, H.J. Yoon, J.H. Kim, W.D. Jang, Y. Lee, W.G. Koh, Photosensitizing 
Hollow Nanocapsules for Combination Cancer Therapy, Angew Chem Int Edit, 50 
(2011) 11968-11971. 
[192] J. Park, S.H. Wrzesinski, E. Stern, M. Look, J. Criscione, R. Ragheb, S.M. Jay, 
S.L. Demento, A. Agawu, P.L. Limon, A.F. Ferrandino, D. Gonzalez, A. Habermann, 
R.A. Flavell, T.M. Fahmy, Combination delivery of TGF-beta inhibitor and IL-2 by 
nanoscale liposomal polymeric gels enhances tumour immunotherapy, Nat Mater, 11 
(2012) 895-905. 
[193] N.L. Spector, K.L. Blackwell, Understanding the Mechanisms Behind 
Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast 
Cancer, J Clin Oncol, 27 (2009) 5838-5847. 
[194] K. Bullock, K. Blackwell, Clinical efficacy of taxane-trastuzumab combination 
regimens for HER-2-positive metastatic breast cancer, Oncologist, 13 (2008) 515-525. 
[195] K. Gelmon, The Taxoids - Paclitaxel and Docetaxel, Lancet, 344 (1994) 
1267-1272. 
[196] S.J. Clarke, L.P. Rivory, Clinical pharmacokinetics of docetaxel, Clin 
Pharmacokinet, 36 (1999) 99-114. 
[197] D. Wang, S.J. Lippard, Cellular processing of platinum anticancer drugs, Nat 
Rev Drug Discov, 4 (2005) 307-320. 
216 
 
[198] M.P. Decatris, S. Sundar, K.J. O'Byrne, Platinum-based chemotherapy in 
metastatic breast cancer: current status, Cancer Treat Rev, 30 (2004) 53-81. 
[199] A.K. Gupta, M. Gupta, Synthesis and surface engineering of iron oxide 
nanoparticles for biomedical applications, Biomaterials, 26 (2005) 3995-4021. 
[200] A.K. Gupta, R.R. Naregalkar, V.D. Vaidya, M. Gupta, Recent advances on 
surface engineering of magnetic iron oxide nanoparticles and their biomedical 
applications, Nanomedicine-Uk, 2 (2007) 23-39. 
[201] C. Prashant, M. Dipak, C.T. Yang, K.H. Chuang, D. Jun, S.S. Feng, 
Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol 
polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent, 
Biomaterials, 31 (2010) 5588-5597. 
[202] P. Chandrasekharan, D. Maity, C.X. Yong, K.H. Chuang, J. Ding, S.S. Feng, 
Vitamin E (d-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) 
micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and 
MRI, Biomaterials, 32 (2011) 5663-5672. 
[203] G. Jego, A. Hazoume, R. Seigneuric, C. Garrido, Targeting heat shock proteins in 
cancer, Cancer Lett, (2010). 
[204] P. Wust, B. Hildebrandt, G. Sreenivasa, B. Rau, J. Gellermann, H. Riess, R. Felix, 
P.M. Schlag, Hyperthermia in combined treatment of cancer, Lancet Oncol, 3 (2002) 
487-497. 
[205] R. Issels, Hyperthermia combined with chemotherapy - Biological rationale, 
clinical application, and treatment results, Onkologie, 22 (1999) 374-381. 
[206] F. Mohamed, O.A. Stuart, O. Glehen, M. Urano, P.H. Sugarbaker, Docetaxel and 
hyperthermia: Factors that modify thermal enhancement, J Surg Oncol, 88 (2004) 
14-20. 
[207] F. Mohamed, P. Marchettini, O.A. Stuart, M. Urano, P.H. Sugarbaker, Thermal 
enhancement of new chemotherapeutic agents at moderate hyperthermia, Ann Surg 
Oncol, 10 (2003) 463-468. 
[208] P.G. Richardson, C.S. Mitsiades, J.P. Laubach, S. Lonial, A.A. Chanan-Khan, 
K.C. Anderson, Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy 
for the treatment of myeloma and other cancers, Brit J Haematol, 152 (2011) 367-379. 
[209] V.P. Torchilin, Structure and design of polymeric surfactant-based drug delivery 
systems, J Control Release, 73 (2001) 137-172. 
217 
 
[210] K. Xiao, J.T. Luo, W.L. Fowler, Y.P. Li, J.S. Lee, L. Xing, R.H. Cheng, L. Wang, 
K.S. Lam, A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer, 
Biomaterials, 30 (2009) 6006-6016. 
[211] M. Ferrari, Cancer nanotechnology: Opportunities and challenges, Nat Rev 
Cancer, 5 (2005) 161-171. 
[212] O.C. Farokhzad, R. Langer, Impact of Nanotechnology on Drug Delivery, Acs 
Nano, 3 (2009) 16-20. 
[213] S.S. Feng, New-concept chemotherapy by nanoparticles of biodegradable 
polymers: where are we now?, Nanomedicine-Uk, 1 (2006) 297-309. 
[214] R.T. Liggins, H.M. Burt, Polyether-polyester diblock copolymers for the 
preparation of paclitaxel loaded polymeric micelle formulations, Advanced drug 
delivery reviews, 54 (2002) 191-202. 
[215] K. Kataoka, A. Harada, Y. Nagasaki, Block copolymer micelles for drug delivery: 
Design, characterization and biological significance, Advanced drug delivery reviews, 
64 (2012) 37-48. 
[216] G. Gaucher, R.H. Marchessault, J.C. Leroux, Polyester-based micelles and 
nanoparticles for the parenteral delivery of taxanes, J Control Release, 143 (2010) 
2-12. 
[217] Y.P. Li, K. Xiao, J.T. Luo, J. Lee, S.R. Pan, K.S. Lam, A novel size-tunable 
nanocarrier system for targeted anticancer drug delivery, J Control Release, 144 (2010) 
314-323. 
[218] G.S. Kwon, K. Kataoka, Block copolymer micelles as long-circulating drug 
vehicles, Advanced drug delivery reviews, 64 (2012) 237-245. 
[219] N. Tang, G.J. Du, N. Wang, C.C. Liu, H.Y. Hang, W. Liang, Improving 
penetration in tumors with nanoassemblies of phospholipids and doxorubicin, J Natl 
Cancer I, 99 (2007) 1004-1015. 
[220] A.N. Lukyanov, V.P. Torchilin, Micelles from lipid derivatives of water-soluble 
polymers as delivery systems for poorly soluble drugs, Advanced drug delivery 
reviews, 56 (2004) 1273-1289. 
[221] L. Mu, S.S. Feng, Vitamin E TPGS used as emulsifier in the solvent 
evaporation/extraction technique for fabrication of polymeric nanospheres for 
controlled release of paclitaxel (Taxol (R)), J Control Release, 80 (2002) 129-144. 
218 
 
[222] J. Pan, Y. Wang, S.S. Feng, Formulation, characterization, and in vitro evaluation 
of quantum dots loaded in poly(lactide)-vitamin E TPGS nanoparticles for cellular and 
molecular imaging, Biotechnol Bioeng, 101 (2008) 622-633. 
[223] Y.C. Dong, S.S. Feng, Poly(D,L-lactide-co-glycolide)/montmorillonite 
nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26 (2005) 6068-6076. 
[224] Y. Zhao, J. Neuzil, K. Wu, Vitamin E analogues as mitochondria-targeting 
compounds: From the bench to the bedside?, Mol Nutr Food Res, 53 (2009) 129-139. 
[225] L. Mu, T.A. Elbayoumi, V.P. Torchilin, Mixed micelles made of poly(ethylene 
glycol)-phosphatidylethanolamine conjugate and D-alpha-tocopheryl polyethylene 
glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin, International 
journal of pharmaceutics, 306 (2005) 142-149. 
[226] H.Z. Zhao, L.Y.L. Yung, Addition of TPGS to folate-conjugated polymer 
micelles for selective tumor targeting, J Biomed Mater Res A, 91A (2009) 505-518. 
[227] J. Pan, S.S. Feng, Targeted delivery of paclitaxel using folate-decorated 
poly(lactide) - vitamin E TPGS nanoparticles, Biomaterials, 29 (2008) 2663-2672. 
[228] Z.P. Zhang, S.H. Lee, S.S. Feng, Folate-decorated 
poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery, 
Biomaterials, 28 (2007) 1889-1899. 
[229] F. Guerittevoegelein, D. Guenard, F. Lavelle, M.T. Legoff, L. Mangatal, P. Potier, 
Relationships between the Structure of Taxol Analogs and Their Antimitotic Activity, 
Journal of medicinal chemistry, 34 (1991) 992-998. 
[230] J. Verweij, Docetaxel (Taxotere(Tm)) - a New Anticancer Drug with Promising 
Potential, Brit J Cancer, 70 (1994) 183-184. 
[231] L. van Zuylen, J. Verweij, A. Sparreboom, Role of formulation vehicles in taxane 
pharmacology, Invest New Drug, 19 (2001) 125-141. 
[232] F. Lavelle, M.C. Bissery, C. Combeau, J.F. Riou, P. Vrignaud, S. Andre, 
Preclinical Evaluation of Docetaxel (Taxotere), Semin Oncol, 22 (1995) 3-16. 
[233] J. Neuzil, J.C. Dyason, R. Freeman, L.F. Dong, L. Prochazka, X.F. Wang, I. 
Scheffler, S.J. Ralph, Mitocans as anti-cancer agents targeting mitochondria: lessons 
from studies with vitamin E analogues, inhibitors of complex II, J Bioenerg Biomembr, 
39 (2007) 65-72. 
[234] R.J. Lee, P.S. Low, Folate-Mediated Tumor-Cell Targeting of 
219 
 
Liposome-Entrapped Doxorubicin in-Vitro, Bba-Biomembranes, 1233 (1995) 
134-144. 
[235] J. Wu, Q. Liu, R.J. Lee, A folate receptor-targeted liposomal formulation for 
paclitaxel, International journal of pharmaceutics, 316 (2006) 148-153. 
[236] Y.N. Xue, Z.Z. Huang, J.T. Zhang, M. Liu, M. Zhang, S.W. Huang, R.X. Zhuo, 
Synthesis and self-assembly of amphiphilic poly(acrylic acid-b-DL-lactide) to form 
micelles for pH-responsive drug delivery, Polymer, 50 (2009) 3706-3713. 
[237] S. Pioge, L. Fontaine, C. Gaillard, E. Nicol, S. Pascual, Self-Assembling 
Properties of Well-Defined Poly(ethylene oxide)-b-poly (ethyl acrylate) Diblock 
Copolymers, Macromolecules, 42 (2009) 4262-4272. 
[238] G.H. Li, C.G. Cho, CMC and dynamic properties of poly(VA-b-St) copolymer 
micelles for drug delivery, Korean J Chem Eng, 25 (2008) 1444-1447. 
[239] P. Decuzzi, M. Ferrari, The role of specific and non-specific interactions in 
receptor-mediated endocytosis of nanoparticles, Biomaterials, 28 (2007) 2915-2922. 
[240] E.S. Lee, K. Na, Y.H. Bae, Polymeric micelle for tumor pH and folate-mediated 
targeting, J Control Release, 91 (2003) 103-113. 
[241] J. Ito, T. Kato, Y. Kamio, H. Kato, T. Kishikawa, T. Toda, S. Sasaki, R. Tanaka, A 
Cellular Uptake of Cis-Platinum-Encapsulating Liposome through Endocytosis by 
Human Neuroblastoma Cell, Neurochem Int, 18 (1991) 257-264. 
[242] C.P. Leamon, P.S. Low, Delivery of Macromolecules into Living Cells - a 
Method That Exploits Folate Receptor Endocytosis, P Natl Acad Sci USA, 88 (1991) 
5572-5576. 
[243] H.S. Yoo, T.G. Park, Folate-receptor-targeted delivery of doxorubicin 
nano-aggregates stabilized by doxorubicin-PEG-folate conjugate, J Control Release, 
100 (2004) 247-256. 
[244] A.T. Rose, D.W. McFadden, Alpha-tocopherol succinate inhibits growth of 
gastric cancer cells in vitro, Journal of Surgical Research, 95 (2001) 19-22. 
[245] J. Quin, D. Engle, A. Litwiller, E. Peralta, A. Grasch, T. Boley, S. Hazelrigg, 
Vitamin E succinate decreases lung cancer tumor growth in mice, Journal of Surgical 
Research, 127 (2005) 139-143. 
[246] C.F. Mu, P. Balakrishnan, F.D. Cui, Y.M. Yin, Y.B. Lee, H.G. Choi, C.S. Yong, 
S.J. Chung, C.K. Shim, D.D. Kim, The effects of mixed MPEG-PLA/Pluronic (R) 
220 
 
copolymer micelles on the bioavailability and multidrug resistance of docetaxel, 
Biomaterials, 31 (2010) 2371-2379. 
[247] F.Q. Hu, L.N. Liu, Y.Z. Du, H. Yuan, Synthesis and antitumor activity of 
doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles, 
Biomaterials, 30 (2009) 6955-6963. 
[248] S.S. Feng, Chemotherapeutic Engineering: Concept, Feasibility, Safety and 
Prospect-A Tribute to Shu Chien's 80th Birthday, Cell Mol Bioeng, 4 (2011) 708-716. 
[249] K.J. Cho, X. Wang, S.M. Nie, Z. Chen, D.M. Shin, Therapeutic nanoparticles for 
drug delivery in cancer, Clin Cancer Res, 14 (2008) 1310-1316. 
[250] J.J. Shi, A.R. Votruba, O.C. Farokhzad, R. Langer, Nanotechnology in Drug 
Delivery and Tissue Engineering: From Discovery to Applications, Nano Lett, 10 
(2010) 3223-3230. 
[251] S.H. Lee, Z.P. Zhang, S.S. Feng, Nanoparticles of poly(lactide) - Tocopheryl 
polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery, 
Biomaterials, 28 (2007) 2041-2050. 
[252] N. Cao, S.S. Feng, Doxorubicin conjugated to D-alpha-tocopheryl polyethylene 
glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in 
vivo evaluation, Biomaterials, 29 (2008) 3856-3865. 
[253] E.R. Jamieson, S.J. Lippard, Structure, recognition, and processing of 
cisplatin-DNA adducts, Chem Rev, 99 (1999) 2467-2498. 
[254] Y.P. Ho, S.C.F. Au-Yeung, K.K.W. To, Platinum-based anticancer agents: 
Innovative design strategies and biological perspectives, Med Res Rev, 23 (2003) 
633-655. 
[255] L. Kelland, The resurgence of platinum-based cancer chemotherapy, Nat Rev 
Cancer, 7 (2007) 573-584. 
[256] Rosenber.B, L. Vancamp, J.E. Trosko, V.H. Mansour, Platinum Compounds - a 
New Class of Potent Antitumour Agents, Nature, 222 (1969) 385-&. 
[257] J. Fujiyama, Y. Nakase, K. Osaki, C. Sakakura, H. Yamagishi, A. Hagiwara, 
Cisplatin incorporated in microspheres: development and fundamental studies for its 
clinical application, J Control Release, 89 (2003) 397-408. 
[258] E. Wong, C.M. Giandomenico, Current status of platinum-based antitumor drugs, 
Chem Rev, 99 (1999) 2451-2466. 
221 
 
[259] J.A. Barreto, W. O'Malley, M. Kubeil, B. Graham, H. Stephan, L. Spiccia, 
Nanomaterials: Applications in Cancer Imaging and Therapy, Adv Mater, 23 (2011) 
H18-H40. 
[260] S.S. Feng, New-concept chemotherapy by nanoparticles of biodegradable 
polymers: where are we now?, Nanomedicine (Lond), 1 (2006) 297-309. 
[261] M. Hans, K. Shimoni, D. Danino, S.J. Siegel, A. Lowman, Synthesis and 
characterization of mPEG-PLA prodrug micelles, Biomacromolecules, 6 (2005) 
2708-2717. 
[262] S. Aryal, C.M.J. Hu, L.F. Zhang, Polymer-Cisplatin Conjugate Nanoparticles for 
Acid-Responsive Drug Delivery, Acs Nano, 4 (2010) 251-258. 
[263] H.H. Xiao, R.G. Qi, S. Liu, X.L. Hu, T.C. Duan, Y.H. Zheng, Y.B. Huang, X.B. 
Jing, Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II), 
Biomaterials, 32 (2011) 7732-7739. 
[264] V. Anbharasi, N. Cao, S.S. Feng, Doxorubicin conjugated to D-alpha-tocopheryl 
polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy, J 
Biomed Mater Res A, 94 (2010) 730-743. 
[265] S.J. Lippard, S. Dhar, N. Kolishetti, O.C. Farokhzad, Targeted delivery of a 
cisplatin prodrug for safer and more effective prostate cancer therapy in vivo, P Natl 
Acad Sci USA, 108 (2011) 1850-1855. 
[266] S.J. Lippard, S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, Targeted delivery of 
cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG 
nanoparticles, P Natl Acad Sci USA, 105 (2008) 17356-17361. 
[267] K.R. Barnes, A. Kutikov, S.J. Lippard, Synthesis, characterization, and 
cytotoxicity of a series of estrogen-tethered platinum(IV) complexes, Chem Biol, 11 
(2004) 557-564. 
[268] P.M.H. Chang, C.H. Tzeng, M.H. Chen, C.J. Tsao, W.C. Su, W.S. Hwang, Y.F. 
Chang, S.Y. Chang, M.H. Yang, Triweekly reduced-dose docetaxel combined with 
cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter 
phase II study, Cancer Chemoth Pharm, 68 (2011) 1477-1484. 
[269] A. Kodama, H. To, T. Kinoshita, I. Ieiri, S. Higuchi, Influence of dosing 
schedules on toxicity and antitumour effects of combined cisplatin and docetaxel 
treatment in mice, J Pharm Pharmacol, 61 (2009) 615-621. 
[270] K. Ridwelski, T. Gebauer, J. Fahlke, H. Kroning, E. Kettner, F. Meyer, K. 
222 
 
Eichelmann, H. Lippert, Combination chemotherapy with docetaxel and cisplatin for 
locally advanced and metastatic gastric cancer, Ann Oncol, 12 (2001) 47-51. 
[271] L.T. Ellis, H.M. Er, T.W. Hambley, The Influence of the Axial Ligands of a Series 
of Platinum(Iv) Anticancer Complexes on Their Reduction to Platinum(Ii) and 
Reaction with DNA, Aust J Chem, 48 (1995) 793-806. 
[272] J. Zhao, Y. Mi, Y. Liu, S.S. Feng, Quantitative control of targeting effect of 
anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable 
copolymer blend, Biomaterials, 33 (2012) 1948-1958. 
[273] L. Gianni, E. Munzone, G. Capri, F. Fulfaro, E. Tarenzi, F. Villani, C. Spreafico, 
A. Laffranchi, A. Caraceni, C. Martini, M. Stefanelli, P. Valagussa, G. Bonadonna, 
Paclitaxel by 3-Hour Infusion in Combination with Bolus Doxorubicin in Women with 
Untreated Metastatic Breast-Cancer - High Antitumor Efficacy and Cardiac Effects in 
a Dose-Finding and Sequence-Finding Study, J Clin Oncol, 13 (1995) 2688-2699. 
[274] J. Crown, M. O'Leary, The taxanes: an update, Lancet, 355 (2000) 1176-1178. 
[275] P.A. Vasey, J. Paul, A. Birt, E.J. Junor, N.S. Reed, R.P. Symonds, R. Atkinson, J. 
Graham, S.M. Crawford, R. Coleman, H. Thomas, J. Davis, S.P.H. Eggleton, S.B. 
Kaye, S.G.C.T. Grp, Docetaxel and cisplatin in combination as first-line chemotherapy 
for advanced epithelial ovarian cancer, J Clin Oncol, 17 (1999) 2069-2080. 
[276] M. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, M. Sliwkowski, D. Coombs, 
D. Baly, F. Kabbinavar, D. Slamon, Inhibitory effects of combinations of HER-2/neu 
antibody and chemotherapeutic agents used for treatment of human breast cancers, 
Oncogene, 18 (1999) 2241-2251. 
[277] J. Baselga, L. Norton, J. Albanell, Y.M. Kim, J. Mendelsohn, Recombinant 
humanized anti-HER2 antibody (Herceptin (TM)) enhances the antitumor activity of 
paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer 
xenografts, Cancer Res, 58 (1998) 2825-2831. 
[278] C. Lin, D.R. Chen, K.J. Chang, T.W. Chang, H.C. Wang, A phase II study of 
neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast 
cancers, Cancer Chemoth Pharm, 69 (2012) 1363-1368. 
[279] J. Hurley, P. Doliny, I. Reis, O. Silva, C. Gomez-Fernandez, P. Velez, G. Pauletti, 
M.D. Pegram, D.J. Slamon, Docetaxel, cisplatin, and trastuzumab as primary systemic 
therapy for human epidermal growth factor receptor 2-positive locally advanced breast 
cancer, J Clin Oncol, 24 (2006) 1831-1838. 
[280] S.S. Feng, Nanoparticles of biodegradable polymers for new-concept 
223 
 
chemotherapy, Expert review of medical devices, 1 (2004) 115-125. 
[281] B.Y.S. Kim, J.T. Rutka, W.C.W. Chan, Current Concepts: Nanomedicine., New 
Engl J Med, 363 (2010) 2434-2443. 
[282] M.S. Muthu, S.A. Kulkarni, A. Raju, S.S. Feng, Theranostic liposomes of TPGS 
coating for targeted co-delivery of docetaxel and quantum dots, Biomaterials, 33 (2012) 
3494-3501. 
[283] C. Prashant, M. Dipak, C.T. Yang, K.H. Chuang, D. Jun, S.S. Feng, 
Superparamagnetic iron oxide - Loaded poly (lactic acid)-D-alpha-tocopherol 
polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent, 
Biomaterials, 31 (2010) 5588-5597. 
[284] N.E. Hynes, H.A. Lane, ERBB receptors and cancer: The complexity of targeted 
inhibitors, Nat Rev Cancer, 5 (2005) 341-354. 
[285] Z. Zhang, S.S. Feng, Nanoparticles of poly(lactide)/vitamin E TPGS copolymer 
for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug 
release, Biomaterials, 27 (2006) 262-270. 
[286] Z. Zhang, S.S. Feng, The drug encapsulation efficiency, in vitro drug release, 
cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl 
polyethylene glycol succinate nanoparticles, Biomaterials, 27 (2006) 4025-4033. 
[287] N. Cao, S.S. Feng, Doxorubicin conjugated to D-alpha-tocopheryl polyethylene 
glycol 1000 succinate (TPGS): Conjugation chemistry, characterization, in vitro and in 
vivo evaluation, Biomaterials, 29 (2008) 3856-3865. 
[288] B.J. Foster, J.A. Kern, HER2-targeted gene transfer, Hum Gene Ther, 8 (1997) 
719-727. 
[289] W.C.W. Chan, B.Y.S. Kim, J.T. Rutka, Current Concepts: Nanomedicine., New 
Engl J Med, 363 (2010) 2434-2443. 
[290] C.W. Gan, S. Chien, S.S. Feng, Nanomedicine: enhancement of 
chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle 
formulation, Curr Pharm Des, 16 (2010) 2308-2320. 
[291] G. Capri, E. Tarenzi, F. Fulfaro, L. Gianni, The role of taxanes in the treatment of 
breast cancer, in:  Conference on Perspectives in Breast Cancer, Phoenix, Az, 1995, pp. 
68-75. 
[292] M.C. Bissery, G. Nohynek, G.J. Sanderink, F. Lavelle, Docetaxel (Taxotere(R)) - 
224 
 
a Review of Preclinical and Clinical-Experience .1. Preclinical Experience, 
Anti-Cancer Drug, 6 (1995) 339-355. 
[293] F. Gueritte-Voegelein, D. Guenard, F. Lavelle, M.T. Le Goff, L. Mangatal, P. 
Potier, Relationships between the structure of taxol analogs and their antimitotic 
activity, Journal of Medicinal Chemistry, 34 (1991) 992-998. 
[294] G.P. Adams, L.M. Weiner, Monoclonal antibody therapy of cancer, Nat 
Biotechnol, 23 (2005) 1147-1157. 
[295] R. Nahta, D.H. Yu, M.C. Hung, G.N. Hortobagyi, F.J. Esteva, Mechanisms of 
disease: understanding resistance to HER2-targeted therapy in human breast cancer, 
Nat Clin Pract Oncol, 3 (2006) 269-280. 
[296] Y. Liu, K. Li, B. Liu, S.S. Feng, A strategy for precision engineering of 
nanoparticles of biodegradable copolymers for quantitative control of targeted drug 
delivery, Biomaterials, 31 (2010) 9145-9155. 
[297] C.S.S.R. Kumar, F. Mohammad, Magnetic nanomaterials for 
hyperthermia-based therapy and controlled drug delivery, Adv Drug Deliver Rev, 63 
(2011) 789-808. 
[298] Z. Zhang, S. Huey Lee, S.S. Feng, Folate-decorated 
poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery, 
Biomaterials, 28 (2007) 1889-1899. 
[299] J. Pan, S.S. Feng, Targeting and imaging cancer cells by folate-decorated, 
quantum dots (QDs)- loaded nanoparticles of biodegradable polymers, Biomaterials, 
30 (2009) 1176-1183. 
[300] S.H. Sun, H. Zeng, D.B. Robinson, S. Raoux, P.M. Rice, S.X. Wang, G.X. Li, 
Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles, J Am Chem Soc, 126 (2004) 
273-279. 
[301] B. Sun, S.S. Feng, Trastuzumab-functionalized nanoparticles of biodegradable 
copolymers for targeted delivery of docetaxel, Nanomedicine (Lond), 4 (2009) 
431-445. 
[302] J.M. Nabholtz, J. Gligorov, Docetaxel/trastuzumab combination therapy for the 
treatment of breast cancer, Expert Opin Pharmaco, 6 (2005) 1555-1564. 
[303] M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, 
S. Chan, D. Grimes, A. Anton, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, M. Green, 
C. Ward, K. Mayne, J.M. Extra, Randomized phase II trial of the efficacy and safety of 
225 
 
trastuzumab combined with docetaxel in patients with human epidermal growth factor 
receptor 2-positive metastatic breast cancer administered as first-line treatment: The 
M77001 study group, J Clin Oncol, 23 (2005) 4265-4274. 
[304] J.P. Zhang, A.H. Dewilde, P. Chinn, A. Foreman, S. Barry, D. Kanne, S.J. 
Braunhut, Herceptin-directed nanoparticles activated by an alternating magnetic field 
selectively kill HER-2 positive human breast cells in vitro via hyperthermia, Int J 
Hyperther, 27 (2011) 682-697. 
[305] M. Kullberg, K. Mann, J.L. Owens, A two-component drug delivery system 
using Her-2-targeting thermosensitive liposomes, J Drug Target, 17 (2009) 98-107. 
[306] Z.P. Zhang, Y.J. Guo, S.S. Feng, Nanoimmunotherapy: application of 
nanotechnology for sustained and targeted delivery of antigens to dendritic cells, 













LIST OF AWARDS 
 Chinese Ministry of Education Award for Best Overseas PhD 
Student 
 Biomacromolecules Poster Prize in The Second Symposium on 
Innovative Polymers for Controlled Delivery (SIPCD 2012 
September 11-14, Suzhou, China) 






























LIST OF PUBLICATIONS 
JOURNAL PUBLICATIONS 
 
1. Mi Y, Zhao J, Feng SS. Prodrug micelles based nanomedicine for cancer 
treatment. . Nanomedicine 2013, 8(10): 1559-1562. (Editorial) 
 
2. Mi Y, Zhao J, Feng SS. Targeted co-delivery of docetaxel, cisplatin and herceptin 
by Vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment 
of Cancer. J. Control. Release 2013, 169: 185-192. Chapter 5 
 
3. Mi Y, Guo YJ, Feng SS. Nanomedicine for multimodality treatment of cancer. 
Nanomedicine 2012, 7(12): 1791-1794. (Editorial) Chapter 1 
 
4. Mi Y, Liu XL, Zhao J, Ding J, Feng SS. Multimodality treatment of cancer with 
herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded 
nanoparticles of biodegradable polymers. Biomaterials 2012, 33: 7519-7529. 
Chapter 6 
 
5. Mi Y, Zhao J, Feng SS. Vitamin E TPGS prodrug micelles for hydrophilic drug 
delivery with neuroprotective effects. Int’l. J. Pharm. 2012, 438: 98-106. 
Chapter 4 
 
6. Mi Y, Li K, Liu YT, Pu KY, Liu B, Feng SS. Herceptin functionalized polyhedral 
oligomeric silsesquioxane-conjugated oligomers-silica/iron oxide nanoparticles 
for tumor cell sorting and detection. Biomaterials 2011, 32: 8226-8233. 
 
7. Mi Y, Liu YT, Feng SS. Formulation of Docetaxel by folic acid-conjugated 
D-a-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2k) micelles 
for targeted and synergistic chemotherapy. Biomaterials 2011, 32: 4058-4066. 
Chapter 3 
 
8. Mi Y, Liu YT, Guo YJ, Feng SS. Herceptin®-conjugated nanocarriers for targeted 
imaging and treatment of HER2-positive cancer. Nanomedicine 2011, 6(2): 
311-315. (Research highlights) 
 
9. Zhao J, Mi Y, Feng SS. siRNA-based nanomedicine for cancer treatment. 
Nanomedicine 2013, 8(6): 859-862. (Editorial) 
 
10. Zhao J, Mi Y, Feng SS. Targeted co-delivery of docetaxel and siPlk1 by herceptin 





11. Zhao J, Mi Y, Liu YT, Feng SS. Quantitative control of targeting effect of 
anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable 
copolymer blend. Biomaterials 2012, 33: 1948-1958. 
 
12. Liu YT, Mi Y, Feng SS. Nanotechnology for multimodal imaging. Nanomedicine 
2011, 6(7): 1141-1144. (Editorial) 
 
13. Liu YT, Mi Y, Zhao J, Feng SS. Multifunctional silica nanoparticles for targeted 
delivery of hydrophobic imaging and therapeutic agents. Int’l. J. Pharm. 2011, 
421: 370-378. 
 
14. Pan J, Mi Y, Wan D, Liu YT, Feng SS, Gong JL. PEGylated liposome coated 
QDs/mesoporous silica core-shell nanoparticles for molecular imaging. Chem. 




1. Mi Y, Zhao J, Feng SS. Multimodality treatment of cancer by co-encapsulation of 
docetaxel and iron oxides in herceptin-conjugated nanoparticles of a blend of 
biodegradable copolymers. J. Control. Release The second symposium on 
innovative polymers for controlled delivery. Sep. 2012, Suzhou, China. 
 
2. Phyo WM, Liu Y, Mi Y, Feng SS. Formulations of lipid shell and polymer core 
nanoparticles for drug delivery. MRS-S Trilateral Conference on Advances in 
Nanoscience: Energy, Water and Healthcare. Aug. 2010, Singapore 
 
